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Using a semi-PBPK modeling/quantitative meta-analysis approach, this project 
investigated what factors affect pulmonary and systemic exposures of Budesonide 
(BUD), Tobramycin (TOB), and Ciprofloxacin (CIP) after inhalation: 
Three structurally different pulmonary disposition models were developed for 
each drug, including pulmonary absorption (all three), excretion (TOB and CIP) and 
sequestration (TOB) in a peripheral and central lung compartment.  Systemic 
disposition parameters were estimated using available human mean plasma (cp(t)) and 
sputum (cs(t)) concentration profiles after IV administration, and GI absorption 
parameters were estimated from these profiles after oral administration.  Pulmonary 
disposition parameters were estimated from cp(t) and cs(t) profiles after inhalation using 
various devices along with their published pulmonary deposition characteristics.  
Appropriate covariate models accounted for effects of Cystic Fibrosis on the systemic 
disposition/GI absorption for TOB and CIP.  Monte Carlo Simulations (MCS) were used 
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to optimize parameters and validate the final models and parameter spaces against 
published data. 
Despite limited available data, especially cs(t) for BUD and CIP (after IV 
administration), the point estimates for the final model parameters were mechanistically 
plausible for all three drugs and consistent with their known differences in 
physicochemical and ADME properties.  Model predictions adequately described the 
observed cp(t) and cs(t) profiles as well as exposure metrics across studies. 
As the most lipophilic drug, BUD showed the fastest pulmonary absorption rates 
and highest Fpul (83%).  TOB, a very hydrophilic drug, exhibited (intracellular) pulmonary 
sequestration, resulting in slow pulmonary absorption and excretion and low Fpul (10%).  
CIP - as zwitterion - showed relatively slow pulmonary absorption and excretion, leading 
to low Fpul (8%); pulmonary excretion accounted for 27% of CIP overall elimination. 
 Results of a formal parameter sensitivity analysis demonstrated that, for all three 
drugs, after inhalation, (1) their systemic exposures (cp(t)) depend primarily on CLtot 
along with Fpul/sequestration combined with Foral; (2) increasing pulmonary exposures 
(cs(t)) can be accomplished by slowing down pulmonary absorption rates (kca) and/or 
slowing down mucociliary clearance from the lungs into the GI tract (kcm) – affirming the 
overall hypothesis guiding the project. 
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CHAPTER 1 
INTRODUCTION 
 
 
1.1. Inhalation as a Dosing Route 
Historical evidence has shown that inhalation (INH) of drugs for medicinal purposes 
has been around since 1554 BC in Egypt.1 INH as an intended route of drug 
administration is typically utilized for either, a) its ability to deliver the drug directly to its 
site of action, i.e. the lungs, or b) delivering the drug into the blood stream (systemic 
circulation) while avoiding any hepatic first-pass elimination, which reduces 
bioavailability after oral administration.2 Delivering drug directly to the lungs may allow 
use of a lower dose, and minimizes the systemic exposure of the drug relative to 
intravenous (IV) or oral dosing (PO) routes. 3  
After INH, a fraction of the dose will:1) remain in the INH device, 2) be deposited in 
the mouth where it may be exhaled, 3) be swallowed and delivered in the GI tract where 
it may be available for GI absorption (similar to PO administration), and 4) deposited in 
the lungs for further disposition, namely pulmonary uptake, sequestration, and 
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mucociliary clearance. Mucociliary clearance can transport drug from the lung into the 
GI for possible GI absorption.4  
The fraction of the dose that undergoes each of the four fates listed will depend on 
factors such as the efficiency of the device, the INH maneuver, patience compliance 
with the INH technique, patient health/disease state, and other factors.5 Some studies 
that evaluate drug deposition after INH further characterize the fraction of the dose that 
is deposited in the lungs by specifying whether it is deposited into the peripheral lung or 
in the central lung.6 Given that some disease states require targeting of the central lung, 
while other disease states require the targeting of the peripheral lung, a number of 
authors have discussed the necessity of obtaining peripheral versus central lung 
deposition device data.7 
 Cellular structure and airway geometry varies based on the region within the 
lung.8 As such, drug disposition once deposited in the lung will also vary. Drugs 
deposited in the lung can undergo processes including: dissolution, absorption, 
enzymatic metabolism, macrophage degradation, intracellular sequestration, and/or 
mucociliary clearance of the drug into the esophagus/GI tract.9 Accordingly, a model 
developed for describe INH of drugs, should attempt to capture these different 
processes.  
 
1.2. Semi-PBPK Modeling of Inhaled Drugs 
While the PK within the systemic circulation can be well described based on 
available experimental data, less is known about the pulmonary kinetics of drugs after 
IV administration or oral INH. To date, no modeling work has been done in an attempt to 
describe or predict the pulmonary drug concentration after IV administration even 
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though this is a frequently utilized dosing route. For example, given that the primary 
function of antibiotics is to prevent/treat pulmonary infections, their site of action is the 
lungs.  
Notably, some authors have attempted to compare isolated sputum drug 
concentrations to minimum inhibitory concentrations (MIC) values for bacteria 
responsible for pulmonary infections, however, no work so far has attempted to develop 
a mathematical model the concentration time profile in the lungs or sputum.10,11 Others 
have looked at of bacteria concentrations in sputum and have drawn conclusions 
regarding the likely effectiveness of various antibacterial therapies.12–14 This method 
however, may not be an appropriate indicator of pulmonary drug exposures. A possible 
method to directly determine drug levels within the lung is to administer the compound 
and obtain a lung biopsy. While this method may be considered the most accurate and 
reliable technique for determining PUL drug concentrations, it is an invasive and 
dangerous procedure.  
Physiologically -based Pharmacokinetic (PBPK) modeling and simulation (M&S) 
is an alternative method to estimate and predict drug concentrations, not only lung 
concentration(s), but also within systemic body compartments, including the blood 
stream. However, PK Modeling, and more so PBPK modeling, is heavily dependent on 
the data available for the construction of the final model and parameter estimation, 
namely the physiological, biochemical, and physicochemical processes that occur in 
biological systems under certain physiological and pathological conditions.15  This 
information, however, may not be readily available, or the reliability of the available data 
may be in question or in conflict with published literature. As such, PBPK models reflect 
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current scientific knowledge, attempting to include all available experimental data, so as 
to provide the best-informed predictions.  It is, however, important to note that the 
validity and quality of the simulations and conclusions reached are highly dependent on 
the utilized model, and how well informed the model is, i.e., the information incorporated 
in the construction of the model.  
1.3. Sputum Composition, Physiological Components, and Purpose 
Lining the surface of the lungs is a substance known as the airway surface liquid 
(ASL), which is composed of the periciliary fluid in immediate contact with the 
pulmonary (PUL) epithelium and the mucus layer resting on top of the periciliary fluid.16 
The periciliary fluid is a low-viscosity aqueous layer that surrounds the cilia of the 
epithelia and allows them to beat in order to propel the mucus layer towards the 
trachea, and ultimately to the esophagus. The principal polymeric components of the 
mucus layer are mucins (specifically MUC5AC or MUC5B), which are high-molecular-
weight, heavily-glycosylated proteins that are produced by epithelial tissues, and serve 
to create the gel-like viscosity of the mucus.17,18 While the periciliary fluid’s main 
function is to allow the cilia to beat, the mucus also serves an immunological purpose as 
a form of chemical barrier against external pathogens. It finally serves to maintain 
airway hydration and plays a role in cell signaling.17 When the mucus layer is propelled 
by the cilia and expectorated, the resulting matrix is called sputum.   
Most studies of airway secretions in people with lung disease have been done 
using expectorated sputum, given the relative ease of obtaining specimens, compared 
to the difficulty in obtaining normal mucus from healthy airways.  
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Researchers have attempted to estimate the volume of the airway surface liquid 
via two primary methods; the first, estimated based on a bronchoalveolar lavage 
method, and the second, morphometry-extrapolation of the area and thickness of the 
fluid layer covering the respiratory epithelia: The bronchial lavage method is thought to 
lead to an underestimation of the ASL volume, as the recovery by lavage is typically 
incomplete, and hence leads to a lower calculated volume.19 The surface area of the 
lung has been previously compared to the area of a tennis court,20 however, more 
recently, researchers have suggested that it would only be half that area,21 and some 
have proposed that the area should be calculated based on body weight.22  
1.4. Fundamentals of Covariate Modeling 
In addition to PBPK modeling, covariate models often need to be used to 
describe observable/ predictable sources of PK variability arising from known patient 
characteristics. A covariate is any patient-specific variable such as body weight, age, 
gender, or renal function that is specific to an individual and may explain some of the 
between-subject variability observed in drug exposure or drug response (PK/PD).  
The implementation of covariate models can be accomplished for either 
continuous or categorical covariates. The most frequently utilized mathematical 
implementation of these covariate models for continuous covariates across literature 
are: linear, proportional, piecewise, power, and exponential. Typically, power models 
(also known as allometric models) have been utilized for both volume of distribution 
(Vdss) and total clearance (CLtot), given biological plausibility and clinical relevance.23 It 
is noteworthy, however, that the scaling factors for both those models are not the same, 
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namely, Vdss typically has a scaling factor of 1.0 and CLtot typically has a scaling factor 
of 0.75.  
As compared to continuous models, categorical models are binary, i.e. 
male/female, or healthy/diseases.  Covariate models are able to aid in bridging the gap 
across various studies in the literature, as they are able to explain some of the inter-
patient variability that may arise due to disease state, body weight, and other patient 
specific factors. 
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CHAPTER 2 
 
HYPOTHESIS, SPECIFIC AIMS AND OVERALL STRATEGY 
 
2.1. Hypothesis 
After inhalation of drugs that target the lungs, increasing pulmonary exposures 
can be accomplished by slowing down uptake from the lungs into systemic circulation 
and/or reducing mucociliary clearance from the lungs into the GI tract. Additionally, 
systemic levels can be decreased primarily by increasing the total clearance of the drug 
from the body rather than reducing pulmonary absorption.  
 
2.2. Specific Aims 
The overall objective of this research is to utilize semi-PBPK modeling for 
selected drugs to determine which physiological processes/PBPK model parameters 
have the most influence on systemic and pulmonary exposures after INH administration. 
The following specific aims will be addressed to accomplish this objective: 
 
1. Collect available literature studies reporting cp(t) and cs(t) profiles for BUD, 
TOB, CIP after IV, PO, and INH administration to humans. 
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2. Develop and validate a structural semi-PBPK model for each drug including 
relevant disease state and appropriate covariate models and optimize model 
parameters. 
a. The final model(s) have a common sub-model describing pulmonary 
disposition in order to allow comparison across drugs.  
b. For each drug, the final model will be validated by matching model 
predictions with available cp(t) and cs(t) profiles, as well as reported 
systemic and pulmonary exposure metrics.  
 
3. Using the final PBPK model and optimized model parameter space, 
determine which model parameters have the most influence on systemic and 
pulmonary exposures using a sensitivity analysis. 
a. Perform a sensitivity analysis to identify which model parameters elicit the 
largest fold-change in both systemic and pulmonary exposure. 
4. Compare across drugs to relate physiochemical properties to pulmonary 
absorption, sequestration, and excretion 
2.3. Selection of Final Three Drugs For Investigation  
To ensure that the sensitivity of the systemic and pulmonary exposure to model 
parameters was not an experimental artifact, as well as to increase the generalizability 
of the results from this work, the semi-PBPK modeling was performed on three drugs: 
budesonide (BUD), tobramycin (TOB), and ciprofloxacin (CIP).  
These drugs were selected based on various criteria:  
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First, these drugs were selected due to the availability of published cp(t) profiles 
(and cs(t) for TOB and CIP) after both IV and INH administration. This was necessary 
since the model development and validation step required these data sets.  
In order to allow for generalization of the conclusions from the results of this work, 
the selected compounds also varied in their underlying physical chemical properties: 
For example, the lipophilicity of the three compounds included BUD as moderately 
lipophilic compound (log(P) = 1.7), while CIP is also a lipophilic compound (log(P) = -
0.13), and TOB which is a hydrophilic compound (log(P) = -7.3).  
Furthermore, their ionizability within physiological pH range varied. BUD will be 
uncharged in the physiological pH range with a pKa = 12.9, TOB is polycationic with 
pKa’s = 6.7, 8.3, and 9.9, and CIP is likely to be zwitterionic (pKa = 6.1, and 8.7). 
However BUD, TOB, and CIP all have similar molecular weight (431, 468, and 331 
g/mole, respectively).  
Presumably due to their difference in lipophilicity and charge, BUD has a plasma 
protein binding of 80% (predominantly to albumin), TOB has negligible plasma protein 
binding, and CIP has a plasma protein binding of 20-40%.  
As a result of, these drugs vary in their clearance pathways: BUD predominantly 
undergoes hepatic metabolism, TOB is virtually exclusively cleared via renal pathways, 
and CIP is known to be subject to both renal and non-renal clearance pathways. Their 
oral bioavailability varies as well, with BUD’s Foral of ≈ 10% due to extensive hepatic 
first-pass metabolism, TOB with negligible Foral as it is too polar to cross the GI 
epithelial, and CIP has a reported Foral 70% presumably due to some first pass 
metabolism and possible GI efflux.  
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As can be seen, while there are sufficient in-vivo PK data available for these 
drugs after the dosing routes of interest, the three selected drugs are sufficiently 
different from each other such that the results from this work should be generalizable. 
2.4. PK and Semi-PBPK Models Utilized for Analysis 
Three structurally different semi-PBPK models were utilized within this work to 
simultaneously describe systemic and pulmonary. 
2.4.1. Model #1 
The first model, Model #1, includes the drug absorption organ only. Figure 1. 
depicts the movement of drug as it is administered by IV, PO, or INH routes:  
After INH, the emitted dose, which is the fraction of the dose that escapes the 
inhalation device, is obtained from deposition information, based on the metered dose 
and the fraction of the dose that remains in the inhaler (Din). The model assumes that a 
fraction of the nominal dose (as known as device dose, or total dose) is instantaneously 
deposited in the oropharynx (DtGI) where it is swallowed and available for subsequent 
absorption from the gastrointestinal (GI) tract.   
Alternatively, portions of the nominal dose are deposited into the lung (DtL). The 
DtL is fractionated into the peripheral lung compartment (Fpd), central lung compartment 
(Fcd). Lastly, a fraction of the dose is exhaled (Fex).  Drug that is deposited in the 
peripheral lung compartment is available for (a) absorption into the central compartment 
by the rate constant kpa or (b) for mucociliary clearance into the central lung 
compartment via kpm.  Similarly, drug that is either transferred (from the peripheral lung 
compartment) or originally deposited (from the device) into the central lung 
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compartment is available for (a) absorption into the central compartment by the rate 
constant kca or for (b) mucociliary clearance into the GIT compartment via kcm.   
Lastly, drug that is either cleared (from the central lung compartment) or 
deposited (from the device) into the GIT compartment is available for gastrointestinal 
absorption into the central compartment by the rate constant kga, given oral 
bioavailability (Foral).   
Drug that reaches the central compartment distributes to and redistributes from 
the peripheral body compartment via first- order rate constants k12 and k21, respectively, 
while also undergoing first order elimination from the central compartment via CLtot.   
Deposition parameters, pulmonary disposition, oral absorption, and systemic 
disposition parameters are color coded in the three figures below as: black, blue, yellow, 
and green parameters.  
 
Figure 1  Semi-PBPK Model #1 
Scheme describing pulmonary deposition, absorption, and systemic disposition 
following IV, PO, or INH administration 
 
dinhaler
dt
= −kin ∗ Dm ∗ (1 − Din) 
dPLU
dt
= kin ∗ Dm ∗ (1 − Din) ∗ Fpd − PLU ∗ (kpa + kpm) 
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dCLU
dt
= kin ∗ Dm ∗ (1 − Din) ∗ Fcd − CLU ∗ (kca + kcm) + PLU ∗ kpm 
dGI
dt
= kin ∗ Dm ∗ (1 − Din) ∗ Fgd + CLU ∗ kcm − GI ∗ kga 
dCC
dt
=  CLU ∗ kca + PLU ∗ kpa + PC ∗ k21 + GI ∗ kga ∗ Foral − CC ∗ (k21 +
CLtot
V0
) 
dPC
dt
= CC ∗ k12 − PC ∗ k21 
Equations 1 Differential equation expression for Model #1 
 
2.4.2. Model #2 
In Model #1, after IV administration of a drug, drug cannot distribute into the 
lungs from the systemic circulation (central compartment). This precludes pulmonary 
exposures after IV administration and is contrary to reported data for some drugs that 
show in-vivo pulmonary exposure after IV administration (i.e., drug concentration in 
sputum). Furthermore, after INH, it may be biologically plausible that drug that is 
absorbed into the systemic circulation is able to redistribute back to the lung, however, 
Model #1 does not allow for this.  
To address this limitation, Model #2, incorporates the lungs as absorption and 
excretion organs. Figure 2. shows Model #2, accounting for distribution from the central 
compartment into the lungs after any dosing route. This is accomplished through the 
addition of two new rate constants; kpd and kcd, which describe distribution from the 
central compartment to the peripheral and central lung compartments, respectively.   
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Figure 2 Semi-PBPK Model #2 
Scheme describing pulmonary deposition, absorption, and systemic disposition 
following IV, PO, or INH administration. 
 
 
dinhaler
dt
= −kin ∗ Dm ∗ (1 − Din) 
dPLU
dt
= kin ∗ Dm ∗ (1 − Din) ∗ Fpd + CC ∗ kpd − PLU ∗ (kpa + kpm) 
dCLU
dt
= kin ∗ Dm ∗ (1 − Din) ∗ Fcd + CLS ∗ kcd − CLU ∗ (kca + kcm) + PLU ∗ kpm 
dGI
dt
= kin ∗ Dm ∗ (1 − Din) ∗ Fgd + CLU ∗ kcm − GI ∗ kga 
dCC
dt
=  CLS ∗ kca + PLU ∗ kpa + PC ∗ k21 + GI ∗ kga ∗ Foral − CC ∗ (kcd + kpd + k21 +
CLtot
V0
) 
dPC
dt
= CC ∗ k12 − PC ∗ k21 
Equations 2 Differential equation expression for Model #2 
 
2.4.3. Model #3 
Some studies have shown that certain compounds, for example TOB, can be 
sequestered within pulmonary epithelium.24 To account for this sequestration, Model #2 
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was expanded to include two pulmonary sequestration compartments along with 
corresponding the rate constants to mimic pulmonary sequestration of drugs.  
Here the drug is an absorption, sequestration and excretion organ. This new 
model is shown in Figure 3. and will be referred to as Model #3:  
kpls1 and kcls1 allow for drug distribution from the central compartment into the 
peripheral and central lung sequestration compartments (PLS and CLS) respectively. 
Similarly, kpls2 and kcsl2 represent absorption from the PLS and CLS into the central 
compartment, respectively. The differential equations describing the intercompartmental 
movement of the drug in Model 3 are reported in Equations 3. 
 
Figure 3 Semi-PBPK Model #3 
Scheme describing pulmonary deposition, absorption, and systemic disposition 
following IV, PO, or INH administration. Plasma concentrations (systemic exposure) are 
calculated by dividing the amount of drug that is in the central compartment by the 
central compartment volume (V0).  For both TOB and CIP, sputum concentrations are 
calculated by dividing the amount of drug in the central lung unbound compartment with 
the central lung volume (CLV). CLV is set to 80% of total lung volume, which was 
obtained from literature.25  
 
dinhaler
dt
= −kin ∗ Dm ∗ (1 − Din) 
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dPLU
dt
= kin ∗ Dm ∗ (1 − Din) ∗ Fpd + PLS ∗ kpd − PLU ∗ (kpa + kpm) 
dCLU
dt
= kin ∗ Dm ∗ (1 − Din) ∗ Fcd + CLS ∗ kcd − CLU ∗ (kca + kcm) + PLU ∗ kpm 
dGI
dt
= kin ∗ Dm ∗ (1 − Din) ∗ Fgd + CLU ∗ kcm − GI ∗ kga 
dPLS
dt
= PLU ∗ kpa −  PLS ∗ (kpd + kpls2) + CC ∗ kpls1 
dCLS
dt
= CLU ∗ kca −  CLS ∗ (kcd + kcls2) + CC ∗ kcls1 
dCC
dt
=  CLS ∗ kcls2 + PLS ∗ kpls2 + PC ∗ k21 + GI ∗ kga ∗ Foral 
−CC ∗ (kcls1 + kpls1 + k21 +
CLtot
V0
) 
dPC
dt
= CC ∗ k12 − PC ∗ k21 
Equations 3 Differential equation expression for Model #3 
 
 
2.5. Model Optimization and Parameter Estimation  
2.5.1. IV NCA  
Estimation of NCA was performed on cp(t) profiles following IV, PO, and INH for 
the three drugs. The slope of the terminal phase (λ) of the cp(t) profile was estimated by 
a log-linear regression in excel using the Analysis ToolPak add-in for Excel 2016. Area 
under the curve and area under the moment curve was estimated using the trapezoidal 
rule as described by Gibaldi.26  AUCt-∞ was estimated by dividing the last measured 
concentration by λ, AUC∞ was then calculated the sum of AUC0-t and AUCt-∞. Total 
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clearance (CLtot) was estimated as the total administered dose divided by AUC∞. 
Systemic mean residence time (MRTIV) was estimated by AUMC∞ divided by AUC∞ (for 
infusion studies the calculation was modified to AUMC∞/AUC∞-Tinf/2), and then was 
used to estimate volume of distribution (Vdss) when multiplied by CLtot.  
A meta-analysis of the available data was performed to explore dose 
proportionality by investigating how AUC relates with the various tested doses after IV 
administration and after INH. 
2.5.2. PO NCA 
For PO studies, Foral was estimated using NCA by dividing the product of AUCPO 
and CLtotIV by the orally administered dose (DosePO). Mean absorption time after oral 
administration (MATpo) was calculated by subtracting the systemic mean residency time 
after IV administration (MRTIV) from the mean residency time after PO administration 
(MRTpo).  Subsequently, kga was estimated initially by taking the ratio of 1 over MATpo.  
The total clearance and systemic mean residence time utilized in estimating Foral 
and MAT, respectively, were the overall means of the HV and CF groups estimated 
using IV data sets. 
2.5.3. INH NCA 
For INH studies, bioavailability after INH (Finh) was calculated as shown in 
Equation 4 below using NCA values for AUC after both INH and IV administration and 
their respective doses. The device dose represents the nominal dose placed in the INH 
device.  
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𝐹𝑖𝑛ℎ =
𝐴𝑈𝐶0−∞
𝐼𝑁𝐻
𝐷𝑒𝑣𝑖𝑐𝑒 𝑑𝑜𝑠𝑒
𝐴𝑈𝐶0−∞
𝐼𝑉
𝐷𝑜𝑠𝑒𝐼𝑉
 
Equation 4 NCA-calculated bioavailability after INH  
After INH, drug can reach systemic circulation after absorption from either the 
lungs or from the GI tract. As such, FINH depends on (1) fraction of the dose that is orally 
bioavailable (Foral), and (2) the fraction of the dose that is bioavailable through the lungs 
(pulmonary bioavailability = Fpul). The contribution of the each of the two pathways is 
weighted by the amount of the dose that is originally deposited in that pathway: 
Specifically, the contribution of Fpul to FINH will depend on the fraction of the dose 
deposited in the lung (DtL), and the contribution of Foral to FINH will depend on the 
fraction of the dose deposited in the GI tract (DtGI). This is expressed in Equation 5.  
 
𝐹𝑖𝑛ℎ = 𝐹𝑝𝑢𝑙 ∗
𝐷𝑡𝐿
𝐷𝑡𝐿 + 𝐷𝑡𝐺𝐼
 +  𝐹𝑜𝑟𝑎𝑙 ∗
𝐷𝑡𝐺𝐼
𝐷𝑡𝐿 + 𝐷𝑡𝐺𝐼
 
Equation 5 FINH as the sum of Fpul and Foral multiplied by their relative contributions to 
Finh.  
 
Rearranging equation 5 to solve for Fpul, we derive Equation 6. Equation 6 allows 
estimation of Fpul based on FINH and Foral.  
𝐹𝑝𝑢𝑙 =
𝐹𝑖𝑛ℎ ∗ (𝐷𝑡𝐿 + 𝐷𝑡𝐺𝐼) − 𝐹𝑜𝑟𝑎𝑙 ∗ 𝐷𝑡𝐺𝐼
𝐷𝑡𝐿
  
Equation 6. Estimating pulmonary bioavailability (Fpul) after inhalation 
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In addition to this equation, there is an additional method that will be used to 
estimate Fpul when adequate systemic exposure data with sufficient plasma data is 
available after with and without administration of a charcoal block solution after drug 
INH. This method will be described in Chapter 5.  
 
2.5.4. Covariate Analysis 
For PO studies, exploratory plots of Foral, MATPO, and kga vs dose, age, body 
weight, and disease state were inspected to determine if any these covariates may 
affect these PK parameters. 
2.5.5. NCA Acceptance Criteria 
The validity of NCA performed was determined based on several criteria. Firstly, 
the log-linear regression performed to obtain lambda for the reported terminal points on 
the cp(t) profiles needed to pass a visual inspection, specifically that all points were 
evenly distributed above and below the regression line. Furthermore, the r2 of the 
regression had to be greater than 0.9. Regression results were deemed acceptable if 
the sampling schedule was long enough such that two terminal half-lives were covered.  
The extrapolated AUC could not contribute more than 30% of the AUC∞. Additional 
confidence in the results of the NCA was gained if the estimated PK parameters were 
similar to the literature reported parameter exposure metrics. Finally, cmax and tmax had 
to be captured for both PO and INH studies i.e. points on both sides of cmax.  
2.5.6. Model Fitting and Parameter Estimation  
Initial estimates for systemic disposition and oral absorption parameters were 
obtained from NCA. Pulmonary disposition parameter initial estimates were obtained 
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from similar modeling works in literature, with exception of mucociliary clearance initial 
estimates, which were obtained from in-vivo studies.27,28  
The acceptability of the model fits that were performed was also based on 
numerous acceptance criteria. Firstly, a visual inspection of the model predicted results 
relative to the reported cp(t) profile was crucial to determine if the estimate fit was 
acceptable. Additionally, the overall goodness of fit for the model was evaluated by 
checking if the r2 was greater than 0.90 and if the model selection criteria (MSC) was 
greater than 3. Lastly, confidence in the estimated values of the various model 
parameters was based on the CV of each of the parameters being less than 30% and 
the correlation between parameters being less than 0.5 and greater than -0.5 model-
estimated parameters. The results of the model fitting were also compared with PK 
parameters obtained from NCA, to confirm agreement.  
2.5.7. Monte Carlo Simulations 
MCS were performed by first specifying the number of simulations (n) the model 
should be run. Parameter variability distributions were specified, with a mean and a 
coefficient of variation.  
The results of MCS were also assessed against several acceptance criteria.  A 
visual predictive check (VPC, 5% - 95% percentiles) relative to reported cp(t) and cs(t) 
profiles was also performed. Mean (and SD when available) had to be within this VPC. 
When possible, studies were grouped together based on dose, route, population, or INH 
device.  Reported mean exposure metrics for both plasma and sputum exposure were 
compared with model-predicted exposures. Individual difference model-predicted and 
reported exposures had to be less than 50% for plasma exposure and less than 150% 
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for sputum exposure. The average of these differences across each of the individual 
data had to be not different from zero. Additionally, an informal comparison between 
model predicted exposure metric variability (SD) and reported variability (SD when 
available) was performed. Comparison of the predicted and reported variabilities was 
used for parameter variability estimation (CV’s associated with parameter estimate 
uncertainty).   
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CHAPTER 3 
 
SEMI-PBPK MODELING OF INHALED BUDESONIDE 
 
3.1. Background 
3.1.1. Pathophysiology of Asthma 
A common chronic disease that affects nearly 26 million individuals across the 
United States, asthma is a complex disease that involves airway inflammation, sporadic 
airflow obstruction, and bronchial hyperresponsiveness.29 According to the Center of 
Disease Control, asthma in the U.S is associated with over fifty-six billion dollars in 
annual expenses.  Patients may experience symptoms such as wheezing, labored 
breathing, chest tightness, coughing, and shortness of breath. Although it has not been 
clearly pinpointed as to why some patients develop asthma and others do not, both 
environmental and genetic factors have been identified as key contributing factors. In 
some patients, exposure to airborne substances, such as pollen, dust mites, mold 
spores, and pet dander have been known to trigger asthma, while in others, physical 
activity (exercise-induced asthma), strong emotions and stress have also induced 
asthma.30  Cells that respond to these triggers include (but are not limited to) mast cells, 
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T-lymphocytes, macrophages, neutrophils, and epithelial cells.31 Exposure to these 
triggers leads the patients to have 1) an inflamed/thickened airway wall, 2) tightened 
muscles leading to a constricted airway, and 3) increased mucus production. These 
three symptoms lead to a narrowed airway and hence limited air flow. It is this limited air 
flow that causes the symptoms mentioned above.  
 
3.1.2. Treatment of Asthma  
Treatment options for asthma include methylxanthines, as well as inhaled β-
adrenergic agonists, muscarinic cholinergic antagonists, and glucocorticoids.  Of these 
treatments, one of the mainstay options used by asthma patients to manage symptoms 
and slow down disease progression are the orally inhaled glucocorticoids, including 
BUD.  BUD has been shown to exhibit anti-inflammatory response in including T 
lymphocytes, eosinophils, mast cells, and dendritic cells both in-vitro and in-vivo.32,33 It 
is potent glucocorticoid, exhibiting high local pulmonary anti-inflammatory activity after 
inhalation.34 When clinically tested at a dose of 800 µg twice daily, it was shown that 
BUD reduced the acute and delayed pulmonary reactions of asthma as measured by a 
reduction in the forced expiratory volume in one minute(FEV1). 35 While it has been 
shown to be efficacious, the use of INH BUD is limited by its systemic absorption, 
leading to inhibition of the hypothalamic-pituitary-adrenal axis, increasing the risk for 
adverse reactions, e.g., stunting of bone growth in pediatric patients.35 
3.1.3. Relevant Physiochemical Properties of Budesonide 
BUD is a small lipophilic molecule with a log(P) value of 1.7 and a molar mass of 
431 g/mole.  The epimer structures of BUD are shown in Figure 4. Additionally, BUD 
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has a pKa of 12.9, which is not physiologically relevant. The aqueous solubility of BUD 
was experimentally determined to be between 19 ᛫ 10-3 and 26 ᛫ 10-3 g/L.36 At a 
concentration of 30 µM in the apical compartment of a Calu-3 cell monolayer model, the 
linear concentration-time profile allowed to determine a Papp value of 8.59 ᛫ 10-6 cm/sec, 
which indicated high permeability.37 Similar studies were also performed in Caco-2 cell 
monolayers. Permeability was estimated in both directions (A-B and B-A) with resulting 
Papp values equal to 11 ᛫ 10-6 cm/sec, and 8.7 ᛫ 10-6 cm/sec respectively.38 Based on 
the experimental Papp values both in Caco-2 and Calu-3 cell models, it can be 
concluded that BUD is a high permeability compound, crossing epithelia via 
transcellular diffusion.   
 
Figure 4 Epimer structures of BUD 
 
3.1.4. Summary of Known PK/ADME Properties of Budesonide 
With a reported plasma protein binding 88% predominantly, to albumin¸ BUD still 
exhibits extensive extravascular distribution throughout the body with a Vdss after a 10 
minute 500-µg IV infusion dose in HV of 2.2 ± 0.46 L/kg. Total clearance values (CLtot) 
are also estimated after the same dosing regiments in those subjects to be 0.86 ± 0.13 
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L/min.39 While there are 16 detectable BUD metabolites, only two metabolites account 
for the majority of the elimination.40 6β-hydroxybudesonide and 16α-hydroxyprednisoine 
are two major metabolites and were predominantly formed by the CYP3A4 enzyme.41 
There was no evidence of BUD undergoing renal elimination, which was well supported 
in literature and is likely due to its lipophilic nature. Additionally, it has been shown that 
BUD can undergo reversible fatty acid conjugation within airway tissue. 42  
When administered with via IV infusion as well as PO administration in HV, the 
calculated experimental Foral was 10.7%. In light of the high clearance value and the 
known metabolic pathways, it was noted that BUD undergoes extensive first-pass 
metabolism and as such is considered a high hepatic extraction ratio drug. After 
inhalation from a Turbuhaler ® (again with a known IV reference data set), the authors 
reported that the systemic availability of BUD was 38%. 43 
3.2. Objectives 
The major objectives of the chapter were to: 
1. Develop a semi-mechanistic PBPK model for INH BUD; 
2. Estimate and optimize model parameters (point and variability estimates); 
3. Validate the final model and parameters on plasma exposures using Monte-
Carlo simulations (MCS); 
4. Determine the sensitivity of plasma exposures to model parameters. 
3.3. Methods 
3.3.1. Summary of Identified IV, PO and INH studies 
All six identified of BUD after IV administration studies were included in the 
analysis performed. Four of the studies utilized HPLC-MS as the analytical method, 
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while the two other studies utilized HPLC-Radiometry methods. All studies were 
performed in HV and provided a total of six mean level cp(t) profiles.  
Four studies were identified in which BUD was administered orally. Of the four 
studies, two studies were not intended to characterize the oral absorption rate constant 
and hence had an insufficient sampling schedule. Additionally, one study utilized an 
inadequate analytical method for measuring plasma concentrations and hence as not 
included in the analysis. One study was included in analysis and provide a single mean 
cp(t) profile. The dose was formulated in tablet form in the included study. 
Thirteen studies were identified where BUD was INH. Of the thirteen studies, 
eight studies did not report any cp(t) profiles, and two studies did not report what device 
were utilized. Accordingly, only three studies where the dose was administered through 
a Turbuhaler were utilized in the analysis that was performed.  
 
3.3.2. Digitization and Noncompartmental PK Analysis 
NCA was performed on the digitized cp(t) profiles for each of the individual 
studies across the dosing routes (IV, PO, and INH). To assess PK dose-linearity, AUC 
vs dose and log(AUC) vs log(dose) plots were inspected. For the PO study, Foral was 
estimated using NCA by dividing the product of AUCPO and CLtotIV by the orally 
administered dose (Dpo).  
Mean absorption time after oral administration (MATpo) was calculated by 
subtracting the systemic mean residency time after IV administration (MRTIV) from the 
mean residency time after PO administration (MRTpo).  Subsequently, kga was estimated 
by taking the ratio of 1 over MATpo. These calculations were performed with CLtot and 
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MRTIV of each of the individual IV studies, a Foral and MATpo range was determined. 
NCA was not performed for INH studies.  
 
3.3.3. Semi-PBPK Models Tested 
Model #1 was used for both fit to the reported data for BUD as well as the MCS 
performed. Elimination from the central compartment was modeled using an elimination 
micro-rate constant k10. The differential equation for the central compartment (CC) was 
derived (Equation 7) and the explicit solution (Equation 8) was solved for using the 
Laplace transformation method.  
 
𝑑𝐶𝐶
𝑑𝑡
 = 𝑃𝐿 ∗ 𝑘𝑝𝑎 + 𝐶𝐿 ∗ 𝑘𝑐𝑎 + 𝐺𝐼 ∗ 𝑘𝑔𝑎 ∗ 𝐹𝑜𝑟𝑎𝑙 + 𝑃𝐶 ∗ 𝑘21 −  𝐶𝐶 ∗ (𝑘12 + 𝑘10) 
Equation 7 Differential equation for central compartment 
𝐶𝐶(𝑡) = 𝐶𝑝𝛼𝑒
(−𝛼𝑡) + 𝐶𝑝𝛽𝑒
(−𝛽𝑡) + 𝐶𝑝𝑐𝑒
(−𝑘𝑐𝑡) + 𝐶𝑝𝑝𝑒
(−𝑘𝑝𝑡) +  𝐶𝑝𝑔𝑎𝑒
(−𝑘𝑔𝑎𝑡) 
 
Equation 8 Explicit solution derived by Laplace transformation calculating central 
compartment concentration at time = t after INH 
3.3.4. Software 
The NCA will then be performed in MS Excel, modeling work was performed with 
Scientist® v3.0, and MCS will be performed with Matlab® R2015a. 
For the included studies, captured cp(t) and cs(t) profiles were digitized using the 
GetData© Graph Digitizer Version 2.24 software. NCA was performed on the plasma 
concentration data. Model parameter fitting was performed in Scientist v. 3.0.0.215 
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Build: 1334 using a stiff integrator. MCS and data visualization was performed in 
Matlab® R2015a. Since the explicit solution was derived via the Laplace transform 
method, differential equations and numerical solvers were not programmatically utilized.  
 
3.4. Results 
3.4.1. Summary of Final IV, PO, and INH Studies Identified  
A search of the literature on PubMed and Google Scholar resulted in the 
identification of 6 publications where BUD was administered as an IV infusion. These 
publications and their respective key study design elements are listed in Table 1.34,44–48 
These studies enrolled between 3 and 24 subjects and tested doses ranging from 0.1 
mg to 0.5 mg that were infused over the course of 5 to 10 minutes.  
An additional four studies were identified in which BUD was administered orally.  
These four studies including the relevant study design parameters are tabulate in Table 
2. 34,48–50The administered doses ranged from 2.0 to 4.8 mg. Only one of the five PO 
administration studies was acceptable. One study was excluded from analysis due to an 
inadequate sampling schedule that would not allow for the estimation of oral absorption 
parameters. A second study was excluded due to an insensitive analytical method that 
was used for the detection of plasma concentrations. Lastly, a study was excluded from 
analysis due to the use of an ad-hoc formulation (an aqueous solution was administered 
instead of a tablet) that showed altered cp(t) and absorption PK parameters.  
A total of 3 studies were identified where BUD was administered by INH. These 
studies and their key study design elements are listed in Table 3. 44,51,52All three studies 
were suitable for analysis as they satisfied the inclusion criteria, and provided cp(t) 
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profiles, and plasma exposure metrics. Only one device was tested in these three 
studies, and the same dose was tested in all three studies (1 mg). The Turbuhaler DPI 
was the inhalation device utilized in this study, for which the deposition data was also 
reported in literature.53  
 
Table 1 Six identified studies with key study design elements wherein BUD was 
administered by IV infusion to HV 
 
Table 2 Four identified studies with key study design elements wherein BUD was 
administered PO to HV. 
BUD 101 BUD 102 BUD 103 BUD 104 BUD 105 BUD 106
Dose (mg) 0.5 0.1 0.4 0.5 0.5 0.5
Infusion Time (min) 9 5 8 10 10 10
First/Latest Sampling 
Time Points (hrs)
0.17 → 8 0.08 → 8 0.24 → 10 0.10→ 8.22 0.14 → 8.22 0.17→10
Number of Data Points 10 10 10 10 10 10
Total Subjects (N) 24 4 16 3 15 15
Gender (Healthy) M= 12 (✓) M= 4 (✓) M= 6 (✓) M= 3 (✓) M= 7 (✓) M= 8 (✓)
Age 39 (22-53) 22-46 31 (20-44) -- 42 (26-56) 37 (27-45)
Body Weight (kg) 68 (42-92) 63-95 67 (53-94) -- 68 (49-88) 68 (50-95)
Assay HPLC - MS
HPLC - 
Radiometry
HPLC - MS
HPLC - 
Radiometry
HPLC - MS HPLC - MS
BUD 201 BUD 202 BUD 203 BUD 204
Dose (mg) 5 1 2 3
Number of Data 
Points
11 5 10 14
Sampling Time 
Scheme
0.5, 1, 1.5, 2, 3, 
4, 5, 6, 8, 12, 24
2, 3, 4, 6, 8
0.5, 1, 1.5, 2, 3, 
4, 6, 8, 10
0.33, 0.5, 0.67, 1, 
1.33, 1.67, 2, 3, 4, 
5 ,6, 8, 12
Total Subjects (N) 6 3 11 12
Gender (Healthy) M= 6 (✓) M= 3 (✓) M= 8 (✓) M= 6 (✓)
Age 46.7(43 - 56) -- 37 (27-45) 43.7 ± 7.1
Adhoc Formulation
Deuterium label 
+ lactose
Tritium label + 
micronized
micronized
10 mL Aqueous 
Solution
Assay (LOQ) LC - MS
HPLC - 
Radiometry
LC - MS LC - MS/MS
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Table 3 Three identified studies with key study design elements wherein BUD was 
administered via INH to HV.  
 
3.4.2. NCA results  
NCA was performed on the six individual data sets obtained from the included 
studies. Visual inspection for each of the log-linear regression of the terminal slope used 
in estimating λ were acceptable, R2 values were all larger than 0.9853, and the AUC 
percent extrapolated did not exceed 15% for each of the individual data sets analyzed. 
The estimated PK parameters are tabulated in Table 4. 
 
Table 4NCA estimated PK parameters for each of the individual data sets from the 
six included IV studies. 
Inspection of the AUC vs IV dose plotted on a linear scale as well as on a log-log 
plot did not provide any evidence of deviation from linear PK after IV administration. 
BUD 308 BUD 309 BUD 313
Dose (mg) 1 1 1
First and Latest Sampling 
Time Points (min) (10, 480) (15, 480) (10, 480)
Number of Plasma Samples 10 11 11
Total Subjects (n) 24 44 6
Gender (Healthy) M= 12 (✓) M= 6 (✓) M= 6 (✓)
Assay HPLC - MS
HPLC - 
MS/MS
HPLC - 
MS/MS
Inhalation Device Turbuhaler Turbuhaler Turbuhaler
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When a linear and a power model was fit to both plots respectively, the resulting R2 
value was 0.8293 and the exponential coefficient of 0.90. These plots are shown in 
Figure 5.  
 
 
Figure 5 BUD IV dose escalation plots 
IV infusion dose escalation plotting AUC with increasing IV dose on a linear plot with a 
linear regression through the estimated AUC values (left plot), and on a log-log plot with 
a power model fit to the estimated AUC values (right plot).  
 
The same analysis could not be performed with the available data after PO 
administration as there was only a single study included in the analysis. 
NCA was performed on the single PO data set available. Visual inspection for the 
log-linear regression of the terminal slope used in estimating λ was acceptable, the R2 
value was 0.9990, and the AUC percent extrapolated was 1.2%. The estimated Foral 
ranged from 8.7% to 13.5% and the estimated kga ranged from 0.0047 to 0.0088 min-1. 
The observed and estimated PK parameters are tabulated in Table 5.  
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Table 5 NCA estimated PK parameters for the available data set from the included 
PO study. 
 
3.4.3. Modeling of IV Data 
Successful fits were obtained for each of the 6 data sets from the seven studies. 
No weighting factor was applied to any of the fits. MSC was higher than 3.6, R2 values 
were above 0.9950 for all the selected fits, correlation matrix values were all below 0.5, 
coefficients of variation for each of the parameter estimates were below 30%, and visual 
inspection of the observed versus simulated values were all acceptable. Table 6 shows 
the resulting parameter values based on the fits produced by the individual data sets. 
The model file for the various fits are reported in the Appendix 1 as Code 1 of this 
chapter. 
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Table 6 IV BUD two compartment body model results 
Two compartment model parameter estimates and goodness of fit validation criteria 
results for each of the twelve data sets obtained from the final seven included IV 
studies.  
 
MCS resulted in an acceptable parameter space that described observed cp(t) 
profiles and exposure metrics after IV administration. The four systemic disposition 
parameters were optimized and the optimized central tendency (mean) and a variation 
(CV) as shown in Table 7. V0 followed a normal distribution with a 20% CV, while the 
three micro-rate constants followed a log-normal distribution with a 20% CV.  
 
 
Table 7 Final optimized systemic disposition model parameters point and 
variability estimates. 
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Table 8 shows the percent difference for predicted vs observed exposure metrics 
for each of the individual studies. The predicted AUC values did not exceed 30% of the 
reported values for each of the studies. Additionally, the calculated PK parameters were 
also within 50% of the reported values. VPC for studies BUD 101, 104, 105, and106 are 
grouped in Figure 6 since these studies all utilized a dose of 0.5 mg infused over 10 
minutes. VPC for BUD 102 and BUD 103 are shown in Figures 7 and 8, respectively. 
 
 
Table 8 Percent difference between reported and predicted values for AUC, t ½β, 
MRTIV, and CLtot. 
 
 
Figure 6 MCS-predicted versus observed cp(t) after IV dosing for BUD studies 
101, 104, 105, and 106. 
Study 101 102 103 104 105 106 Mean SD
AUC∞ 29% 16% 25% 7.9% 5.4% 12% 16% 9
t½
β 40% 6% 11% 21% 31% 30% 23% 12
MRTIV 37% 1.2% 5.4% 24% 21% 14% 17% 12
CLtot 14% 32% 11% 2.6% 18% 25% 17% 10
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Figure 7 MCS-predicted versus observed cp(t) after IV dosing for BUD 102 
 
 
Figure 8 MCS-predicted versus observed cp(t) after IV dosing for BUD 103 
 
3.4.4. Modeling of PO Data 
MCS resulted in an acceptable parameter space that described observed cp(t) 
profile and exposure metrics after PO administration. The two oral absorption 
parameters were optimized and the optimized central tendency (mean) and a variation 
(CV) as shown in Table 9. Parameter variation was 40%, which was twice the variation 
associated with the systemic disposition parameters.  
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Table 9 Final optimized oral absorption model parameters point and variability 
estimates. 
 
Table 10 indicates the percent difference for each of the predicted exposure 
metrics; namely, AUC, cmax, tmax, and MRTpo. The predicted AUC value was 3.7% 
different than the reported in the study. Additionally, the remaining exposure metrics 
were also within 50% of the reported values. VPC for the reported cp(t) profile is shown 
in Figure 9. 
 
Table 10 Percent difference between reported and simulated values for AUC, cmax, 
tmax, and MRTPO 
 
 
Figure 9 MCS-predicted versus observed cp(t) after PO dosing for BUD 201 
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3.4.5. Modeling of INH Data 
MCS resulted in an acceptable parameter space that described the observed 
cp(t) profiles and corresponding exposure metrics after INH administration. Published 
scintigraphy results indicated that 27.9% of the device dose is delivered to the lungs. 
Parameter optimization resulted in approximately a 3:1 deposition ration favoring the 
peripheral lung compartment. The fraction of the drug exhaled was less than 1%, and 
the fraction of the dose that remained in the inhaler was 14%. As such, the remaining 
57% of the dose was deposited into the GI compartment. The variation for these 
deposition parameters followed a log-normal distribution and ranged from 9% to 57% as 
reported in literature. A summary of the central tendencies of these parameters along 
with their associated variabilities is reported in Table 11. 
Both optimized mucociliary clearance values were below the literature estimates 
that were used for initial estimates. The resulting values of kcm and kpm were 0.016 and 
0.0078 min-1 respectively. The optimized value for kpa was twice that of kca; 0.066 and 
0.033 min-1 respectively. The variation associated with these four pulmonary disposition 
parameters was 30%. These parameters along with their associated variabilities are 
also reported in Table 11. 
   
 
 
37 
 
 
Table 11 Final optimized pulmonary deposition and pulmonary disposition model 
parameters point and variability estimates. 
Deposition data obtained from pharmacoscintigraphy studies and final optimized 
pulmonary disposition model parameters point and variability estimates. Deposition 
parameters are experimental values, while pulmonary disposition was optimized using 
the semi-PBPK model. 
 
Since the three INH studies analyzed all utilized the same device, the MCS were 
grouped and the VI plot is shown on both a linear and a logarithmic scale in Figure 10. 
The model slightly underpredicted the reported cp(t) profiles; however, all the observed 
concentrations were within the 5-95th percentiles. This slight underprediction is also 
observed in the under prediction of AUC as reported in Table 12. The difference 
between the predicted and reported AUC was below 30% for the three studies, and the 
difference between the predicted and the remaining exposure metrics reported in Table 
12 did not exceed 50%.  
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 Table 12 Percent difference between reported and simulated values for AUC, 
cmax, tmax, and MRTINH 
 
 
Figure 10 MCS-predicted versus observed cp(t) after INH dosing for BUD 308, 309, 
and 313 
 
3.4.6. Parameter Sensitivity Analysis Results  
Sensitivity analysis results were generated for all model parameters (including 
the device deposition parameters) and are tabulated in Table 13.  
AUC and cmax were most sensitive to V0 with a 25-fold change in V0 directly 
resulting in a 25-fold change in both AUC and cmax. k10 was the second most influential 
model parameter on AUC, while Fpd was most influential on cmax, as expected. The top 
three most influential parameters are tabulated in Table 14. Predicted cp(t) profile after 
Study 101 102 103 Mean SD
AUC∞ -18% -5% -22% -15.0% 7.26
cmax 4% -11% 10% 0.9% 8.80
tmax 32% 8.7% 32.0% 24.2% 10.98
MRTINH -26% -15% -4% -15.0% 8.98
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the 25-fold change in Fpd and kpa is shown in Figure 11, and those for Fcd and kca in 
Figure 12. 
 
Table 13 Sensitivity analysis results after INH of a single 2323 nmol dose. 
 
Table 14 Top three most influential parameters for each of the evaluated exposure 
metrics and PK parameters 
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Figure 11 Resulting cp(t) profile from a 25-fold change in Fpd (left plot) and kpa 
(right plot) after INH of 2323 nmol dose. 
 
 
Figure 12 Resulting cp(t) profile from a 25-fold change in Fcd (left plot) and kca 
(right plot) after INH of 2323 nmole dose. 
 
3.5. Discussion and Conclusions 
3.5.1. Study Limitations 
Given that BUD was developed a while ago, and the majority of the clinical 
investigations were performed in the early 1960’s and 1970’s, there was only limited 
availability of data and poor the reliability of some of the analytical methods that were 
experimentally used: For the IV studies, BUD given as IV infusion. IV infusion data 
leads to greater uncertainty in estimating distribution and redistribution rate constants 
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(k12 and k21) in the two-compartment open body model. This is because as those two 
processes are occurring, the drug is also being infused. As such, it is difficult to 
accurately determine these parameters unless very frequent plasma samples are 
collected during both the dosing and distribution phase is. IV bolus studies with frequent 
early sample collection is considered optimal for determining those two parameters.   
Furthermore, no sputum samples were available after any of the dosing routes. 
The availability of such data would have allowed for more confidence in the pulmonary 
disposition parameters. Additionally, there was no repeated dosing studies available for 
IV, PO, or INH. These studies would have been useful in studying drug accumulation in 
the various compartments as well as time dependence. We were also unable to obtain 
any data for the pediatric population. This is notable since they may often be the 
targeted population for this treatment. The lack of access to patient level data (both 
plasma and sputum) limited the ability to study the possible effects of covariate on both 
plasma and sputum exposure. 
Lastly, the INH data available was produced from the same device across the 
four studies. Additional data for various devices including pressurized inhalers and 
nebulizers would have been useful in studying the effect of device of plasma and 
sputum exposure. 
 
3.5.2. PK Dose-Proportionality 
The dose dependence plots after IV infusion shown in Figures 5 support linear 
PK based on the high r2 value for the linear model. Additionally, when the same data 
were plotted on a log-log scale (shown in the same figure), and a power model was 
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utilized for fitting the data, the coefficient of the exponential coefficient is close to 1.0 
which also indicates linear PK. This finding is in agreement with the literature as several 
authors have also reported that BUD experience’s linear PK across a similar dose 
range.18 These pieces of evidence provided a strong basis for the major modeling 
assumption, namely that all rate constants were first-order rate constants. 
 
3.5.3. Final Parameter Space after IV Administration 
An empiric open body two compartment model of BUD with an optimized model 
parameter space resulted in mechanistically plausible parameter estimates and was 
able to adequately predict the reported cp(t) profiles from six clinical PK studies with HV 
after single IV doses.  
Model-optimized values indicated that are consistent with that BUD undergoes 
high hepatic clearance as its clearance value (k10*V0= 1170 ml/min) approaches hepatic 
blood flow (1200 ml/min). This results in a short β-half-life (t½k10 = 27 min). The 
peripheral tissue compartment is a shallow compartment (
𝑘10
𝑘12
= 0.26) with intermediate 
capacity (
𝑘21
𝑘12
= 1.2). The model indicated that BUD is widely distributed throughout the 
body with a Vdss of 190 L. This is likely due to its lipophilicity as mentioned in the 
introduction of this chapter. All systemic disposition parameter point estimates are 
consistent with published values.  
 
3.5.4. Final Parameter Space after PO Administration 
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The final optimized oral absorption model and parameters for BUD suggest that 
BU has a low Foral of 10% that is due to extensive hepatic first pass metabolism. 
Additionally, its oral absorption was noted to be slow with an oral absorption half-life of 
95 minutes. As such, BUD may experience “flip-flop” PK in, ie, the rate constant of 
absorption (kga) maybe slower than the rate constant of elimination of BUD (k10).  
Some authors have already demonstrated that this slow absorption rate is due to 
the absorption of BUD throughout the entire GI tract, and therefore the absorption rate 
may be affected by GI motility.10 
 
3.5.5. Final INH Model 
The final INH model incorporated the two-compartment systemic disposition 
model, the oral absorption model, and two pulmonary compartments. This is Model #1 
as described in chapter two. The selection of this model was based on the lack 
availability of sputum data, specifically, after IV administration. The model allowed for 
(unidirectional) absorption from the lungs (central and peripheral) to the central 
compartment through kpa and kca, however, the model did not allow redistribution from 
the central compartment back to the lungs due to the absence of any evidence. 
Mucociliary clearance was possible from both the peripheral and the central lung into 
the central lung and the GI tract compartments, respectively.  
The explicit solution for each of the five compartments in the model were derived. 
This solution for the central compartment indicated that the four hybrid rate constants 
are calculated from model micro rate constants. Five intercepts incorporate dose, 
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deposition fractions and ratios of rate constants and had a sum of zero (i.e., some are 
negative). 
3.5.6. Final Parameter Space after Inhalation 
The final parameter set (listed in Table 15) that was optimized using the available 
inhalation data, was able to adequately describe the available cp(t) profiles as well as 
the exposure metric. The final, optimized PBPK model parameters (point estimates) 
indicate a small fraction exhaled from Turbuhaler (Fex = 0.9%) as well as 3-1 relative 
peripheral-to-central pulmonary deposition (Fpd = 21% vs. Fcd = 7%) with an absorption 
t½ of 11 min for kpa and 21 min for kca, preferential absorption from peripheral vs central 
compartment, respectively.  Model optimization during MCS required addition of 
parameter variability, ranging from to 9% to 57% (CV), primarily in pulmonary deposition 
parameters.  Furthermore, mucociliary clearance from the central lung was twice as fast 
as from the peripheral lung. However, due to the lack of sputum data, the ability to 
accurately resolve these parameters was limited.  
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Table 15 Final (optimized) model parameters, point and variability estimates 
 
3.5.7. Sensitivity Analysis  
The sensitivity analysis indicated that AUC depends primarily on V0, k10, and Fpd; 
cmax on V0, Fpd, and k12; tmax on kpa, k12, and k21; and MRT on k10, k12, and k21. While the 
results of the sensitivity analysis allowed for a numerical comparison between each of 
the model parameters on the various exposure metrics, there appeared to be an 
apparent overarching theme. After inhalation, the model appears to be most sensitive to 
the systemic disposition parameters and least sensitive to the oral absorption 
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parameters within the BUD model parameter space. None of the pulmonary disposition 
parameters were found to be important for plasma exposure.  
3.5.8. Overall Conclusions 
The final semi-PBPK model incorporated published in-vitro and in-vivo 
information and established a model parameter space for BUD that gave acceptable 
predictions and mechanistically plausible parameter estimates.  Pulmonary absorption 
parameters (kpa and kca) were the most uncertain estimates.  Most of the model 
parameter variability was associated with pulmonary deposition parameters.  Overall, 
plasma exposure metrics for BUD after inhalation are more sensitive to differences in 
systemic disposition rather than pulmonary deposition/absorption or GI absorption.  
 
 
 
  
 
 
47 
 
 
 
 
 
 
CHAPTER 4 
 
SEMI-PBPK MODELING OF INHALED TOBRAMYCIN 
 
4.1. Background 
4.1.1. Background on Cystic Fibrosis demographics, pathophysiology, effects on 
pulmonary functioning 
Cystic Fibrosis (CF) diagnoses are increasing at a rate of 1000 new cases per 
year and over 70,000 reported worldwide which are caused by mutations in the Cystic 
Fibrosis Transmembrane Regulator (CFTR) gene.54  While there are over 400 reported 
gene mutations that cause the disease in these patients, pulmonary (PUL) infections 
leading to exacerbation of the disease symptoms have been reported as the leading 
cause of death in CF patients and the leading cause for a shortened average life span 
of only 37 years.54,55 Irrespective of the patient’s disease severity classification, the 
most common pulmonary infection that leads to exacerbations is Pseudomonas 
aeruginosa, which is a gram-negative bacteria infection.56  This gram-negative infection 
occurs because the mutated CFTR gene leads to the accumulation of chloride ions 
within the cell, which results in the accumulation of sodium ions. Therefore, water 
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content increases intracellularly and decreases extracellularly.57 The decreased 
extracellular concentration of water leads to a thickening of the mucus in the intestine 
(leading to malnutrition), and in the lungs, resulting in the aforementioned potentially 
fatal infection.54  Patients are spending annually on average $29,000 for hospitalization 
related costs, and an additional $20,000 on prescription medication for treatment.55 
Despite this spending, patient prognosis is still relatively bleak, with 30% of children and 
47% of adults being hospitalized at least once for exacerbations of lung infections 
reported in 2007.56 As a result of these incidents, most pharmaceutical treatments thus 
far, have been aimed at symptom relief and treatment of these lung infections to prevent 
the aforementioned fatal pulmonary infections. 57 
 
4.1.2. Treatments, IV and INH, MOA, efficacy/toxicity  
Antibiotics, steroids, bronchodilators, inhaled hypertonic saline solution, oxygen 
therapy, mucolytic agents (Dornase Alfa), and lung transplants (for patients in which the 
disease is more advanced), are the current treatment options for CF pulmonary 
exacerbations, with administration of antibiotics being the most widely used method.54 
According to the Cystic Fibrosis Foundation, some of the current classes of antibiotics 
that are clinically used include: penicillins, cephalosporins, aminoglycosides (AGs), 
macrolides, tetracyclines, quinolones, and aztreonam.58   
While their exact mechanism of action is not fully understood, AGs are known to 
prevent sensitive bacteria from synthesizing proteins vital for growth, by disrupting the 
ribosomal mRNA reading process.  AGs are also responsible for creating fissures in the 
outer membranes of bacterial cells.  Given this dual mechanism of action, AGs are 
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considered to be potent antibiotics that exhibit strong bactericidal activity against 
aerobic gram-negative and certain gram-positive bacteria.59  
Due to their strong bactericidal effects against gram-negative bacteria, AGs are 
often used for lung infections in CF.  Patients often require several courses of IV 
antibiotics per year to combat these infections.  Typically, these treatments require that 
a certain concentration be achieved such that concentration-dependent killing of 
bacterial cells can be accomplished. As a consequence of antibiotic use, the survival of 
patients with CF has improved, but the side effects of treatments have become 
increasingly important. A number of studies have extensively discussed the systemic 
toxicity of AGs (namely ototoxicity and nephrotoxicity).12,60,61  AGs can accumulate in 
the proximal tubule epithelial cells (either in the cytoplasm or in the endoplasmic 
reticulum) within the kidney where they can activate the intrinsic pathways leading to 
apoptosis. 62 The apoptotic cascade can also be initiated within the hair cells of the 
inner ear by free radicals (specifically oxygen and nitrogen free radical species) which 
have been documented to lead to permanent hearing loss, i.e. ototoxicity. 63 
It has also been reported that IV administered AGs have poor penetration into 
the lung, reaching mean peak sputum concentrations that are only 12% to 20% of the 
peak serum concentrations.  Hence there is a desire to shift from IV administration to 
inhalation (INH) as this is likely to increase the pulmonary local concentrations while 
minimizing systemic exposures.64–66 While most of the aforementioned classes of 
antibiotics have IV dosage forms, few have oral (PO) dosage forms, and even fewer 
have orally inhaled dosage forms. Only AGs (tobramycin (TOB), gentamycin (GEN), 
and amikacin), Quinolones (ciprofloxacin, and levofloxacin), and aztreonam are 
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available for both IV and INH administration.58 Among the AGs, TOB has been reported 
to be the most active against isolated Pseudomonas aeruginosa with an MIC50 of 
1µg/ml and a MIC90 of 8µg/ml.67  In addition to its efficacy against Pseudomonas 
aeruginosa, it was one of the earliest antibiotics (of those available for inhalation) 
introduced for clinical use. Accordingly, TOB has the most available data sets across 
the literature.  
 
4.1.3. Relevant TOB-Specific Physiochemical Properties  
Tobramycin is a low molecular weight compound with a molar mass of 468 
grams per mole and a chemical formula of C18H37N5O9. Based on its chemical structure 
depicted in Figure 13 below, it has an experimentally determined partition-coefficient 
log(P) value of -7.3, indicating that it is a hydrophilic compound that is very soluble in 
water(according to the USP definition) with a solubility of 1000 mg/ml.68,69  Accordingly, 
it has been shown to have low permeability across Caco-2 cell models with an apparent 
permeability of Papp = 1.78 ᛫ 10-6 cm/sec, at a tested concentration of 5 mg/ml.70 
Additionally, at a tested concentration of 100 µM, only 32% of the initial concentration 
was detected in the basolateral compartment, hence a Papp could not be calculated for a 
Calu-3 cell model, but was assumed to be low.68 Caco-2 and Calu-3 cell models are 
used to gauge permeability in the GI tract and lungs, respectively.  This is likely due to 
both its hydrophilic structure, as well as its likely polycationic charge within the 
physiological pH range. TOB is known to be stable at a pH range from 1-11 at 
temperatures ranging from 5 to 37°C.71 
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Figure 13 Chemical Structure of TOB 
 
4.1.4. Summary of ADME of TOB, IV and INH 
While TOB has not been identified as a substrate for any major metabolic 
pathways in mice after IV administration, its oral bioavailability has been reported as 
negligible, primarily due to this low GI permeability, and not due to a first-pass effect.14  
Due to its hydrophilic nature, TOB is primarily eliminated by the kidneys by glomerular 
filtration, with 60% of the dose showing up unchanged in urine within 6 hours, and by 24 
hours 85% has been recovered in urine.72 Some authors have suggested that up to 
10% of the IV administered dose could be eliminated via extrarenal mechanism such as 
elimination in the lung or elimination via other non-renal pathways.73  Another plausible 
explanation for the remaining 15% that is not recovered in urine at the 24-hour sampling 
time point, is that the drug may still be distributed in tissues throughout the body.  
It is known that TOB has negligible plasma protein binding, with a reported 
binding that is not statistically different from zero when tested under controlled 
conditions of physiological pH, and temperature, by means of an ultrafiltration method in 
human serum.74  When a dose of 60mg/m2 was administered IV in CF patients, the 
authors reported a volume of distribution of 0.30 ± 0.5 L/kg, and a CLtot value of 4.9 ± 
 
 
52 
 
2.1 L/h/1.73m2.  Similarly, in HV with a similar dose of 55 mg/m2, the reported values 
were 0.23 ± 0.07 L/kg and 6.12 ± 1.17 L/h/1.73m2, respectively.75 After 6 CF patients 
received a 600mg dose via an ultrasonic nebulizer, the estimated apparent volume 
(Vdss/Foral) was higher than that after IV dosing at 1.74 ± 0.96 L/kg and the apparent 
clearance (CLtot/Foral)  values were reported to be 6.98 ± 2.89 L/h.76  
PK parameter estimation has been noted to suffer from larger standard 
deviations, as there are numerous sources or variability that are difficult to regulate 
including but not limited to: device efficiency, inhalation maneuver technique, and lung 
function of study subjects.  
 
4.1.5. Summary of Literature Effect of CF on ADME, Focus on TOB 
Gastrointestinal absorption of TOB is known to be negligible due to its 
aforementioned hydrophilic nature, hence, there is unlikely to be detectable difference in 
GI absorption between HV and CF patients.57   
Pulmonary absorption on the other hand has been noted as highly variable; thus 
while there may exist a difference in pulmonary absorption between HV and CF 
patients, there has not been conclusive evidence of this presented in the literature.76 
However, compared to healthy volunteers, CF patients have been documented to 
have higher volumes of distribution and higher CLtot.77Some authors have noted that the 
higher volumes of distribution in CF patients is secondary to their state of malnutrition 
and reduced levels of adipose tissue. The decrease in adipose tissue leads to a higher 
percentage of lean body mass, potentially explaining the larger Vd.78,79  CF patients 
have also been noted to suffer from hypoxemia (low concentration of oxygen in blood) 
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which leads to erythrocytosis (increase in red blood cells). The increase in red blood 
cells ultimately leads to an increase in blood volume which may be the cause for the 
increased volume of distribution for TOB.80 
Some investigators have theorized that the increase in CLtot in CF patients is due 
to their enlarged kidneys, which leads to glomerulomegaly (abnormal enlargement of 
glomeruli) which causes hyperfiltration. This hyperfiltration results in an increase in 
glomerular filtration rate and an increased urine flow, thereby increasing the renal 
clearance of TOB.77,81  Others, however, have speculated that in an effort to 
compensate for the CFTR defect, tubular cells have higher activity of other types of 
cellular membrane channels or increased paracellular diffusion.64  Both of these 
phenomena would result in higher CLtot of TOB. Finally, the contribution of clearance 
from the lung has also been noted as a possible explanation for the increased total 
clearance in CF patients, as they are known to have increased sputum production.82 
 
4.2. Objectives 
1) Collect available cp(t) and cs(t) and exposure metrics for TOB after IV, and 
INH administration to HV and CF patients in addition to all relevant dosing 
information such as dose, infusion time, fraction of the dose left in the inhaler, 
and the dose deposited into lung.  
2) Develop a structural semi-PBPK model with a nested covariate model(s) to 
describe sputum and plasma concentrations of TOB, after IV administration 
and INH in both HV and CF patients. 
 
 
54 
 
3) Validate the model developed for specific aim 3.3.2 with the collected data 
from aim. 
4) Assess the sensitivity sputum and plasma exposure to each of model 
parameters. 
5) Assess pulmonary bioavailability (Fpul) after INH administration of TOB. 
 
4.3. Methods 
4.3.1. PK Data collection 
A systematic review of literature to identify studies where TOB was administered 
IV or was INH. Studies were included if: (1) study population size and covariates (body 
weight and disease state) were clearly identified, (2) either individual or mean level 
plasma concentration time (cp(t)) profile or PK exposure metrics were reported, (3) the 
analytical method was deemed to be reliable (specifically, that the observed cp are 
larger than Lower Limit of Quantification (LLOQ)), and (4) the sampling schedule was 
appropriate to capture drug disposition. Optimal studies will also have reported data 
regarding sputum concentrations at known time points (cs(t)) or sputum exposure 
metrics, however this was not necessary for the incorporation of a study into the 
analysis. When available, the central tendency and its dispersion or variability of any 
reported exposure metrics were also collected. Additionally, for INH studies, 
scintigraphy data describing the percentage of the dose that was placed in the 
inhalation device that ultimately reached the lungs (Dose to Lung or DtL) was also 
sought after from the identified studies for the tested inhalation devices or from 
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references studies that provided this information for the devices of interest. This data 
collection would directly satisfy specific aim 3.3.1  
4.3.2. Digitization and Non-compartmental PK analysis  
For the included studies, captured cp(t) and cs(t) profiles were digitized using the 
GetData© Graph Digitizer Version 2.24 software. A non-compartmental analysis (NCA) 
was performed on the plasma concentration data.  
 
4.3.3. SEMI-PBPK Models Tested (Models 1 – 3) 
The three semi-PBPK models schematically depicted in chapter 2 (Figure 1 - 
Model 1, Figures 2 - Model 2, and Figures 3 - Model 3) were tested to determine which 
model best described the collected data from the IV and INH studies sequentially. As 
depicted below, model 1 assumes (1) that equilibration of TOB within a given 
compartment is much faster than equilibration between compartments, (2) linear PK (all 
rate constants describe non-saturable non-inducible first order processes), and (3) that 
drug elimination only occurs through the central compartment. Model 1 was utilized to 
determine the systemic disposition parameters by fitting model parameters to the four IV 
data sets (from three studies) that did not contain sputum data. A single repeated 
dosing IV study was identified that contained sputum data that was utilized for obtaining 
model parameter estimates. Due to the presence of detectable sputum levels after IV 
administration, Model 1 could not be utilized for further investigation, as it did not allow 
for the distribution of TOB from the central compartment to the pulmonary 
compartments. While the introduction of the distribution pathway from the central 
compartment to the pulmonary compartments in Models 2 and 3 allows the models to 
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describe sputum levels after IV administration, it violates the third assumption listed 
above in that the drug is administered systemically, can now be eliminated through the 
GI tract after distribution to the pulmonary compartments in addition to clearance 
through the central compartment. These distribution pathways however, allow for the 
simulation of sputum concentrations after IV dosing which satisfies the model 
requirements listed in specific aim 3.3.2.  
With the systemic disposition parameters fixed (as the average of the four 
individual fits generated with model 1), an attempt was made to fit pulmonary disposition 
parameters from model 2 and model 3 using Scientist 3.0 utilizing both the method of 
least-squares as well as simplex fit, to the IV data set that included both plasma and 
sputum values. The software however was unable to converge on values for the six or 
ten parameters that were to be estimated from model 2 and model 3 respectively. To 
minimize the number of parameters that needed to coverage while satisfying the least 
square optimization algorithm, mucociliary clearance (kpm, and kcm) values were fixed to 
values estimated from a previous work, and a second attempt to estimate the remaining 
four or eight parameters from model 2 and 3 respectively. Although various initial 
estimates for the model parameters were tested, this approach did not lead to the 
software converging on a parameter set. Since the standard least square optimization 
algorithms technique did not lead to a final parameter space, the Monte Carlo 
Simulation approach described below was utilized to obtain the final parameter 
estimates.   
In model 3, TOB was dosed into the central compartment (CC) of a two-
compartment open body model with volume of distribution V0, distribution and 
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redistribution rate constants k12 and k21, and total clearance CLtot. Both V0 and CLtot 
were dependent on body weight power covariate models that were centered around the 
population body weight for either healthy or CF patients as shown in Equation 9 and 10.  
The lung was modeled with four compartments: (1) peripheral lung unbound (PLU), (2) 
peripheral lung sequestered (PLS), (3) central lung unbound (CLU), and (4) central lung 
sequestered (CLS). The CC distributes drug to both PLS and CLS via kpls1 and kcls1 and 
the drug redistributes back to CC via kpls2 and kcls2 respectively. PLS and CLS are also 
each connected to PLU and CLU via distribution (kpa and kca) and redistribution rate 
constants (kpd, and kcd). The PLU connects to the CLU via mucociliary clearance (kpm), 
and CLU is connected to the GI compartment via mucociliary clearance/swallowing 
(kcm).  CLU and PLU were characterized with a total lung volume (TLV) which followed 
the covariate model expressed in Equation 11.  
 
𝑪𝑳𝒕𝒐𝒕
𝒊 =  𝑪𝑳𝒑𝒐𝒑 ∗ (
𝑩𝑾𝒊
𝑩𝑾𝒑𝒐𝒑
)
𝟎.𝟕𝟓
∗ 𝜺𝒊
𝑪𝒍𝒕𝒐𝒕 
Equation 9 Total clearance covariate model for the ith patient. 
 
𝑽𝟎
𝒊 =  𝑽𝟎𝒑𝒐𝒑 ∗ (
𝑩𝑾𝒊
𝑩𝑾𝒑𝒐𝒑
) ∗ 𝜺𝒊
𝑽𝟎 
Equation 10. Volume of the central compartment covariate model for the ith patient. 
 
𝑻𝑳𝑽𝒊 =  𝑻𝑳𝑽𝒑𝒐𝒑 ∗ (
𝑩𝑾𝒊
𝑩𝑾𝒑𝒐𝒑
) ∗ 𝜺𝒊
𝑻𝑳𝑽 
Equation 11. Total volume of the lung covariate model for the ith patient. 
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4.3.4. Monte Carlo Simulation MATCHING/ACCEPTABILITY criteria 
Monte-Carlo simulations (MCS) were then performed with model 2 and model 3 
to determine if there existed an optimal parameter space to describe all the collected IV 
data (both plasma and sputum). Parameter point and variability estimates were 
optimized using the MCS simulation by simultaneously (1) attempting to minimize the 
sum of the residual error for both plasma and sputum concentrations, (2) performing a 
visual predictive check (VPC, 5% - 95% percentiles) relative to reported cp(t) and cs(t) 
profiles, and (3) matching model-predicted with observed (mean) cp(t) profiles and 
exposure metrics.  For the final IV parameter space to be accepted, the percent 
difference between the observed plasma and sputum exposure metrics and the 
simulated exposure metrics had to be less than ±40% for IV. Due to the increased level 
of variability associated with INH, the plasma exposure metrics had to be less than 
±45% for AUC and 75% for cmax, and the sputum exposure metrics had to be less then 
±120% for both AUC and cmax. The MCS were performed using log-normal distributions 
for each parameter, and initial estimates for parameter optimization were obtained from 
a previous study modeling BUD in HV administered via IV, PO, and oral inhalation.83 
The number of subjects to simulate (n) for the MCS was determined by comparing 
various simulations, and selecting the lowest n (to minimize computational time) while 
ensuring the observed variability did not appear to be minimized due to a lower value of 
n. This MCS approach served as the validation step required to address specific aim 
3.3.3. MCS were performed in Rstudio Version 1.0.136 with the deSOLVE package 
add-in.  
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An attempt was made to utilize model 3 and the final optimized parameters from 
the IV data sets to predict cp(t) and cs(t) from INH studies (approach #1). Additionally, 
we attempted to identify a universal parameter space that was capable of describing 
both the IV and INH data sets by re-optimizing the parameters to both the IV and INH 
data sets simultaneously (approach #2). Given that there was no identifiable parameter 
space that was capable of describing all the available IV and INH data sets 
simultaneously, the parameter optimization was then preformed solely on the available 
INH data sets. Optimization was performed by attempting to minimize the sum of the 
residual error for both plasma and sputum concentrations by preforming a visual 
predictive check (VPC, 5% - 95% percentiles) relative to reported cp(t) and cs(t) profiles, 
and match model-predicted with observed (mean) cp(t) profiles and exposure metrics for 
a single inhalation study. The optimized parameters were then utilized to predict the 
reported cp(t) and cs(t) as well as the exposure metrics of the three-remaining studies. 
To be acceptable, predictions were to be within the aforementioned VPC criteria and not 
show any systematic bias of over-prediction or under-prediction (approach #3). Next, 
parameter optimization was performed using only the data sets from each of the four 
INH studies where the Pari nebulizer was used as the inhalation device. Parameter 
estimates were deemed acceptable once the predicted plasma exposure metrics were 
within 40% of the reported exposure metrics for the four data sets. Once the parameter 
space was identified, predictions of the remaining inhalation data sets (where other 
inhalation devices were utilized) were generated and evaluated for a systematic bias 
relative to the reported exposure metrics in addition to the evaluation of the VPC 
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(approach #4).   Lastly, the sixteen sets of data including the all available cp(t) profiles, 
cs(t) profiles, plasma exposure metrics, and sputum exposure metrics from the four 
selected inhalation studies were all simultaneously utilized for validation. In this fifth 
approach, results were checked to ensure that there was no consistent over or 
underprediction (bias) for any of the sub-group of data (HV vs CF, a specific inhalation 
device, a given dose, or a specific study).  
4.3.5. Sensitivity analysis 
As an indicator of how sensitive plasma and sputum levels are to the model 
parameters, a sensitivity analysis was performed with the final parameter estimates for 
both the IV and INH parameters for model 3. Variability across the parameters was 
disabled by setting all the CV’s to zero, parameter values were set to either one-fifth or 
five times the mean optimized value, and simulations were performed to the 24-hour 
timepoint. AUC and cmax values in plasma and sputum were calculated at each of the 
extremes. The fold change was calculated as the ratio between the maximum and 
minimum values of the simulated plasma AUC multiplied by a negative one if the 
maximum value was obtained from when the parameter being tested was multiplied by 
1/5. This was also calculated for plasma cmax, as well as sputum AUC and cmax. Both 
cp(t), and cs(t) profiles were generated for comparison. The top three parameters to 
cause the largest fold change in the four exposure metrics were determined at the end 
of the sensitivity analysis. This sensitivity analysis would then allow for a better 
understanding as to how to increase sputum concentrations or how to minimize 
systemic exposure as well as specifically address specific aim 3.3.4.  
4.3.6. Mass balance and overall excretion simulations 
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The cumulative drug eliminated via each pathway (CLtot, and kcm (given that TOB 
has no oral bioavailability)) was investigated after IV administration and after INH. 
These mass balance excretion simulations were performed to t= 4 days with a 
resolution of 1 hour. Additionally, Finh (fraction of the drug that shows up in systemic 
circulation after inhalation) will be calculated for each of the inhalation studies using the 
reported dose and AUC as well as the reported dose and AUC from IV study TOB 
103A. This was performed to aid in estimating pulmonary bioavailability and to address 
specific aim 3.3.5. 
4.4. Results 
4.4.1. Summary and Discussion of final IV and INH studies identified  
A search of the literature on PubMed and Google Scholar resulted in the 
identification of 8 publications where TOB was administered as an IV infusion. These 
publications and their respective key study design elements are listed in Table 
16.10,11,73,84–88 Due to study design flaws, studies TOB 105 – 108 were excluded from 
the data analysis. Some of these studies did not have a sufficiently low enough LLOQ to 
capture the cp(t) reliably, others did not have an appropriate sampling scheme that 
permitted any type of data analysis, and others did not report a cp(t) or a cs(t) profile. For 
the purpose of the following analysis, only studies TOB 101 – TOB 104 were utilized for 
analysis. These studies were characterized by infusion doses ranging from 1.5 mg/kg to 
10 mg/kg administered to both healthy subjects and CF patients. The authors in TOB 
103 investigated two dosing regiments; 3.3 mg/kg administered as a 30-minute infusion 
every 8 hours (TOB103A), and 10 mg/kg infused over 60 minutes every 24 hours 
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(TOB103B). TOB 104 was a unique study in that it provided both cp(t) and cs(t) profiles 
after 8 mg/kg repeat dosing.  
A total of 10 studies were identified where TOB was inhaled in either HV or CF 
patients. These studies and their key study design elements, such as number of 
subjects (n), mean body weight, mean age, etc., are listed in Table 17.76,89–97  
Additionally, the availability of cp(t), cs(t), exposure metrics for either plasma or sputum, 
and availability of deposition data is also tabulated. Of the ten identified studies, six 
studies were not suitable for analysis either for similar reasons as those excluded 
among the IV studies or due to lack of pulmonary deposition data that was necessary to 
perform the modeling described above. A summary of the four INH studies that were 
included in the analysis is reported in Table 17 along with the reported exposure metrics 
available for plasma and sputum data. The four studies were all single dose studies 
testing doses ranging from 28 mg to 300 mg that were inhaled through the Pari 
nebulizer, AeroDose inhaler, PulmoSphere inhaler, or the eFlow nebulizer in HV and CF 
patients.  
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Table 16 Identified TOB IV studies 
Eight identified studies wherein TOB was 
administered IV. Tabulated key study design 
elements: year of publication, number of 
subjects (n), subject disease state (Healthy, 
CF – cystic Fibrosis, or other), dose strength 
and regiment, analytical method, sampling 
schedule, age (yrs), body weight, availability 
of cp(t) profile, and the availability of cs(t) 
profile 
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Table 17 Identified TOB INH studies 
Eight identified studies wherein TOB 
was INH. Tabulated key study design 
elements: year of publication, number 
of subjects (n), body weight (kg) age 
(yrs), number of male participants, 
subject disease state (Healthy, CF – 
cystic Fibrosis, or other), analytical 
method (LLOQ if reported), dose 
strength and regiment, inhalation 
device, availability of cp(t) profile, and 
the availability of cs(t) profile 
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4.4.2. Dose Linearity for IV and INH studies 
 
Table 18 NCA results for the four selected IV studies 
 
The NCA results of the cp(t) profiles from TOB 101 – TOB 104 are shown in 
Table 18. The estimated half-lives (t1/2) for the hour studies ranged from 125 minutes to 
167 minutes which was in line with reported literature values. This short half-life is 
known to be a consequence of the small volume of distribution which was between 16 
and 18 liters in the NCA, and clearance values approaching glomerular filtration which 
range from 78 to 105 ml/min in the NCA performed in this study. When the administered 
dose was corrected for bodyweight (BW), there did not appear to be a difference in CLtot 
or Vdss between healthy and CF subjects as shown in Figure 14. Given that there is no 
difference between CF patients and HV, the data from these studies can be pooled for 
performing a dose dependence study. When comparing CLtot and Vdss as the nominal 
dose is increased from 1.5 mg/kg to 10 mg/kg, there is no evidence to support non-
linear PK after IV infusion dosing within the tested dose range as shown in Figure 15. 
This is further supported by the dose escalation graph with dose (on the x-axis) plotted 
against AUC (on the y-axis) which had a linear model fit r2 of 0.9998 (Figure 16) and the 
Log-Log plot where the exponent in the power model is 1.0898 (Figure 17). These 
TOB 101 TOB 102 TOB 103A TOB 103B TOB 104
Cltot   (mL/min) 105 96 94 89 78
BW Normalized 
Cltot (ml/min/kg)
1.3 1.2 1.7 1.6 1.4
Vdss (Liter) 18 16 16 16 18
BW Normalized 
Vdss (L/kg)
0.230 0.201 0.284 0.289 0.314
AUC  (mg*min/L) 1120 1652 1949 6166 5913
MRTsys (min) 172 165 167 179 232
t1/2 (min) 131 125 135 154 167
% Extrapolated 8.0% 14% 8.0% 2.9% 16%
r
2
, VI 0.9973, (✓) 0.9988, (✓) 0.9939, (✓) 0.9873, (✓) 0.9440, (✓)
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results were in line with literature and supported the use of disease state and BW as 
covariates to be modeled.  
 
 
Figure 14 NCA CLtot and Vdss plotted against BW corrected doses for TOB 101 – 
TOB 103B  
 
 
Figure 15 NCA CLtot and Vdss plotted against none BW corrected doses for TOB 
101 – TOB 103B 
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Figure 16 Dose escalation plotting AUC with increasing dose on a linear plot with 
a linear regression through the estimated AUC values. 
 
 
Figure 17 Dose escalation plotting AUC with increasing dose on a log-log plot 
with a power model fit to the estimated AUC values. 
 
Similar to the IV meta-analysis, the meta-analysis incorporating plasma exposure 
metrics (namely AUC and cmax) after inhalation did not show any evidence of non-dose 
linearity and or any differences between HV and CF patients. Sample results from the 
meta-analysis are shown in Figures 18 and 19 where the reported AUC was plotted 
against the device and the calculated dose to lung respectively. A linear model and a 
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power model was fit to these data points to emphasize the lack of conclusive 
information suggesting non-linearity, and hence the assumption of a linear model.     
 
Figure 18 Reported serum AUC plotted against the device dose.  
Blue circles represent HV studies and red circles represent studies conducted in CF 
patients. 
 
Figure 19 Reported serum AUC plotted against the calculated lung dose (device 
dose*dose to lung). 
Blue circles represent HV studies and red circles represent studies conducted in CF 
patients.  
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4.4.3. IV Data Modeling Results 
Successful fits were obtained for each of the four data sets from the three studies 
(TOB 101-103). Model selection criteria was higher than 4.1, R2 values were above 0.99 
for all the selected fits, correlation matrix values were all below 0.5, coefficients of 
variation for each of the parameter estimates were below 30%, and the visual inspection 
of the observed versus simulated values were all acceptable. A weighting factor of 1/y2 
was used for all but TOB 101 which did not utilize a weighting factor in fitting the model 
to the collected data. The model file for the various fits are reported in Appendix 2 as 
Code 1 of this chapter along with the results of all the attempted fits (Table 1 – 4) and 
the visual inspection plots for the various weighting factors (Figures 1 – 8).  
 
4.4.4. IV MCS Optimization  
No parameter space could be identified for models 1 and 2 that would have been 
able to describe all the observed data. While there was a parameter space for model 1 
that accurately described the observed cp(t) profiles, due to its lack of pulmonary 
distribution, it was incapable of capturing the reported cs(t) profiles. On the other hand, 
model 2 was able to capture the plasma concentration time profile and some of the 
sputum levels, but was not able to describe the measured accumulation of the drug in 
sputum after repeated IV dosing as shown in TOB 104 (Figure 9 and 10 in Appendix 2). 
Model 3 was able to predict the observed data well as the observed cp(t) and cs(t) 
profiles data fell within the predicted 5%-95%-percentiles. The VPC plots and visual 
comparison of PK parameters from study TOB 104 are shown in Figure 20 below and 
the remaining VPCs are shown in Appendix 2 as Figures 11 – 14.  
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Figure 20 TOB 104 VPC and exposure metric variability comparison. 
Top left -cp(t) profile, top center – cs(t) profile, top right PLU(t) profile, bottom left – cmax 
box and whisker plot (WHP), bottom center- c60 WHP, bottom right – beta WHP 
 
Additionally, in the figure above there are box and whisper plots that compare the 
reported exposure metrics to their respective simulated exposure metrics. As can be 
seen there is no evidence that would support a difference between the reported and 
simulated exposure metrics. A sample code used for both the optimization process as 
well as for generating these plots is listed in Appendix 2 as Code 2. The numerical 
comparison of the reported and simulated exposure metrics is reported in the Appendix 
2 of this chapter as Tables 5 – 9. The optimized parameters for these simulations are 
listed with their associated variability in Table 19. For the MCS, an n = 3000 has not 
shown improvements in matching the reported cp(t) and cs(t) profiles or reported PK 
parameter variability compared to an n =300. The time interval for the simulations for 
TOB 101- TOB 103B was 0.5 minutes, and for TOB 104 was 1 minute.  Drug amounts 
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in all the model compartments as well as the cumulative amount eliminated via 
pulmonary excretion and central compartment elimination are shown in Figure 21. 
Based on this, the CC elimination accounts for 92% of the total elimination of the drug 
from the body while pulmonary elimination accounts for the remaining 8%. 
 
Table 19 Model 3 parameter point and variability estimates with their respective 
distributions after final optimization with IV data sets 
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Figure 21 Amounts of drug in various compartments of Model 3 simulated over 
5760 minutes after IV administration using the final optimize IV parameters 
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4.4.5. IV Sensitivity analysis results 
With a single dose of 105 mg infused over 10 minutes, simulations run to 24 
hours showed AUC in plasma was sensitive to changes in CLtot, kpls1, kpls2, such that a 
25-fold change in these parameters resulted in -13, -1.3, -1.3-fold change respectively 
in AUC. Similarly, the fold change in k12, CLtot, and k21 resulted in a -1.7, -1.5, 1.1-fold 
change in cmax respectively. In addition to CLtot, which was one of the top three most 
influential parameters on sputum AUC and cmax, kca resulted in a -4.6, and -5.1-fold 
change to AUC and cmax respectively, and kcm resulted in a-5.4, and -4.9-fold change to 
AUC and cmax respectively. Similar results were obtained after a repeated dosing 
sensitivity analysis study where 105mg was administered as an IV infusion for three 
consecutive days. Plasma AUC was still predominantly altered by CLtot, kpls1, and kcls1, 
and cmax was no longer influenced by k21, with only CLtot and k12 leading to any notable 
fold changes in cmax. The fold change elicited in each of the exposure metrics as a 
response to a 25-fold change in each of the model parameter is tabulated in Table 20 
for the single dose and Table 21 for the repeated dosing experiment. The resulting 
plasma and sputum profiles after single dose are shown in the appendix as Figure 15 – 
27 and Figures 28 – 40 for the repeated dose. The code used to perform the sensitivity 
analysis is shown in the appendix under Code 3. 
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Table 20 TOB SD sensitivity analysis results 
Single IV dose sensitivity analysis results for IV optimized parameter space. Table 
reports the fold change (Max/Min * -1(if lower parameter value results in larger exposure 
metric value)) in exposure metric given a 25-fold change in the model parameter (from 
1/5 to 5 times mean optimized value). Simulation parameters were set to a BW of 70kg, 
Dose = 1.5mg/kg (105mg), Infusion time = 30 min, and sampling schedule from 0 to 24 
hours.  
 
Table 21  TOB RD sensitivity analysis results 
Repeated IV dose sensitivity analysis results for IV optimized parameter space. Table 
reports the fold change (Max/Min * -1(if lower parameter value results in larger exposure 
metric value)) in exposure metric given a 25-fold change in the model parameter (from 
1/5 to 5 times mean optimized value). Simulation parameters were set to a BW of 70kg, 
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Dose = 1.5mg/kg/day (105mg), Infusion time = 30 min, and sampling schedule from 48 
to 72 hours.  
 
4.4.6. INH Modeling Approach #1 – #4 as Negative results  
The first approach attempted to utilize the final IV optimized model parameters 
and model 3 to predict cp(t) and cs(t) from INH studies (approach #1). After repeated 
attempts to optimize the fraction of the dose that was deposited in the peripheral lung 
(Fpd) (and by consequence, the fraction deposited in the central lung-Fcd), no value of 
Fpd allowed for acceptable prediction of the observed cp(t) and cs(t) profiles. As can be 
seen in Figure 73, there was an underprediction of the plasma concentrations, and an 
overprediction of sputum concentrations. In the second approach, we attempted to 
identify a universal parameter space that was capable of describing both the IV and INH 
data sets by re-optimizing the parameters to describe both the IV and INH data sets 
simultaneously (approach #2). This approach was also unsuccessful as it was not 
possible to capture both plasma profiles while at the same time capturing both sputum 
profiles as seen in Figure 74. Approach 1 and 2 were likely unsuccessful due to the fact 
that there was very limited sputum data after repeated dosing via IV administration and 
the available data was a clustered close to the LOQ.  
Given that there was no identifiable parameter space that was capable of describing all 
the available IV and INH data sets simultaneously, the parameter optimization was then 
preformed solely on the available INH data sets from study 307. Optimization was 
considered successful as it was capable of describing the cp(t) and cs(t) profiles for the 
four tested doses as shown in Figure 75. However, when attempting to predict the 
exposure metrics from the remaining studies, there was a systematic overprediction of 
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the exposure metrics across the three remaining studies (sample case shown in table 
12). This systemic overprediction resulted in approach #3 being deemed unacceptable. 
In approach #4, data from across the four inhalation studies for the same device (Pari 
Nebulizer) was used to optimize the parameter space. This approach resulted in a 
parameter space that was able to, without bias, predict the four data sets used in the 
optimization process (307A, 303A, 30A, and 309F) (Table 13) but still resulted in the 
systemic overprediction of the plasma exposure metrics for the remaining studies 
(Figure 20).  
4.4.7. Approach #5 as successful results 
Initial estimates for the fifth approach for model 3 parameter optimization were 
taken from the final estimated IV parameters. Model parameters were optimized to 
match predicted with observed exposure metrics, incorporating up to 40% random 
variability following a log-normal distribution. Clinical PK studies with inhaled TOB (28 - 
300 mg in HV and CF after single dose) were used as reference for this optimization. 
The four studies included in the analysis provided a total of 16 data sets (either cp(t) 
profiles, cs(t) profiles, plasma exposure metrics, or sputum exposure metrics). All 
sixteen data sets had plasma information while 10 of the 16 had sputum information that 
was utilized for validation. Across studies, doses and inhalation devices, predicted cp(t) 
and cs(t) profiles (95-percentiles) included observed profiles; predicted AUC and cmax 
were within ±20% on average as can be seen in Table 22 below. The accepted VPC 
plots for both cp(t) and cs(t), as well as the visual comparison for the reported and 
simulated PK parameters from study TOB 104 are shown in Figure 22 below and the 
remaining results are shown in Appendix 2 as Figures 41 – 55. Additionally, the 
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simulated exposure metric central tendency and variability was compared with those 
reported in each of the publications. These comparisons are shown below in Table 23 
and for the remaining studies included in Appendix 2 as Tables 10 – 25. The final 
optimized parameter space that was deemed acceptable and used to generate the 
various tables and figures is listed in Table 24 below. Secondary derived model 
parameters that allow for a comparison between the IV and INH optimized parameters 
are reported in Table 25. 
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Table 22 Percent difference between the reported exposure metrics for plasma 
and sputum from the four selected inhalation studies. 
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Figure 22 TOB 307D VPC and exposure metric variability comparison. 
Top left -cp(t) profile, top center – cs(t) profile, top right - cs AUC box and whisker plot 
(WHP), bottom left – cs,max WHP, bottom center- cp AUC WHP, bottom right – cp,max 
WHP 
 
 
Table 23 Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 307D 
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Table 24 Model 3 parameter point and variability estimates with their respective 
distributions after final optimization with INH data sets 
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Table 25 Model 3, secondary derived parameters based on the final optimized 
parameters 
 
4.4.8. Pulmonary Bioavailability 
Across the four inhalation studies analyzed, the traditional method of evaluating 
Fpul via the AUC ratio method demonstrated that the mean Fpul was 18% and ranged 
from 3.6% to 31%. The calculated Finh values (based on Equation 2) for each of the 
studies are shown below in Table 26. Since TOB is not orally bioavailable (Foral ~0%), 
the low Fpul reflects poor absorption of deposited TOB across pulmonary epithelia.  
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Table 26 Calculated Finh values using AUC-ratio method with study TOB 103A as 
IV reference. 
 
Using the parameters optimized with the available IV data, and performing mass 
balance execration simulation after IV administration, demonstrated that 91% of the 
administered dose was eliminated from the central compartment while the remaining 
9% of the dose was eliminated from the central unbound lung compartment through 
mucociliary clearance. Similarly, when the parameters optimized with the available INH 
data were used to perform the same IV administration simulations, 91% was eliminated 
from the central compartment while 1% was eliminated via the other pathway. After INH 
simulations, however, using both the final IV and INH parameter space, results were not 
as similar. 93% was eliminated from the central compartment and 7% via the other 
pathway after INH administration simulation using the optimized INH parameters, and 
82% eliminated from the central compartment and 18% via the other pathway after INH 
Study ID Calculated Fpul (%) 
307A 9.3
307B 27
307C 28
307D 25
303A 3.9
303B 31
309A 26
309B 28
309C 25
309D 23
309E 23
309F 9.0
302A 6.2
302B 6.8
302C 9.4
302D 3.6
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administration using the optimized IV parameter space. A simulation depicting the 
amount in each compartment after INH administration using the final optimized INH 
parameters is shown in Figure 23 below. The cumulative amount execrated plots for the 
four bioavailability simulations are reported in Appendix 2 as Figures 56 – 59.  
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Figure 23 Amounts of drug in various compartments of Model 3 simulated over 
5760 minutes after INH administration using the final optimize INH parameters 
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4.4.9. INH Sensitivity analysis results  
With a single dose of 300 mg inhaled over 10 minutes, simulations run to 12 
hours showed AUC in both plasma was sensitive to changes in CLtot, kpls1, kpls2, such 
that with a 25-fold change in these parameters resulted in -4.8, -3.3, 2.9-fold change 
respectively in AUC. Similarly, the fold change in kca, kpls1, and kcm resulted in a 1.7, -
1.5, -1.5-fold change in cmax respectively. In addition to kca, which was one of the top 
three most influential parameters to sputum AUC, kcm and kpa, resulted in a -18, -1.7 and 
-1.6-fold change to AUC respectively. kca, kpa and kpd resulted in a-118, -23, and 23-fold 
change to sputum cmax respectively. The fold change elicited in each of the exposure 
metrics as a response to a 25-fold change in each of the model parameter is tabulated 
in Table 27. The resulting plasma and sputum profiles after single dose are shown in 
Appendix 2 as Figure 60 – 72. The code used to perform the sensitivity analysis is 
similar to that utilized for the IV sensitivity analysis shown in Appendix 2 under Code 3. 
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Table 27 INH TOB sensitivity analysis results 
Single INH dose sensitivity analysis results for INH optimized parameter space. Table 
reports the fold change (Max/Min * -1(if lower parameter value results in larger exposure 
metric value)) in exposure metric given a 25-fold change in the model parameter (from 
1/5 to 5 times mean optimized value). Simulation parameters were set to a BW of 70kg, 
Dose = 300mg, Inhalation time = 10 min, and sampling schedule from 0 to 12 hours.  
 
4.5. Discussion and Conclusions 
4.5.1. Study Limitations 
Confidence in the results generated by any model is highly dependent on the 
data used in the development of the model. As such, the data used in the development 
of a given model often needs to be critically evaluated. For the semi-PBPK model that 
was developed within this work, the data that was utilized in validating the constructed 
model was evaluated based on the inclusion standards described in the methods 
above. Of the collected IV studies listed above in Table 16, studies TOB 105 - 108 were 
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excluded from the data analysis for four primary reasons. First, these studies did not 
sample plasma concentrations frequently enough such that the reported cp(t) profiles 
could not have been analyzed nor used for estimating model parameters. With 
infrequent and/or insufficient plasma concentrations samples, as is the case with those 
studies, parameter identifiability is challenging. Second, the analytical method was not 
considered to be reliable in those four studies. The method utilized for determining the 
concentration of TOB in plasma was antibiotic activity using an Agar-well diffusion 
method specific to the bacteria Bacillus subtilis. This method is known to be a 
nonselective method for detecting TOB, and hence the concentrations reported were 
associated with a high level of variability. Third, if measured concentrations were below 
the lower limits of quantitation (LLOQ), they typically were replaced with zero. This was 
problematic since the reported cp(t) profile is typically a mean profile, and individual 
profiles are often not included. Thus, the mean plasma concentration at a given time 
point can be skewed to a lower value due to these zero replacements.  Concentrations 
that are more susceptible to being below LLOQ are those that at later time points occur 
after drug levels have had time to decrease throughout the body due to drug 
elimination. The zero substitution for concentrations below LLOQ is more so 
problematic with older analytical detection methods as they typically had higher LLOQs. 
Fourth, the reported mean cp(t) data from these studies often were indistinguishable 
from each other given their reported variability. Using this data would lead to very poor 
parameter estimation as parameter identifiability would again not be possible with such 
data sets.  
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Aside from evaluating the available data to determine whether or not it was acceptable 
for inclusion and analysis, it is also vital to discuss the lack of availability of certain data 
sets. All the identified IV studies were performed as short 10 to 60-minute infusions and 
none where administered as IV bolus. Assuming an appropriate data collection 
schedule was followed, and IV bolus study would have been valuable in approximating 
the distribution and re-distribution parameters (k12 and k21) with certainty. This is not the 
case with IV infusion studies because while the drug is still being infused, the already 
administered dose will be undergoing distribution. Hence distribution and redistribution 
parameters become much more difficult to estimate after an IV infusion study.  
In addition to the lack of IV bolus studies, there were also no IV SD studies performed in 
HV or CF patients that reported sputum data. Study TOB 104 was the only study that 
reported sputum data, namely a cs(t) profile and a cmax in sputum, however this was only 
performed in CF patients and there were no HV studies available. In both IV and INH 
studies, there is a scarcity of repeat dose studies providing sputum concentration data. 
In addition, there were no repeat dosing INH studies available in either HV or CF 
patients, and while there were single dose studies in for both HV and CF patients, no 
sputum data was available for HV after single does INH. The lack of available sputum 
data for HV either after IV or INH administration can be explained as HV do not naturally 
expectorate, naturally limiting sputum data collection. This lack of data limits the validity 
of the pulmonary parameters of the model as well as the ultimate generalizability of the 
model.   
 
4.5.2. Dose linearity after IV and INH and compare with literature findings 
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As can be seen in Figure 14, when the IV infused dose was corrected for 
bodyweight (BW), there was no apparent difference in CLtot or Vdss between HV and CF 
subjects. Given the absence of a difference, PK exposure metric data was pooled 
across studies, allowing the testing of dose dependence across the IV studies. When 
comparing CLtot and Vdss as the nominal dose increased from 1.5 mg/kg to 10 mg/kg, 
there was no evidence to support non-linear PK after IV infusion dosing within the 
tested dose range. This can be clearly observed on Figure 15 with no changes 
observed in both CLtot and Vdss values as dose increased along the x-axis. Dose 
independent clearance and volumes are both key defining factors of linear PK. 
Furthermore, in the linear dose escalation plot shown in Figures 16 comparing the 
administered dose to the NCA calculated AUC, the high r2 value of the linear model 
further suggested linear pk. Additionally, when the same data was plotted on a log-log 
scale as in Figure 17, and a power model was utilized for fitting the data, the coefficient 
of the exponential term is close to 1.0 which would also indicate suggest linear PK. After 
INH administration the same conclusions were reached after evaluating the calculated 
AUC as the administer dose increased. As seen in Figure 19, AUC increased in linear 
fashion as dose to lung increased. The scatter of the reported AUC on this plot is likely 
due to the variability associated with the INH device, INH technique and sampling of the 
data.  This finding is in agreement with the literature as several authors have also 
reported that TOB experience’s linear PK across a similar dose range.15,57  Moreover, 
given that there are no saturable processes (absorption, distribution, metabolism, or 
elimination) involved in kinetics of TOB, it is unlikely that additional data would 
contradict these results.   
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4.5.3. Final IV Parameter Space 
This semi-PBPK model of I.V. administered TOB with an optimized model 
parameter space resulted in mechanistically plausible parameter estimates, and was 
able to predict both cp(t) and cs(t) profiles from clinical PK studies with HV and CF after 
single or repeated therapeutic doses. This, however, was only plausible after the 
addition of the pulmonary sequestration compartments, which was singularly driven by a 
repeat-dose sputum data set that clearly demonstrated TOB accumulation in sputum, 
but not in plasma. Based on the final optimized parameter value, and as peripheral 
compartments to the central compartment, these pulmonary sequestration 
compartments appeared to be deep and high capacity compartments. It appears that 
they functioned as reservoir or donor compartments maintaining sputum concentration 
for the repeated dosing study validation. As can be seen in Figure 21, the amount of 
drug in the peripheral and central sequestration lung compartments is among one of the 
larger levels, and remains higher than most compartments for a prolonged period of 
time. Previous dissertation work by Min Li has shown in-vitro evidence supporting the 
idea that the lung has the capacity to sequester drug and thus maintain sputum levels 
after drug administration. 24 
Furthermore, the secondary derived model parameters shown in Table 25 also 
show that the sequestration compartments capacity rate constants (kplsratio and kclsratio) 
given the final IV parameter space were greater than 1.0. These values therefore 
indicate that with respect to the central compartment, the sequestration compartments 
are high capacity compartments. Based on the capacity rate constants (kpratio and kcratio), 
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however, the unbound peripheral and central lung compartments are relatively lower 
capacity compartments. Equilibration rate constants (the sum of the input and output 
rate constant from a given compartment) help elucidate how rapidly a compartment 
equilibrates with respect to adjacent compartments. Larger values denote a more rapid 
equilibration, while smaller values a slower equilibration. This is best observed when 
these rate constants are instead converted to half-lives. For the unbound peripheral and 
central lung compartments, the equilibration half-lives were 102 and 0.77 minutes 
respectively, while for the sequestration peripheral and central lung compartments both 
equilibration half-lives were much longer at 1155 and 990 minutes respectively.  
IV administered TOB is expected to be predominantly cleared through the total 
clearance route with nearly 93% of the dose eliminated via CLtot and the remaining 7% 
being eliminated through the mucociliary clearance (kcm).  
 
4.5.4. Sensitivity analysis results for IV parameter space 
After a single IV administered dose, sputum exposures were found to be 
sensitive to CLtot, but insensitive to all other systemic disposition parameters; with 
regards to pulmonary disposition, only mucociliary clearance and pulmonary absorption 
from the central lung appeared to influence these parameters.  Unlike sputum 
exposures, systemic exposures are not very sensitive to PUL disposition rates. 
Systemic exposures were found to be insensitive to pulmonary and systemic disposition 
parameters, except CLtot. Similarly, the sensitivity analysis after repeated dosing 
displayed similar results (Table 20) in comparison to single dosing (Table 21). These 
results reveal that in order to maximize pulmonary concentrations after IV administration 
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while minimizing systemic concentrations, an optimization process needs to occur were 
CLtot should be increased while kpa and kcm should be decreased. This supports the 
hypothesis listed of the study.  
 
4.5.5. Limitation of data leading to change of IV-> INH model  
As discussed above, the only study that provided sputum data after IV 
administration was a repeat dose study that provided a total of four mean sputum 
concentrations. The first of these four concentrations, was a non-zero pre-dose 
measurement of the concentration of TOB in sputum. This single data point was the 
predominate driving factor in parameter optimization and selection. It was this data point 
that lead to the introduction of the deep, high capacity pulmonary sequestration 
compartments. Despite this, after INH administration, there was no repeated dose 
studies available to provide sputum concentration. In addition, the data obtained from 
the available INH studies did not support the use of the same parameter space 
optimized in the IV studies (negative results shown in Appendix 2 Figure 73) nor was 
there a single parameter space that was capable of simultaneously describing both the 
available IV and INH data (negative results shown in Appendix 2 Figure 74). Therefore, 
a separate parameter space was required to describe the INH data.  
4.5.6. Final INH Parameter space 
The final parameter set (listed in Table 24) that was optimized using the available 
inhalation data sets indicated that with exception to PLS, the three-other remaining 
pulmonary compartments (namely, PLU, CLU, and CLS) were low capacity 
compartments as suggested by their respective secondarily derived ratio parameters 
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summarized in Table 25. This can be clearly observed in the PLS plot in Figure 23 as 
this plot showed that the amount of drug in PLS was notably higher than the remaining 
compartments. In addition to being a higher capacity compartment, PLS also appears to 
be a slowly equilibrating compartment relative to the remaining three pulmonary 
compartments. This slower equilibration is evidenced by the prolonged levels in the PLS 
plot mentioned above as well as a prolonged equilibration half-life of 36 min (kplssum = 
0.019 min-1). 
Given the available data there was no evidence of differences in the pulmonary 
disposition of TOB between CF patients and HV. Inspection of the reported PK data for 
each of the inhalation publications included in the analysis showed that when the same 
inhalation device was used to inhale a similar dose, no differences could be observed in 
plasma exposure metrics. This is clearly observed in Table 26 of Appendix 2 when 
comparing TOB studies 302A and 303A, as representative studies of HV using a Pari 
inhaler, with studies 302C and 307A where CF patients were using the same device to 
inhale the same 300 mg dose. Sputum information was not available for comparison 
between the two groups. Due to the variability associated with sputum data, even if the 
data were available, it is unlikely that a difference would have been detected. Likewise, 
by evaluating the same reported exposure metrics, no difference was observed 
between the various inhalation devices tested in the studies. When 300 mg was inhaled 
with both the Pari inhaler and the eFlow nebulizer, no difference was evident in either 
HV (TOB 302A vs 302B) and CF patients (TOB 302C vs 302D). While there are known 
physiological differences between CF and HV patients, the lack of data and the 
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resolution of the available data sets both lead to an inability to characterize these 
physiological differences.  
 
4.5.7. Sensitivity analysis results for INH parameter space 
After a single dose inhalation, sputum exposures were found to be sensitive to 
kca, kpa, kcm, and kpd, but insensitive to all other systemic disposition parameters. 
Systemic exposures were found to be predominantly sensitive to pulmonary disposition 
parameters: kca, kpls1, kpls2, and kcm, but were insensitive to systemic disposition 
parameters except CLtot. As hypothesized in Hypothesis 3.2, slowing down PUL uptake 
(kca and kpa) and mucociliary clearance (kcm) would in fact increase pulmonary exposure 
as characterized by AUC and cmax. In addition to this, the results also indicated that 
increasing kpd, efflux in the peripheral lung, would also lead to increased pulmonary 
concentrations.  
 
4.5.8. Reconciling IV and INH parameter spaces 
While there was no parameter space that was capable of simultaneously 
describing the available IV and INH data, there was an identifiable parameter space to 
describe the IV data, and another parameter space was identified to describe the 
available INH data.  In comparing Figure 21 and Figure 23, as well as the numerical 
values of the secondarily derived model parameters listed in Table 25, it becomes 
apparent that major differences between the IV and INH parameter sets can be 
observed in the CLS compartment. While the IV parameter space indicated that this 
compartment is a high capacity slowly equilibrating compartment, the INH parameter 
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space specified that it is a low capacity fast equilibrating compartment. The increase in 
the equilibration rate may likely be due to the route of administration. Since TOB is 
being administered via INH, pulmonary concentrations will likely be much higher than 
those after IV administration. Consequently, cellular sequestration may be saturated 
and hence a more rapid equilibration occurs. This therefore alters the CLS from 
behaving as a reservoir compartment to behaving as a pass-through compartment. The 
remaining three pulmonary compartments are comparable given both parameter 
spaces.  
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CHAPTER 5 
 
SEMI-PBPK MODELING OF INH CIPROFLOXIN 
 
5.1. Background 
5.1.1. Treatment of CF with Ciprofloxacin 
Discovered in 1981 as the first oral broad-spectrum antibiotic of its class, 
Ciprofloxacin (CIP), a fluoroquinolone antibiotic,  has since been approved by the FDA 
for use in treatment of urinary tract infections, chronic bacterial prostatitis, chronic 
bacterial prostatitis, lower respiratory infections, and numerous other indications.98,99 It 
also has numerous off-label and investigational uses such as in the treatment of 
chlamydia infections, inflammatory bowel diseases, and pelvic inflammatory disease.100–
102 CIP is known to exhibit bactericidal effects on both gram positive and gram-negative 
bacteria.  Pseudomonas aeruginosa, a gram-negative bacterium, is known to be 
susceptible to CIP, with CIP being very potent against it with an experimental MIC50 of 
0.19 mg/L and a MIC90 of 32 mg/L.103 The bactericidal action of CIP results from 
inhibition of the enzymes topoisomerase II and topoisomerase IV, which are required for 
bacterial DNA replication, transcription, repair, and recombination.104  
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5.1.2. Relevant Physiochemical Properties of Ciprofloxacin 
Often deemed as a small molecular weight compound, CIP has molecular weight 
of 331.3 grams per mole.  Additionally, it is moderately lipophilic with an experimentally 
obtained partition coefficient log(P) value of -0.13 and is categorized as a sparingly 
soluble compound according to the USP with a solubility than 40 mg/mL at a pH of 4.  At 
a concentration of 50 µm in the apical compartment, CIP has shown to have an 
apparent permeability (papp) of 2.99·10-6 ± 2.92·10-7 cm/s in the Caco-2 cell line.105 
When a similar study was conducted in a Calu-3 cell line with concentrations of either 
10 or 20 µM, results were similar, indicating a larger Papp of 3.52·10-4 cm/s. Based on its 
experimentally determined solubility and permeability, CIP was classified as a BCS 
class IV compound.106 Additionally, it was noted that while 81% of the CIP was present 
at the basolateral compartment at the end of the study when the initial concentration 
was 10 µM, only 48% was recovered in the basolateral compartment when 20 µM was 
tested.105 This indicate the possibility of transporter involvement, however, the authors 
noted that further studies needed to be conducted. When the permeability of CIP was 
compared with the permeability of fluorescein (a low permeability, paracellular marker) 
in studies performed in the small intestine of rats, both compounds had similar 
permeability values.107 This led the authors to conclude that CIP is a low permeability 
drug. The same authors also tested the permeability of CIP in the same system with 
benzbromarone (a MRP2 inhibitor), verapamil (a Pgp/MRP2 inhibitor) and quinidine (an 
OCT1 inhibitor). There was no difference in the permeability of CIP when tested alone 
versus when tested with any of these inhibitors. Accordingly, the authors concluded that 
CIP was not a substrate for any of the tested transporters. However, Papp of CIP from 
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the serosal to the mucosal was studied alone vs in presence of quinidine, a significant 
difference was found suggesting the involvement of an efflux protein in CIP secretion. 
107 
5.1.3. Summary of Known PK/ADME Properties of Ciprofloxacin 
With a reported plasma protein binding 20-40%¸ CIP still exhibits extensive 
distribution throughout the body with a Vdss (after a 100 mg IV infusion dose in HV) of 
2.64 ± 0.5 L/kg and a similar volume of 2.54 ±1.2 L/kg in CF patients.13,104,108 Total 
clearance values (CLtot) are also calculated after the same dosing regimens in those 
subjects. For HV, the reported CLtot value was 0.51 ± 0.12 L/kg/hr which was slightly 
lower than that of CF patients 0.61 ± 0.21 L/kg/hr, with renal clearance accounting for 
53% of the total clearance in HV and 62% in CF patients.78  After oral administration of 
radiolabeled CIP, 15% of the dose was detected in feces, and an additional 15% of the 
dose was detected in the form of four metabolites eliminated in urine. Some authors 
have shown that 15% of an orally administered dose is recovered in feces, while others 
have indicated that recovery may be as high as 35%.104,109 Both authors, however, have 
indicated that this may likely be due to biliary clearance or transintestinal elimination. In 
their Clinical Pharmacology and Biopharmaceutics review of ®Cipro, the FDA identified 
body weight, creatinine clearance, and the presence of CF in a patient, as significant 
covariates in the Pop-PK modeling of CIP.110 
 
5.2. Objectives 
The major objectives for this chapter were to: 
a) Develop and validate semi-PBPK model for CIP after the INH; 
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b) Determine sensitivity of plasma and sputum exposure to model parameters; 
c) Investigate route-dependent elimination pathways. 
 
5.3. Methods 
5.3.1. Summary and Discussion of final IV, PO, and INH studies identified  
Out of the nine identified CIP IV studies, one study was eliminated from analysis 
inclusion because of the non-selective, poorly sensitive microbiological assay utilized for 
plasma concentrations. 111 Older microbiological assays are known to have poor 
selectivity and have been shown to overpredict concentrations in plasma, and hence 
this study was not included for analysis. 112 There was also another study that did not 
report individual or a mean level plasma concentration time profile, and hence was 
excluded from analysis. 113 
Twelve studies were identified where CIP was administered orally to both HV and 
CF patients. Two of those studies were excluded due to the use of the aforementioned 
unreliable microbiological assay for plasma concentration analysis. One study was not 
included in analysis as it only reported data from a single subject. Lastly, the study by 
Michael et al. was also excluded from analysis as the reported exposure metrics, and 
cp(t) profiles were inconsistent with each other and with the text.  
All available and collected Ciprofloxacin studies satisfied inclusion criteria and hence 
were utilized and all the performed analysis and modeling within this study. Studies 
involving patients on Dialysis, or patients suffering from other medical conditions were 
not collected. 
5.3.2. Comparative NCA Results 
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NCA was performed on the digitized cp(t) profiles for each of the individual 
studies across the dosing routes (IV, PO, and INH). To ensure dose-linearity, AUC vs 
Dose and log(AUC) vs log(Dose) plots were inspected. For IV studies, CLtot, CLnonren, 
CLren, and Vdss were plotted against administered dose, age, body weight, and disease 
state. This was done in an attempt to see if change in any of these potential covariates 
led to a significant change in any of the estimated PK parameters. Additionally, since it 
is known that CF patients have a lower BW on average relative to HV (due to their 
malnutrition), the four PK parameters were also corrected for body weight and plotted 
against disease state (i.e., HV vs CF patients).  
5.3.3. Semi-PBPK Models Tested 
An open two-compartment body model was used to fit the collected IV data. The 
model incorporated loss from the central compartment via CLtot. Initial estimates for this 
model were estimated obtained from the previously discussed work with TOB. Three 
separate fits were performed: 1) with no weighting factor applied, 2) with a 1/y weighting 
factor, and lastly, 3) with a 1/y2 weighting factor. Parameter selection was based on the 
highest r2, MSC, as well as parameter certainty (lowest CV’s for the parameters). Model 
parameter estimates from the individual studies were averaged and used as the initial 
estimate for the MCS. MCS were performed to optimize the parameter space to 
describe all the observed cp(t) profiles as well as minimize the percent difference for the 
individual exposure metrics. Parameter variability was also optimized during the MCS. 
CV for each of the parameters was increased in increments of 5% until the model-
precited SD for the exposure metrics from each of the individual studies were 
comparable to those that are reported. In addition, CVs were also optimized such that 
 
 
101 
 
the majority of the reported cp(t) profiles were within the 5th-95th percentiles of the 
simulated cp(t) profiles. 
Final optimized systemic disposition parameters identified using the IV data sets 
were fixed, and the model was expanded to include a GI compartment. Initial estimates 
for Foral and kga were obtained from the NCA estimation. Alternatively, MCS were 
performed with this expanded oral administration model to optimize the central tendency 
and the distribution values for the oral absorption parameters.  
INH studies were grouped by dose and disease state during parameter 
optimization and were individually simulated, once the final parameter space was 
obtained. Specifically, cp(t) data from CIP 301A and CIP 303A were averaged for each 
of the time points for which both studies reported a concentration. Both those studies 
were conducted in HV, and a dose of 32.5 mg was inhaled through the same device. 
Data from CIP 302A and CIP 304A, as well as CIP 302B and CIP 304B were also 
combined as both sets of studies were conducted in CF patients where a dose of 32.5 
mg and 65 mg was inhaled respectively. Data was combined due to the observed 
variability across cp(t) profiles for studies at the tested the same dose in the same 
patient population, suggesting considerable inter-study variation.  
  There was no evidence of pulmonary sequestration for CIP, and hence the 
pulmonary sequestration rate constants kpls1, kpls2, kcls1, and kcls2 were all set to a value 
of 10,000, ie virtually instantaneous transfer. This modification to inhalation Model 3 in 
essence converts the sequestration compartment to high-throughput transfer 
compartments. MCS were performed in an attempt to optimize the six remaining 
pulmonary disposition parameters (kpa, kca, kpd, kcd, kpm, and kcm) with the systemic 
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disposition and oral parameter fixed at their previously optimized values. No acceptable 
parameter space was identified, primarily due to the inability to simultaneously simulate 
the rapid distribution phase as well as the terminal phase specifically in CF data sets 
after inhalation.  
Therefore, a global re-optimization with IV, PO, and INH data sets was performed 
to simultaneously optimize the systemic disposition, oral absorption, and pulmonary 
disposition parameters. It was necessary to introduce a disease state specific covariate 
model on each of the systemic disposition and oral absorption parameters.  
5.3.4. Parameter Sensitivity Analysis 
As an indicator of how sensitive plasma and sputum exposures are to the final 
model parameters, a sensitivity analysis was performed with the final parameter 
estimates after IV, PO, and INH dosing. BW was set to either 70 kg or 55 kg for HV and 
CF patients, respectively. For the IV sensitivity analysis, a dose of 300 mg was infused 
over 10 minutes, for the PO sensitivity analysis a dose of 100 mg was administered, 
and for the INH sensitivity analysis a dose of 32.5 mg was inhaled. The models utilized 
for parameter optimization were the same models utilized for the sensitivity analysis 
(i.e., open two compartment body model, open two compartment body model with GI 
compartment, and the full inhalation semi-PBPK model 3). Variability across the 
parameters was disabled by setting all the CV’s to zero, systemic and oral absorption 
parameter values were set to either one-fifth or five times the mean optimized values to 
cover a 25-fold range around the point estimate. Pulmonary uptake, distribution and 
redistribution parameters were set to one-tenth or ten-times the mean optimized values 
to cover a 100-fold range around the point estimate. Simulations were performed for up 
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to 24hrs. AUC and cmax values in plasma and sputum were calculated at each of the 
extremes. The fold change was calculated as the ratio between the maximum and 
minimum values of the simulated plasma AUC multiplied by a negative one if the 
maximum value was obtained from when the parameter being tested was multiplied by 
1/5. This was also done for plasma cmax, as well as sputum AUC and cmax. Both cp(t), 
and cs(t) profiles were generated for comparison. The top three parameters to cause the 
largest-fold change in the four-exposure metrics were determined at the end of the 
sensitivity analysis. This sensitivity analysis would then allow for a better understanding 
as to how to increase sputum concentrations or how to minimize systemic exposure.  
 
5.3.5. Assessment of Pulmonary Kinetics 
To gain insight of pulmonary disposition, and the contribution of pulmonary 
exposure on systemic exposure, pulmonary kinetics were investigated. The total fraction 
of the dose that was absorbed into systemic circulation was denoted as FINH and was 
calculated as the sum of the Fpul and Foral as seen in Equation 12.  
 
FINH *(DtL+ DtGI) = Fpul*DtL + Foral* DtGI 
Equation 12 Calculation of bioavailability after inhalation with and without charcoal 
block data.  
 
The NCA estimate of FINH can also be described as the product of AUCINH and 
𝐶𝑙𝑡𝑜𝑡
𝐼𝑉  divided by the total dose as in Equation 13. This calculation assumes that charcoal 
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block does not affect CLtot, however it does assume that the concurrent administration 
of charcoal black is able to prevent any oral absorption (essentially making Foral = 0). 
 
𝐴𝑈𝐶𝐼𝑁𝐻∗𝐶𝑙𝑡𝑜𝑡
𝐼𝑉
𝐷𝑡𝐿+𝐷𝑡𝐺𝐼
 *(DtL+ DtGI) = Fpul*DtL + Foral* DtGI                               
Equation 13 NCA method for adding Fpul and Foral to determine Finh 
 
The availability of CIP cp(t) profiles after CIP inhalation with co-administration of 
charcoal allows for the derivation of Equation 14 by dividing Equation 13 utilizing the no 
charcoal block data by the same equation with the charcoal data set. The result is 
shown in 5.3.5.3, is a NCA approach to estimating pulmonary bioavailability (Fpul).  
 
𝐹𝑝𝑢𝑙 =
𝐹𝑜𝑟𝑎𝑙∗𝐷𝑡𝐺𝐼
(𝐴𝑈𝐶 𝑅𝑎𝑡𝑖𝑜 −1)∗𝐷𝑡𝐿
  
Equation 14 Explicit Solution for pulmonary bioavailability after inhalation calculated 
using with and without charcoal block data 
 
Equation 15 below describes the MRTINH as the weighted sum of pulmonary 
absorption and oral absorption in addition to the MRTsys. AUC Ratio referrers to the ratio 
of the AUC obtained from the Charcoal study divided by the AUC obtained from the 
data from when charcoal was not administered. Mean pulmonary absorption time from 
the pulmonary compartments into systemic circulation was therefore calculated using a 
modified solution of Equation 15. 
                        𝑀𝑅𝑇𝐼𝑁𝐻 =  𝑀𝐴𝑇𝑝𝑢𝑙 (
𝐷𝑡𝐿
𝐷𝑡𝐺𝐼+𝐷𝑡𝐿
) + 𝑀𝐴𝑇𝑃𝑂 (
𝐷𝑡𝐺𝐼
𝐷𝑡𝐺𝐼+𝐷𝑡𝐿
) + 𝑀𝑅𝑇𝑠𝑦𝑠 
Equation 15 Calculating mean residency time after INH 
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5.3.6. Assessment of Mass Balance 
The cumulative drug eliminated systemically, and via GI Tract (not absorbed and 
pulmonary transfer via mucociliary clearance) was investigated after IV, PO, and INH 
administration. These mass balance excretion simulations were performed up to 48 
hours with a resolution of 10 minutes. These simulations were performed to understand 
the contribution of each elimination pathway to total drug elimination since the 
pulmonary model allows for transfer of CIP into the GI tract.  
5.3.7. Software 
For the included studies, captured cp(t) and cs(t) profiles were digitized using the 
GetData© Graph Digitizer Version 2.24 software. NCA was performed on the plasma 
concentration data. Model parameter fitting was performed in Scientist v. 3.0.0.215  
Build: 1334 using a stiff integrator. MCS and data visualization was performed in R-
studio using the deSolve tool package with lsoda switching automatically between stiff 
and non-stiff methods to handle the ordinary differential equations associated with the 
model. 
 
5.4. Results 
5.4.1. Summary of Final IV, PO, and INH Studies Identified  
A search of the literature on PubMed and Google Scholar resulted in the 
identification of 9 publications where CIP was administered as IV infusion. These 
publications and their respective key study design elements are listed in Table 
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28.13,111,112,114–118 Two studies were excluded from the analysis, specifically CIP 103 and 
CIP 109. The remaining seven studies enrolled between 6 and 32 volunteers including 
both HV and CF patients. Doses ranged from 50 mg to 400 mg and were infused over 
the course of 5 to 60 minutes to both HV and CF patients. These studies only provided 
cp(t) profiles, and no cs(t) profiles were available after IV administration.  
Six of the included IV studies also included PO administration data, and another five 
studies were identified where CIP was administered orally. Only one of the five PO 
administration studies was acceptable. As such a total of 7 studies were included in the 
PO analysis and resulted in 12 cp(t) profiles (2 of which were from CF patients). The 
administered doses ranged from 100 mg to 1020 mg. All but one study specified that 
the administrated formulation was a tablet, and for the study in which the formulation 
was not specified, it was assumed to be as a tablet. The included PO administration 
studies along with the relevant study design parameters are tabulated in Table 29. 
13,108,112,115,116,118,119 
A total of 4 studies were identified where CIP was inhaled either HV or CF 
patients (n=2 for both). These studies and their key study design elements, such as 
number of subjects (n), mean body weight, mean age, etc., are listed in Table 30.120–123 
Additionally, the availability of cp(t), cs(t), exposure metrics for either plasma or sputum, 
and availability of deposition data is also tabulated. All four studies were suitable for 
analysis as they satisfied the inclusion criteria. Only one device was tested in these four 
studies, and only two doses were tested (32.5 mg or 65 mg). The available date from 
these studies included 8 cp(t) profiles and matching exposure metrics, as well as 2 cs(t) 
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profiles. The Novartis' T-326 DPI was the inhalation device utilized in this study, for 
which the deposition data was also reported in literature.  
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Table 28 Identified IV CIP studies  
Seven included studies wherein CIP was 
administered IV. Tabulated key study design 
elements: number of subjects (n), subject 
disease state (HV - Healthy, CF – cystic Fibrosis, 
or other), dose regimen, bioanalytical method, 
sampling schedule, age (yrs), body weight, 
availability of cp(t) profile, and the availability of 
cs(t) profile 
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   Table 29  Identified PO CIP studies  
Seven included studies wherein CIP was 
administered PO. Tabulated key study design 
elements: number of subjects (n), subject 
disease state (HV - Healthy, CF – cystic 
Fibrosis, or other), dose regimen, 
bioanalytical method, sampling schedule, age 
(yrs), body weight, availability of cp(t) profile, 
and the availability of cs(t) profile 
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Table 30  Identified INH CIP studies 
Four included studies wherein CIP was administered via INH. Tabulated key study 
design elements: number of subjects (n), subject disease state (HV - Healthy, CF – 
cystic Fibrosis, or other), dose regimen, bioanalytical method, sampling schedule, age 
(yrs), body weight, availability of cp(t) profile, and the availability of cs(t) profile 
 
5.4.2. Assessment of PK Dose-Proportionality 
NCA was performed on the 12 individual data sets obtained from the seven 
included studies. Visual inspection for each of the log-linear regression of the terminal 
slope used in estimating λ were acceptable, R2 values were all larger than 0.9645, and 
the AUC percent extrapolated did not exceed 10% for each of the individual data sets 
analyzed. The estimated PK parameters are tabulated in Table 31. 
 
Study 
Identifier
301 302 303 304
n 6 6 12 6
Subject 
Disease State
HV CF HV CF
Dose Strength 32.5 mg 32.5, 65 mg 32.5 mg
32.5, and 65 mg qd 
32.5 mg  BID
Device Novartis' T-326 DPI Novartis' T-326 DPI Novartis' T-326 DPI Novartis' T-326 DPI
Assay 
method
HPLC/MS/MS (0.0015 mg/L) HPLC/MS/MS (0.0015 mg/L) HPLC/MS/MS (0.0015 mg/L) HPLC/MS/MS (0.0015 mg/L)
PK Sampling 
(min)
0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 
2.5, 3.0, 4.0, 6.0, 8.0, 12, 16, 
24, 36 and 48 hrs
0, 0.083, 0.25, 0.5, 0.75,1, 
1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 
24, 36, and 48 hrs
0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 
8, 12, and24 hr
0, 0.083, 0.25, 0.75, 1, 1.5, 2, 
3, 4, 6, 8, 12, and 16 hrs
Age (years) 32.8 (27-42) 
31.5 (21-39)
26.8 (20-39)
34.8 (21-52)
31 (19 - 40), 31 (20-39), 
26.8 (19-40)
Body weight 
(kg)
80.2 (13.3)
58.5 (10.4)
64.5 (11.8)
NA
58.3 (10.7), 59.5  (13.1), 
63.8 (5.7)
Cp(t) Profile ✔ ✔ ✔ ✔
Cs(t) Profile X ✔ X (Patient level)
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Table 31 NCA estimated PK parameters for each of the individual data sets from 
the seven included studies.  (CIP IV administration) 
 
Inspection of the AUC vs IV dose plotted on a linear scale as well as on a log-log 
plot did not provide any evidence of deviation from linear PK after IV administration. 
When a linear and a power model was fit to both plots respectively, the resulting R2 
value was 0.851 and the exponential coefficient of 1.44. These plots are shown in 
Figure 24.  
 
Figure 24 CIP IV dose escalation plots 
IV infusion dose dependence plotting AUC with increasing IV dose on a linear plot with 
a linear regression through the estimated AUC values (left plot), and on a log-log plot 
with a power model fit to the estimated AUC values (right plot).  
 
The same analysis was performed with the available data after PO 
administration. When a linear and a power model was fit to both plots respectively, the 
101A 102A 102B 102C 104A 105A 105B 106A 107A 107C 108A 108B
Cltot   (mL/min)
579 803 737 844 678 327 436 270 424 316 643 467
BW Normalized Cltot 
(ml/min/kg)
12.07 12.0 11.0 12.6 9.0 4.5 6.0 3.3 11.09 6.87
Vdss (Liter)
96 206 196 216 148 77 102 85 100 74 125 90
BW Normalized Vdss 
(L/kg)
2.002 3.073 2.930 3.226 1.974 1.048 1.397 1.042 2.162 1.320
AUC  (mg*min/L) 345 62 136 237 147 918 918 1480 942 1267 541 582
MRTsys (min) 166 256 266 256 218 234 234 316 236 234 195 192
t1/2 (min) 153 225 230 230 229 228 228 293 226 235 180 191
% Extrapolated 3.3% 8.4% 9.2% 8.3% 7.5% 7.0% 7.0% 1.6% 3.4% 3.7% 4.8% 5.2%
VI ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
r2 0.9862 0.9993 0.9983 0.9966 0.9972 0.9946 0.9946 0.9645 0.9978 0.9964 0.9872 0.9966
Non-Compartmental 
Analysis
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resulting R2 value was 0.854 and the exponential coefficient of 1.05. These plots are 
shown in Figure 25. Additionally, a linear model was fit to PO dose vs cmax data set, and 
the resulting R2 was 0.82. The data and linear fit model are shown in Figure 26 below. 
 
Figure 25  CIP PO dose escalation plots 
PO dose dependence plotting AUC with increasing PO dose on a linear plot with a 
linear regression through the estimated AUC values (left plot), and on a log-log plot with 
a power model fit to the estimated AUC values (right plot). Blue dots indicate data 
reported for HV while orange dots indicate data reported for CF patients. 
 
 
Figure 26 CIP cmax with increase PO dose 
PO dose escalation plotting cmax with increasing PO dose on a linear plot with a linear 
regression through the estimated cmax values (left plot). Blue dots indicate data reported 
for HV while orange dots indicate data reported for CF patients. 
 
For the available data after INH, the analysis was performed on the total dose 
that was deposited in the body. That deposited dose was defined as the sum of the 
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dose deposited in the lungs and the dose deposited in the GI tract. When a linear and a 
power model was fit to both plots respectively, the resulting R2 value was 0.7125 and 
the exponential coefficient of 1.08. These plots are shown in Figure 27. Additionally, a 
linear model was fit to inhaled dose vs cmax data set, and the resulting R2 was 0.68. The 
data and linear fit model are shown in Figure 28 below. As such, there was no evidence 
of nonlinearity.  
 
 
Figure 27  CIP INH dose escalation plots 
Pulmonary deposition dose dependence plotting AUC with increasing total deposited 
dose in the lungs and the GI on a linear plot with a linear regression through the 
estimated AUC values (left plot), and on a log-log plot with a power model fit to the 
estimated AUC values (right plot). Blue dots indicate data reported for HV while orange 
dots indicate data reported for CF patients. 
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Figure 28 CIP cmax with increase INH dose 
INH dose escalation plotting cmax with increasing INH dose on a linear plot with a linear 
regression through the estimated cmax values (left plot). Blue dots indicate data reported 
for HV while orange dots indicate data reported for CF patients. 
 
Overall, there is no evidence of deviation from dose-proportional PK after IV, PO, 
and INH administration. 
5.4.3. Pulmonary Bioavailability 
Across the four inhalation studies analyzed, the Fpul via the AUC ratio method 
demonstrated discussed above ranged from 11% to 76%. Study 303B was the study 
where CIP was co-administered with charcoal.  The average Fpul for HV was 46% while 
the average for CF patients was 34%. It is of note however, that only two studies were 
available with data for HV. Similarly, the average MATpul was 593 min for HV, and 268 
minutes for CF patients. The individual values for each of the studies in tabulated below 
in Table 32.   
 
 
115 
 
 
Table 32 CIP INH NCA analysis 
Calculated Fpul values using NCA estimates values and CIP 303B as the charcoal 
reference. MATpul also used NCA estimates from IV and PO studies as a reference.  
 
5.4.4. PK Covariate Exploration 
CLtot, CLnonren, CLren, and Vdss were plotted against administered dose, age, body 
weight, and disease state. Disease state appeared to be the only covariate that may be 
related to the PK parameters. For HV, both Vdss and CLnonren were 129 L and 309 
ml/min respectively which were notably larger than those for CF; 111 L and 207 mL/min, 
respectively. However, the opposite was try for CLtot and CLren with CF patients having 
values of 611 mL/min and 381 mL/min, respectively, while HV had a CLtot value of 530 
mL/min and a CLren values of 279 mL/min. These comparisons are visually represented 
in Figures 29 through 32 below. When each of the PK parameters were body weight 
normalized and compared across disease state, the difference was magnified.  
Study Fpul (%) MATpul (min) kinh (min
-1)
301A 17 678 0.003
302A 22 196 0.012
302B 36 286 0.007
303A 76 508 0.005
303B 46 377 0.005
304A 21 305 0.010
304B 78 338 0.008
304C 11 213 0.020
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Figure 29 Comparison between NCA and model optimized Vdss 
Vdss obtained through NCA plotted against disease state for individual data sets within 
studies. Blue dots resemble individual studies while red lines represent model optimized 
values. 
 
Figure 30 Comparison between NCA and model optimized CLtot 
CLtot obtained through NCA plotted against disease state for individual data sets within 
studies. Blue dots resemble individual studies while red lines represent model optimized 
values. 
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Figure 31 Comparison between NCA and model optimized CLren 
CLren obtained through NCA plotted against disease state for individual data sets within 
studies. Blue dots resemble individual studies while red lines represent model optimized 
values. 
 
Figure 32 Comparison between NCA and model optimized CLnonren 
CLnonren obtained through NCA plotted against the disease state for individual data sets 
within studies. Blue dots resemble individual studies while red lines represent model 
optimized values. 
 
For PO studies, exploratory plots of Foral, MATPO, and kga vs dose, age, body 
weight, and disease state were inspected to determine if there were covariates for those 
PK parameters. Similar to the data shown for the IV studies, the PO PK parameters 
appeared to be related to BW. Foral MATpo, and kga were 56%, 53 min, and 0.028 min-1, 
respectively for HV, while 78%, 95 min, and 0.011 min-1 for CF patients, respectively. 
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These three PK parameters are plotted against the disease state in Figures 33, 34, and 
35 respectively.   
 
Figure 33 Comparison between NCA and model optimized Foral 
Foral obtained through NCA plotted against disease state for individual data sets within 
studies. Blue dots resemble individual studies while red lines represent model optimized 
values.  
 
Figure 34 Comparison of MATPO between HV and CF patients 
MATpo obtained through NCA plotted against disease state for individual data sets 
within studies. Blue dots resemble individual studies. 
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Figure 35 Comparison between NCA and model optimized kga 
kga obtained through NCA plotted against disease state for individual data sets within 
studies. Blue dots resemble individual studies while red lines represent model optimized 
values. 
 
5.4.5. Modeling of IV Data 
Successful fits were obtained for each of the twelve data sets from the seven studies. 
MSC values are higher than 4.9, R2 values were above 0.9950 for all the selected fits, 
correlation matrix values were all below 0.5, coefficients of variation for each of the 
parameter estimates were below 30%, and the visual inspection of the observed versus 
simulated values were all acceptable. Weighting factor varied from data set to data set 
and was selected based on the weight factor that resulted in the most acceptable 
results. Table 33 shows the resulting parameter values based on the fits produced by 
the individual data sets. The model file for the various fits are reported in Appendix 3. 
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Table 33 NCA results for the seven selected CIP IV studies 
Two compartment model parameter estimates and goodness of fit validation criteria 
results for each of the twelve data sets obtained from the final seven included IV 
studies.  
 
Global MCS across studies and across dosing routes resulted in an acceptable 
parameter space that described observed cp(t) profiles and exposure metrics after IV 
administration. The five systemic disposition parameters were optimized with a binary 
disease state covariate model for HV or CF following a normal distribution. For each 
disease state, there was an optimized central tendency (mean) and a variation (CV) as 
shown in Table 34. Optimized parameter values indicate HV have lower CLren (315 
mL/min) as compared to CF (425 mL/min), however, the optimized CLnonren was faster 
(315 mL/min) compared with the CF patients (225 mL/min). k12 and k21 were both faster 
for CF patients than for HV; 0.050 and 0.020 min-1 respectively, and 0.025 and 0.015 
min-1 respectively.  Lastly, HV had a notably higher V0 (75 L) than the optimized V0 
value for CF patients (20 L). With exception of k12 and k21 for HV, which followed a 
normal distribution with a 25% CV, all other systemic disposition parameters followed a 
normal distribution with a 20% CV.  
101A 102A 102B 102C 104A 105A 105B 106A 107A 107C 108A 108B
Vdss (L) 139 238 221 250 105 149 137 58 119 101 100 72
Vo   (L) 36.13 63.36 67.74 98.67 25.31 32.09 30.91 14.92 24.72 21.46 35.38 10.56
k12   (min
-1) 0.031 0.055 0.039 0.025 0.076 0.064 0.047 0.010 0.042 0.046 0.052 0.087
k21   (min
-1) 0.011 0.020 0.017 0.016 0.024 0.018 0.014 0.003 0.011 0.012 0.029 0.015
Cltot   (mL*min
-1) 607 871 791 915 900 768 597 205 536 432 719 496
Visual inspection ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
r2 0.9979 0.9951 0.9973 0.9964 0.9978 0.9988 0.9974 0.9993 0.9983 0.9972 0.9991 0.9996
MSC 5.0 5.0 5.5 5.5 5.1 5.1 4.9 5.4 5.7 5.1 5.5 6.7
Vo CV 3.3 14.0 8.2 10.4 2.9 10.9 10.1 21.3 4.9 0.0 8.4 3.0
k12 CV 9.7 19 14 21 9 18 16 9 9 14 12 4
k21 CV 18 8.4 6.8 11.5 15.8 10.6 9.7 12.2 6.9 9.1 6.1 6.2
Cltot CV 10 2.2 1.6 2.0 9.4 3.7 2.7 6.2 2.1 2.8 3.8 4.3
Two Compartment  
Model Paramter 
Estimates
Two Compartment  
Model Validation
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Table 34 Final optimized systemic disposition model parameters for CIP with 
specified underlying covariate models and distributions 
 
Table 35 indicates the acceptability of the VI of the cp(t) profiles as well as the 
percent difference for the exposure metrics for each of the data sets. The predicted 
AUC was on average 7.9% lower than the reported AUC, with a 12% standard 
deviation. Additionally, predicted SD for each of the individual studies were below the 
reported SD in 10 out of 12 of the analyzed data sets. Sample results of the VI of the 
cp(t) profile can be seen in Figure 36 for study CIP 104A where 100 mg was IV infused 
in HV. The remaining VI are included in Appendix 3. 
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Table 35 Predicted vs reported AUC exposure metrics for individual analyzed IV 
data sets using MCS approach 
 
Figure 36 CIP 104 cp(t) VPC after a 100 mg IV dose in HV 
 
5.4.6. Modeling of PO Data 
Global MCS across studies and across dosing routes resulted in an acceptable 
parameter space that described observed cp(t) profiles and exposure metrics after PO 
administration. Both oral absorption parameters were optimized with a binary disease 
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state covariate model for HV or CF following a normal distribution. For each disease 
state, there was an optimized central tendency (mean) and a variation (CV) as shown in 
Table 36.  Foral for HV was optimized to mean a point estimate of 73% with a 35% CV, 
and 85% with a 30% CV for CF. kga was optimized to 0.020 min-1 with a 10% CV for HV, 
and 0.011 min-1 with a CV of 50% for CF patients.  
 
Table 36 Final optimized oral absorption model parameters for CIP with specified 
underlying covariate models and distributions 
 
Table 37 indicates the acceptability of the VI of the cp(t) profiles as well as the 
percent difference for the exposure metrics for each of the PO data sets. The predicted 
AUC was on average 0.12% lower than the reported AUC, with a 17% standard 
deviation. Additionally, there was, on average an underprediction in cmax by 13% with a 
15% SD. The predicted SD for both AUC and cmax for each of the individual data sets 
was numerically similar for all but three data sets where the predicted SD was +50% 
larger than the reported SD.  Sample results of the VI of the cp(t) profile can be seen in 
Figure 37 for study CIP 204B where 500 mg was orally administered in HV. The 
remaining VI are included in Appendix 3.  
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Table 37 Predicted vs reported AUC exposure metrics for individual analyzed PO 
data sets using MCS approach 
 
 
Figure 37 CIP 204B cp(t) VPC after a 500 mg PO dose in HV 
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5.4.7. Modeling of INH Data 
Global MCS across studies and across dosing routes resulted in an acceptable 
parameter space that described observed cp(t) profiles and exposure metrics after INH 
administration. All 6 pulmonary disposition rate constants followed the same log-normal 
distributions for both HV and CF as shown in Table 38. Both mucociliary clearance 
values (kpm and kcm) were identical at 0.02 min-1, while kpa was half of kca (0.01 and 0.02 
min-1, respectively). kpd was optimized to a value of 0.008 min-1 and kcd was much 
slower at a value of 0.0002 min-1. All pulmonary rate constants were associated with a 
variability of 20% CV.  
 
Table 38 Final optimized pulmonary disposition model parameters with specified 
underlying distributions 
 
Table 39 demonstrates the acceptability of the VI of the grouped cp(t) profiles as 
well as the percent difference for the exposure metrics for each of the INH data sets. 
Both reported cs(t) profiles were compared with the predicted cs(t) profiles and were 
deemed acceptable per the VI criteria specified in Chapter Two. No sputum exposure 
metrics were available for comparison. The predicted plasma AUC was on average 
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8.2% higher than the reported AUC, with a 26% SD. Additionally, there was on average 
an underprediction in cmax by 4.9% with a 7.2% SD. Sample results of the VI of the 
combined cp(t) profile can be seen in Figure 38 for studies CIP 302A and 304A where 
32.5 mg was INH by CF patients. A comparison of one of the two reported cs(t) profiles 
with the predicted cs(t) profiles after 65 mg was inhaled by CF patients is shown in 
Figure 39.  The remaining VI are included in Appendix 3. 
 
Table 39 Predicted vs reported AUC exposure metrics for individual analyzed INH 
data sets using MCS approach 
 
Figure 38 CIP INH cp(t) VPC Plot for CIP 302A and 304A 
VPC for model predicted cp(t) compared with the average reported cp(t) profiles from 
study CIP 302A and CIP 304A VPC after a 32.5 mg dose was inhaled by CF patients 
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Figure 39 CIP INH cs(t) VPC Plot for CIP 302B 
VPC for model predicted cs(t) compared with the reported cs(t) profile from study CIP 
302B after a 65 mg dose was inhaled by CF patients 
 
5.4.8. Parameter Sensitivity Analysis Results 
SD sensitivity analysis results for both HV and CF patients were generated for 
the five systemic disposition parameters and are tabulated in Table 40. For a 25-fold 
change in the model parameters, AUC was most sensitive to changes in CLren in HV 
and CF patients (3.7- and 7.2-fold, respectively), and cmax was most sensitive to V0 in --
both groups (21- and 14-fold respectively). Predicted cp(t) profile after the 25-fold 
change in CLren is shown in Figure 40 for HV and CF patients.  
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Table 40 Single IV dose sensitivity analysis results for both HV and CF patients 
after a 100 mg infusion over 10 minutes 
 
 
Figure 40 Resulting cp(t) from a 25-fold change in CLren after a SD IV infusion of 
100 mg over 10 minutes in HV (left plot) and CF (right plot). 
 
SD sensitivity analysis results for both HV and CF patients were generated for 
the five systemic disposition parameters as well as both oral absorption parameters and 
are tabulated in Table 41. AUC and cmax were most sensitive to Foral with a 25-fold 
change in Foral directly resulting in a 25-fold change in both AUC and cmax in HV and CF 
patients, as expected. CLren was the second most influential model parameter on AUC 
exposure, while kga was most influential on cmax. Predicted cp(t) profile after the 25-fold 
change in CLren is shown in Figure 41 for HV and CF patients.  
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Table 41 Single PO dose sensitivity analysis results for both HV and CF patients 
after a 100 mg administration 
 
 
Figure 41 Resulting cp(t) from a 25-fold change in kga after a SD PO administration 
of 100 mg in HV (left plot) and CF (right plot). 
 
SD sensitivity analysis results for both HV and CF patients were generated for all 
model parameters (five systemic disposition, two oral absorption, and six pulmonary 
disposition parameters) and are tabulated in Table 42 Plasma AUC depends primarily 
on Foral, V0, and CLren in HV, and CLren, k12, and CLnonren in CF patients. Plasma cmax 
depends primarily on V0, Foral, and k12 in HV, and V0, k12, and kga in CF patients. Sputum 
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AUC depends primarily on kcm, kca, and kpd in both HV and CF patients. Predicted cp(t) 
and cs(t) profiles after the 100-fold change in kcm is shown in Figure 42 and Figure 43 for 
HV and CF patients, respectively.  
 
 
Table 42 Sensitivity analysis results for both HV and CF patients after inhalation 
of a single 32.5 mg dose 
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Figure 42 Resulting cp(t) and cs(t) (left and right plot respectively) from a 100-fold 
change in kcm after a SD INH of 32.5 mg in HV. 
 
 
Figure 43 Resulting cp(t) and cs(t) (left and right plot respectively) from a 100-fold 
change in kcm after a SD INH of 32.5 mg in CF. 
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The resulting plasma and sputum profiles after SD are shown in Appendix 3 as 
Figure 15 – 27. The code used to perform the sensitivity analysis is shown in Appendix 
3. 
5.4.9. Assessment of Mass Balance Results 
After an IV infusion in HV, 1.3% of the dose is predicted to be eliminated through 
distribution into the lungs and subsequently being mucociliary cleared into the GI tract 
for elimination. This percentage was notably larger in CF patients, with an estimated 8% 
of the dose being cleared through the same pathway.  98.7% and 92% respectively for 
HV and CF patients was cleared through either renal or nonrenal clearance after IV 
administration.   
 
Figure 44 CIP IV administration cumulative excretion 
Cumulative excretion from the GI tract after IV administration of a 300 mg dose in HV 
(left plot) and CF patients (right plot)  
 
After PO administration, 33% and 16% was eliminated from the GI tract in both 
HV and CF patients respectively, and the remaining portions were eliminated through 
systemic clearance mechanisms from the central compartment.  
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Figure 45  CIP PO administration cumulative excretion 
Cumulative excretion from the GI tract after PO administration of a 100 mg dose in HV 
(left plot) and CF patients (right plot)  
 
However, after INH, 27% and 12% of the deposited dose was eliminated from the 
GI tract while the remaining 73% and 88% was eliminated from the central compartment 
in HV and CF patients, respectively.  
 
Figure 46 Cumulative excretion from the GI tract after INH of a 32.5 mg dose of 
CIP in HV 
 
 
134 
 
 
 
 
Figure 47 Cumulative excretion from the GI tract after INH of a 32.5 mg dose of 
CIP in CF patients  
 
5.5. Discussions and Conclusions 
5.5.1. Study Limitations 
For IV study CIP 101, the infusion time was not specified within the study, as 
such, a 15-minute infusion time was assumed. This was based on other studies 
performed during the same time period. From the nine identified IV studies, two studies 
were eliminated due to an inadequate analytical method, and insufficient reported data. 
The remaining seven studies provided a total of twelve cp(t) profiles for analysis. Out of 
the twelve PO studies, only 6 studies that provided twelve cp(t) profiles used in analysis. 
Lastly, all four INH studies identified were included in analysis and provided a total of 8 
cp(t) and 2 cs(t) profiles. Given that CIP was developed and the majority of the clinical 
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investigations were performed in the early 1980s, this resulted in the limited availability 
of data or the reliability of some of the analytical methods that were experimentally 
used.  
Furthermore, none of the IV and PO studies provide sputum exposure data in 
either HV or CF patients, and there were needed limited sputum data available for CF 
patients after INH and none was available for HV after INH. The availability of such data 
would have allowed for more confidence in the pulmonary disposition parameters. 
Additionally, there was no repeat dose studies available for IV, PO, or INH in either HV 
and CF. These studies would have been useful in studying possible drug accumulation 
in the various compartments as well as time dependence. We were also unable to 
obtain any data for the pediatric population, whether HV or CF patients. This is notable 
since they may often be the targeted population for this treatment. The lack of access to 
individual patient level data (both plasma and sputum) limited the ability to study the 
possible effects of covariate on both plasma and sputum exposures. Lastly, the INH 
data available was produced from the same device across the four studies. Additional 
data for various devices including pressurized inhalers and nebulizers would have been 
useful in studying the effect of device of plasma and sputum exposure.  
5.5.2. PK Dose-Proportionality 
The linear dose dependence plot after IV infusion shown in Figures 24 comparing 
the infused dose to the NCA calculated AUC, supported linear PK based on the high r2 
value for the linear model. Additionally, when the same data were plotted on a log-log 
scale (shown in the same Figure), and a power model was utilized for fitting the data, 
the exponential term is close to 1.0 which would also indicate linear PK. The PO data 
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available also supported linear PK as can be seen in both the linear fit as well as the 
power fit of the dose vs AUC data shown in Figure 2. Additionally, PO dose vs cmax was 
inspected in Figure 26 and also supported the linear PK conclusion. The same 
conclusion can be drawn after CIP is INH based on the results shown in Figure 27 and 
Figure 28. This finding is in agreement with the literature as several authors have also 
reported that CIP follows linear PK across a similar dose range. 109,124 These pieces of 
evidence provided a strong basis for the major modeling assumption, namely that all the 
rate constants were all first order rate constants. 
5.5.3. Final Parameter Space after IV Infusion  
An empiric two compartment open body model of IV infused CIP with an 
optimized model parameter space resulted in mechanistically plausible parameter 
estimates and was able to adequately predict the reported cp(t) profiles from clinical PK 
studies with HV and CF after a single dose. For both HV and CF patients, the peripheral 
compartment behaved as a high capacity, shallow compartment. Model optimized 
values indicated that CIP undergoes both renal and nonrenal clearance. The renal 
clearance values exceeded 120 mL/min suggesting that CIP undergoes net tubular 
secretion. CF patients had similar nonrenal clearance values as HV, and the numerical 
difference between both groups was further minimized when CLnonren was normalized by 
BW. However, for CLren, there was a stark difference between CF patients and HV; that 
difference was made more apparent when their respective values were BW normalized. 
Some authors have suggested that this increased renal clearance in CF patients may 
be due to overexpression for heightened activity of other transporters in the renal-tubule 
due to the mutation of the CFTR transporter. 125 
 
 
137 
 
When the optimized pulmonary disposition and oral absorption parameters were 
introduced to the empiric model, and CIP was administered via IV infusion, CIP was 
predominantly cleared through clearance from the central compartment with nearly 99% 
and 92% of the dose eliminated via systemic clearance (sum of renal or nonrenal 
clearances) in HV and CF patients respectively. After pulmonary excretion and transfer 
into GI tract, the remaining 1% for HV and 8% for CF was eliminated from the GI tract. 
These results may explain why none of the in-vivo clinic studies reported sputum 
exposure after IV administration. Additionally, this would also explain that IV 
administration is a sub-optimal dosing route when the lungs are being targeted as the 
site of action as in the case of CF. 
5.5.4. Final Parameter Space after PO Administration 
The final optimized oral absorption model and parameters for CIP suggested that 
HV and CF patients have a similar extent of absorption (73% and 85% respectively). 
Since it has already been shown that CF have lower nonrenal clearance (likely hepatic 
extraction), it is plausible that this lower nonrenal clearance would lead to higher Foral 
due to reduced hepatic first-pass effect. The difference between both groups was more 
evident in the rate of absorption (kga) where HV had an absorption rate constant that 
was nearly double that of CF patients (0.020 and 0.011 min-1, respectively). Since CIP 
is known to be zwitterionic within the physiological pH range of the GI tract, it is likely 
that in CF patients (where some transporters are overexpressed to compensate for the 
mutated CFTR transporter) CIP may undergo increased efflux transport.  
5.5.5. Final INH Model 
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The final INH model incorporated the two-compartment systemic disposition 
model, the oral absorption model, and two pulmonary compartments. This is model #1 
as described in Chapter Two. The selection of this model was based on the lack 
availability of sputum data, specifically, after IV administration. The model allowed for 
absorption from the lungs (central and peripheral) to the central compartment through 
kpa and kca, however, the model did not show that drug can redistribute from the central 
compartment back to the lungs. Mucociliary clearance was possible from both the 
peripheral and the central lung into the central lung and the GI tract compartments 
respectively.  
5.5.6. Final Parameter Space after Inhalation 
 
 
 
139 
 
Table 43 Final optimized model parameters with specified underlying covariate 
models and distributions 
 
The final parameter set, listed in Table 43, that was optimized using the available 
inhalation data and was able to describe the available cp(t) and cs(t) profiles as well as 
the exposure metrics. A single parameter space was used to describe both HV and CF 
patients. While CF patients are known to have altered lung physiology (such as thicker 
mucus and altered airway morphology), there were insufficient data to resolve the 
differences between both groups. Furthermore, mucociliary clearance from both the 
peripheral and the central lung was numerically identical. Experimental in-vivo data has 
suggested otherwise, and similar modeling efforts with other drugs have also suggested 
that mucociliary clearance values are different for both compartments.126 However, 
again due to the limited sputum data the ability to resolve these parameters was limited.  
Both the peripheral lung and the central lung compartments favored absorption 
into systemic circulation as compared to distribution from the central compartment into 
the lungs. This is especially evident in the central lung compartment where the  
𝑘𝑐𝑎
𝑘𝑐𝑑
 ratio 
is 100 relative to the 
𝑘𝑝𝑎
𝑘𝑝𝑑
 which is only 1.25. Due to the limited availability sputum data, a 
75% CV was associated with all pulmonary rate constants.  
5.5.7. Sensitivity Analysis  
While the results of the sensitivity analysis were numerically different between 
HV and CF, the rank order of most influential parameters was the same: IV sensitivity 
analysis results showed that AUC for both HV and CF with mostly dependent on both 
CLren and CLnonren, and for cmax, V0 was the most influential parameter.  
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After PO administration, a 25-fold change in Foral directly lead to a 25-fold change 
in both AUC and cmax for both HV and CF patients, as expected. Among the remaining 
parameters, CLren was most influential on AUC, and V0 was the second most influential 
parameter on cmax.  
After INH, both HV and CF plasma exposures were most sensitive to systemic 
disposition and oral absorption parameters. However, loss from the central lung 
compartment (whether through absorption or mucociliary clearance) was the most 
influential of pulmonary exposure/sputum in both HV and CF patients. This is plausible 
since loss from a compartment would likely directly and proportionally influence levels in 
that compartment.   
5.5.8. Overall Conclusions 
The validated IV, PO, and INH models were capable of describing the observed 
cp(t) and cs(t) profiles as well as the reported exposure metrics. Linear PK was validated 
across all three dosing routes. The data supported the application of a disease state 
covariate model that distinguished between HV and CF patients on the systemic 
disposition as well as the oral absorption parameters. This was most likely due to limited 
sputum data. Pulmonary disposition parameters were the same for both groups and 
followed log-normal distribution. The greatest parameter uncertainty was associated 
with the oral absorption parameters. Across all three dosing routes, elimination from the 
central compartment through renal or nonrenal pathways was the predominant 
mechanism of drug elimination. In both HV and CF patients, CLren was most influential 
on AUC and V0 was most influential on cmax after IV administration, while Foral was most 
influential on plasma exposure after PO administration. After INH, systemic exposure 
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was dependent on systemic disposition and oral absorption parameters, while 
pulmonary exposure was dependent most on loss from the central lung compartment. 
Lung disposition favored systemic uptake from the pulmonary compartments over 
excretion from plasma into the lung compartments. CIP has a high bioavailability after 
INH, but pulmonary excretion is a minor elimination pathway (relative to CLren and 
CLnonren). Lastly, sputum exposures are driven primarily by (rapid) pulmonary absorption 
and mucociliary clearances and not by systemic CIP exposure. 
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CHAPTER 6 
 
OVERALL CONCLUSIONS, LIMITATIONS AND FUTURE DIRECTIONS 
 
6.1. Available Data Used for Semi PBPK Modeling 
As described in Chapter 2, three semi-PBPK models for lung disposition were 
developed and validated to describe the experimentally observed data from published 
literature, and the final parameter estimates were interpreted physiologically for each of 
the three drugs. This chapter compares the individual models/model parameter 
estimates, and prospective predictions for the three drugs. 
Model #1 was used to describe the available cp(t) data for BUD, Model #2 was 
used to describe the available cp(t) and cs(t) data for CIP, and Model #3 was used to 
describe the available cp(t) and cs(t) data for TOB. In each of the three cases, the final 
model that was selected based on its ability to adequately describe the existing data, 
both mean concentration-time profiles and mean (±SD) exposure metrics as available 
after IV, PO (BUD and CIP only), and INH. 
Note, however, that Model #1 is a sub-model of Model #2, and Model #2 is sub-
model of Model #3. This does allow proper comparison of the final parameter sets: For 
Model #1 (BUD), kpd and kcd were set to 0 (i.e., unidirectional pulmonary uptake), and 
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the pulmonary sequestration compartments were assumed to equilibrate virtually 
instantaneously (i.e., kpls1, kpls2, kcls1, and kcls2 = 10,000 min-1). For Model #2 (CIP), the 
pulmonary sequestration compartments equilibrate virtually instantly (i.e., kpls1, kpls2, 
kcls1, and kcls2 = 10,000 min-1), but drug can be absorbed from and excreted into the 
pulmonary (unbound) compartments. 
A summary of the available data after each route of administration for each of the 
three drugs is shown in Table 44. These collected data sets satisfied specific aim #1 
listed in Chapter 2. 
 
 
Route of 
Administration 
Drug 
BUD TOB CIP 
cp(t) cs(t) cp(t) cs(t) cp(t) cs(t) 
IV 6 0 5 1 11 0 
PO 1 0 0 0 12 0 
INH 3 0 16 10 6 2 
INH Devices 1 5 1 
 
Table 44 Number of available data sets (cp(t) and cs(t)) after each route of 
administration for each of the three drugs of interest. 
As discussed in earlier chapters, only a limited number of studies were available 
for modeling. Major limitations included the absence or scarcity of sputum data for BUD 
and CIP; this obviously impacted estimation of their respective final pulmonary 
disposition parameters. 
Additionally, only a single repeat-dose study for TOB after IV administration, but 
not after INH, and none for BUD or CIP were reported in the literature. For BUD and 
CIP, this prevented formal assessment of drug accumulation in the lungs, that may not 
be discernible seen in plasma, as was the case for TOB.  
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In addition, all 13 sputum profiles (1 IV TOB, 10 INH TOB, and 2 INH CIP) were 
obtained from CF patients, and no information was available for HV; this prevented 
evaluation of any disease effect on pulmonary disposition.   
Moreover, there were only a few studies available in the desired patient 
populations, including CF patients for TOB and CIP, and asthmatic patients for BUD. 
Finally, some of the studies had to be excluded due to the use of an insensitive 
analytical method, or inadequate sampling schedule.   
In spite of these limitations, the available data sets were useful in generating 
appropriate disease and BW covariate models for systemic and GI absorption 
parameters.  For pulmonary disposition, only TLV was assumed to be allometrically 
related to BW, as discussed in chapter 1 and 4. As pointed out above, disease effect 
could not be discussed from available data.  
For BUD, Model #1 allows for unidirectional uptake of drug from the central and 
peripheral lung compartments into the systemic circulation. There were no sputum data 
available at all after IV administration of BUD, nor was there in-vitro or other evidence 
data supporting pulmonary sequestration and or excretion of BUD.  
For TOB, Model #3 allows for bidirectional movement, i.e., uptake from and 
excretion into pulmonary (unbound) compartments to account for the fact that TOB 
concentrations were achieved in sputum after IV administration; it also introduced 
pulmonary sequestration compartments to account for known in-vitro (intracellular) 
accumulation as well as reported in-vivo sputum accumulation after repeated INH 
dosing. Thus, the lung was considered an absorption, sequestration and excretion 
organ.  
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For CIP, Model #2 allowed for bidirectional flow of drug from the pulmonary 
compartments to and from the central compartment. This bidirectional flow allowed the 
model to adequately describe sputum concentrations profiles after INH. Thus, the lung 
was considered an absorption and excretion organ. 
 
6.2. Comparison Across Parameter Spaces for the Three Drugs 
6.2.1. Systemic Disposition Properties 
Pertinent key physicochemical properties of the three drugs are summarized in 
Table 45. As can be seen from Table 45, all three drugs have similar molecular weights, 
however they have different experimental log(P) values, ionization within physiological 
pH, and different solubility. Additionally, there A to B Papp values in both Caco-2 cell 
models and Calu-3 cell models are also different. The final optimized systemic 
disposition parameters for each of the three drugs are listed for comparison in Table 46. 
All parameters are for HV (BW = 75 kg).  
 
Table 45 Physicochemical properties of the three selected drugs. (Both Papp 
values are reported for A→B permeability).  
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Parameter BUD TOB CIP 
CLtot (mL/min) 1170 70 630 
V0 (L) 45 10 75 
k12 (min-1) 0.100 0.010 0.025 
k21 (min-1) 0.031 0.015 0.015 
k10 (min-1) 0.026 0.007 0.008 
Vdss (L) 190 17 200 
Depth (k10/k21) 0.84 0.47 0.53 
Capacity (k12/k21) 3.2 0.67 1.7 
 
 
Table 46 Comparison across the final optimized systemic disposition parameters 
for BUD, TOB, and CIP 
 
 
As expected, BUD shows the highest CLtot, followed by CIP, and TOB has the 
lowest value. Lipophilic compounds have been shown to undergo predominantly hepatic 
metabolism/biliary excretion.127  
Based on its lipophilicity, BUD, which is the most lipophilic of the three tested 
drugs, has the largest total clearance approaching hepatic blood flow, indicating high 
hepatic extraction. This also explains its low Foral as result of high pre- systemic hepatic 
extraction (see below). 
Based on its estimated CLtot and Foral values, its intermediate lipophilicity, as well 
as its zwitterionic properties, CIP is known to undergo both hepatic and renal 
elimination. Its renal clearance is reported in Chapter 5 and indicates net tubular 
secretion, involving drug transporters (OATs). Renal excretion is the major route of 
elimination as the fraction of the administered dose that is eliminated unchanged in 
urine after IV administration is between 40% to 60%. 108,112  
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Lastly, TOB, which has the lowest CLtot, virtually exclusively undergoes renal 
excretion due to its hydrophilicity; specifically, it undergoes net tubular reabsorption due 
to the possible involvement of some cationic transporters.128 
The peripheral body compartment for all three drugs - needed to properly model 
systemic disposition data - is a shallow body compartment, equilibrates rapidly with the 
central compartment (plasma): Final parameter estimates for both BUD and CIP 
indicate that these peripheral tissue compartment is a low-capacity compartment, i.e., 
contain only a small portion of the administered dose, while, for TOB, it is an 
intermediate-capacity compartment. This increased capacity noted for TOB may be due 
to the aforementioned intracellular tissue sequestration observed in in-vitro studies in 
the lung.24  
As both BUD and CIP are sufficiently lipophilic and small to cross epithelia, they 
both have large Vdss, indicating extensive extravascular distribution. CIP has a slightly 
smaller Vdss, which may be attributed to its zwitterionic charge in the physiological pH 
range. On the other hand, TOB has quite a small Vdss, indicating limited extravascular 
distribution. In addition to being a hydrophilic drug, TOB is highly charged and is likely to 
be a polycationic drug within physiological pH range.  
To better emphasize their differences in systemic PK properties comparative 
simulations of cp(t) and cs(t) were performed. Using the final parameter estimates for 
each of the three drugs, a 10-minute IV infusion of a non-therapeutic dose of 200 mg 
was simulated. The results of these simulations are shown in Figure 48.  
 
 
148 
 
As can be seen, there are no BUD concentrations in sputum after IV 
administration. This is expected since the model (Model #1) does not allow distribution 
from the systemic circulation to the pulmonary compartments.  
However, the final models (Model #2 and #3) for both TOB and CIP predict drug 
concentrations in sputum after IV administration. The magnitude of concentration 
difference between plasma and sputum for TOB is greater than that for CIP. Notably, 
TOB plasma concentrations are 100-fold higher than sputum concentrations due to its 
limited distribution to the lungs, given the minor capacity the of central lung 
sequestration compartment (kcls1/kcsl2 = 0.0007). Although the peripheral lung 
sequestration compartment is a high-capacity compartment (kpls1/kpls2 = 3.75), the 
peripheral unbound lung compartment that moves TOB via mucociliary clearance into 
the central unbound lung compartment is a low-capacity compartment (kpd/kpa = 0.009). 
As result, the central unbound lung compartment/sputum concentrations are quite small, 
and most of TOB in the lung is trapped in the peripheral sequestration compartment, 
which serves as reservoir for TOB to redistribute primarily into the central 
compartment/plasma and, to a much lesser extent, into the central unbound lung 
compartment/sputum.  Additionally, the terminal slopes in the plasma and sputum 
profiles appear to be parallel for both TOB and CIP. This indicates that the central 
unbound lung and central (body) compartments are in equilibrium, and the rate-limiting 
step for both compartments is distribution from the systemic circulation to the lungs, i.e. 
pulmonary excretion with some intrapulmonary recycling.  
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Figure 48 Simulations for BUD, TOB, and CIP after IV administration (Infusion of 
200 mg over 10-minutes) 
 
 
6.2.2. Oral Absorption Properties 
The final optimized oral/GI absorption parameters for each of the three drugs are 
listed for comparison in Table 47. 
Foral for BUD is low, only about 10% due to high hepatic first-pass effect, given 
that it is a high hepatic extraction ratio drug.  
As previously discussed, TOB is hydrophilic and highly charged. These 
characteristics lead to a negligible Foral of ~0%, predominantly due to poor GI 
permeability (consistent with poor Caco-2 permeability, as shown in Table 45).  
Foral for CIP was estimated to be 73% for HV and 85% for CF patients. These 
values are in line with a small degree of first-pass effect and/ or the possible 
involvement of GI efflux transporters. The difference between Foral for HV and CF 
 
 
150 
 
patients has been discussed by several authors, who have theorized that it may be due 
to the overexpression of GI uptake transporters to compensate for the mutated CFTR 
transporter.125,129 
 
Parameter BUD TOB CIP 
kga (min-1) 0.007 0 0.020 
Foral (%) 10 0 73 
 
Table 47 Comparison across the final GI absorption parameters for BUD, TOB, 
and CIP 
 
To better understand the implications of these differences in GI absorption 
properties, comparative simulations of cp(t) and cs(t) were performed with a non-
therapeutic dose of 1000 mg. The results of these simulations are shown in Figure 49.  
Although there are concentrations of BUD in plasma, there are no sputum 
concentrations of BUD, as is expected since the model (Model #1) does not allow 
distribution from the systemic circulation to the pulmonary compartments. 
Since TOB is not orally bioavailable, there are no plasma nor sputum 
concentrations.  
Lastly, CIP is absorbed well from the GI into plasma, and distributes into the 
(unbound) lung compartments as shown by the sputum profile. Peak sputum 
concentration for lags behind the peak plasma concentration due to slow distribution 
from the central compartment into the (unbound) lung compartments. Additionally, the 
terminal slopes in plasma and sputum profiles appear to be parallel for CIP, which 
indicates that the (unbound) central lung compartment and the central body 
compartment are in equilibrium, and the rate-limiting step for is distribution from the 
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systemic circulation to the lungs, i.e., pulmonary excretion with some intrapulmonary 
recycling.  
 
 
Figure 49 Simulations for BUD, TOB, and CIP after PO administration (1000 mg) 
 
6.2.3. Pulmonary Disposition Properties 
Parameter BUD TOB CIP 
kpa (min-1) 0.066 0.900 0.010 
kca (min-1) 0.033 0.650 0.020 
kpm (min-1) 0.008 0.020 0.020 
kcm (min-1) 0.016 0.080 0.020 
kpd (min-1) 0 0.008 0.008 
kcd (min-1) 0 0.0002 0.0002 
kpls1 (min-1) 10000 0.015 10000 
kpls2 (min-1) 10000 0.004 10000 
kcls1 (min-1) 10000 0.002 10000 
kcls2 (min-1) 10000 0.3 10000 
Table 48 Comparison of the final, optimized pulmonary disposition parameters for 
BUD, TOB and CIP.  
Absence of pulmonary sequestration is indicated by large values (10,000) for kpls1, kpls2, 
kcls1, and kcls2.  
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Overall, the final parameters indicate that: a) BUD undergoes pulmonary 
absorption only, b) TOB undergoes pulmonary absorption/sequestration and excretion, 
and c) CIP undergoes pulmonary absorption and excretion. Both BUD and CIP are not 
sequestered in the lungs and are absorbed rapidly into systemic circulation from their 
pulmonary compartments.   Both TOB and CIP also undergo intrapulmonary recycling 
due bidirectional pulmonary uptake into and efflux from the central compartment, along 
with mucocililary clearance from the peripheral to the central (unbound) lung 
compartment. 
Values for kpa and kca for BUD are notably faster when compared to CIP. This is 
likely due to the lipophilicity as well as the neutral state of BUD, which would facilitate its 
pulmonary membrane permeability and rapid uptake of the deposited dose. 
On the other hand, TOB, which is hydrophilic and has polycationic charges, has 
the fastest kpa and kca values but, slow kpls2 and kcls2 values. The latter micro rate 
constants govern the movement of the drug from the pulmonary sequestration 
compartments to the central compartment. The low values associated with TOB point to 
a slow pulmonary absorption into systemic circulation. This again is in line with its 
hydrophilic and cationic nature and consistent with the low Papp values in CaLu cell lines 
(see Table 45). 
 A study of mucociliary clearance values for inhaled substances indicated that 
mucociliary clearances values can depend on the pulmonary solubility of the inhaled 
drug. 87   Specifically, more soluble compounds were shown to have mucociliary 
clearance rate constants between 0.0167 and 0.0083 min-1, while less soluble 
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compounds had a mucociliary clearance rate constant of 0.0013 min-1.  TOB, had the 
highest experimental solubility, with a solubility of 1000 mg/mL, followed by CIP with a 
solubility 40 mg/mL, and BUD with a solubility 19 ᛫ 10-3 mg/mL. This rank order of 
solubility leads to the observed rank order of the estimated kcm values, with TOB having 
the fastest, CIP having the intermediate, and BUD having the slowest kcm values, 
respectively.  
 The final optimized pulmonary deposition parameters and pulmonary 
bioavailability estimates for each of the three drugs are listed for comparison in Table 
49. 
 
Parameter BUD TOB CIP 
DtL 28% 15% 53% 
DtGI 58% 8.5% 40% 
Device Dose (mg) 1 300 32.5 
Fpul (%) 83% 10% 8% 
Finh (%) 34% 6% 36% 
 
Table 49 Comparison across the final optimized pulmonary deposition 
parameters and pulmonary bioavailabilities for BUD, TOB, and CIP.   
(Deposition values for BUD, TOB, and CIP are for the Turbuhaler, Pari LC Jet 
Nebulizer, and Novartis T-326 DPI device, respectively) 
 
The value for Finh depends on the composite of pulmonary and GI tract deposition 
along with the respective bioavailabilities; i.e., Fpul and Foral (Equation5 in Chapter 2).  
On the other hand, Fpul depends solely on the pulmonary disposition micro rate 
constants. 
For BUD, of the total inhalation device dose, 28% is deposited in the lungs while 
58% is deposited in the GI tract. Pulmonary bioavailability (Fpul) for BUD is 83%, 
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meaning that of the 28% deposited in the lungs, 83% is subsequently absorbed into 
systemic circulation. On the other hand, the 58% deposited in the GI tract is available 
for GI absorption but limited by a Foral of 10% due to high pre-systemic hepatic 
metabolism. As such, after inhalation, the total bioavailability (Finh) for BUD is only 34%, 
despite a high Fpul, but due to poor pulmonary deposition and poor oral bioavailability  
For TOB, only 15% of the nebulized dose is deposited in the lungs, and only 8.5% 
is deposited in the GI tract (due to the poor efficiency of the Pari Nebulizer). For TOB, 
Fpul is only 10% - due to poor pulmonary permeability/sequestration-, and Foral is 0%, 
which leads to a low Finh of 6%. 
For CIP, while a large fraction of the dose (53%) of the inhalation device dose is 
deposited the lung, Fpul is only 8%.  The low Fpul value is the result of efficient 
mucociliary clearance and pulmonary excretion, which reduced pulmonary absorption.  
However, due to its high Foral and the fact that 40% of the dose are deposited in the GI 
tract, Finh for CIP is 36%, similar to BUD  
Overall, for both TOB and CIP Fpul values were low (10% and 8%, respectively) 
due to their excretion from the central body compartment/plasma into the lungs. 
Specifically, TOB was excreted from the central body compartment into the peripheral 
lung sequestration compartment while CIP was excreted from the central body 
compartment into the peripheral unbound lung compartment. 
The final parameter spaces for both TOB and CIP was utilized in Chapters 4 and 
5, respectively, to study the contribution of pulmonary excretion to the overall excretion 
from the body after IV administration: For TOB and CIP, the lung contributed 7% and 
1.3%, respectively, of the total dose to overall excretion.  This indicates that the lung is 
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not a major elimination organ, however, pulmonary excretion plays a major role in 
pulmonary disposition and the resulting sputum concentrations. 
All three models and validated model parameter estimates, satisfied specific aim 
#2 as described in Chapter 2. 
 
To better understand the differences between the three drugs in their pulmonary 
disposition properties, comparative simulations of cp(t) and cs(t) were performed with a 
non-therapeutic INH dose of 500 mg. Deposition data for each drug was set to the 
values noted for the devices discussed earlier, and inhalation time was set to zero (i.e., 
instantaneous deposition was assumed). The results of these simulations are shown in 
Figure 50.  
As can be seen in Figure 50, for BUD after INH, the cs(t) profile shows a rapid 
decrease, which reflects rapid (unidirectional) absorption of the deposited dose from 
both peripheral and central (unbound) lung compartments into the central body 
compartment/plasma. Plasma concentrations initially increase rapidly due to pulmonary 
absorption, and, after reaching a maximum concentration, they decline in a first-order 
fashion with systemic elimination (k10) as the rate-limiting step. 
Concentrations of TOB in the central unbound lung compartment/sputum at first 
decrease very rapidly due to a fast kca (faster than BUD or CIP); i.e., rapid uptake into 
the central lung sequestration compartment, however, show a second peak. This 
second peak is likely due to intrapulmonary recirculation through the peripheral lung 
sequestration compartment, which behaves as a reservoir.  After initial rapid pulmonary 
uptake into this high-capacity compartment, TOB distributes from the central body 
compartment/plasma into this peripheral lung sequestration compartment and is slowly 
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released into the peripheral unbound lung compartment and subsequently moved into 
the central unbound lung compartment/sputum via mucociliary clearance – leading to 
the second peak. This is also in agreement with published literature, showing TOB 
accumulation in sputum after repeated dosing. Accordingly, the lung compartments 
behave as absorption/excretion and sequestration compartments for TOB. Plasma 
concentrations of TOB after inhalation peak rapidly due to fast, initial pulmonary 
absorption (kca and kcls2). This is followed by a distribution phase which is likely 
governed by equilibration with the peripheral sequestration lung compartment, before 
reaching its terminal phase, which is governed by equilibration with the central lung 
compartment (kcls1). 
For CIP, sputum concentrations follow a biphasic decline after inhalation: The 
initial decline is due to rapid absorption from the lung compartments into the central 
body compartment/plasma (kca and kpa). The slower terminal decline is due to the 
subsequent distribution from the central compartment back to the central lung 
compartment (kcd) and pulmonary excretion. This further proves that the lung 
compartments for CIP behave as absorption/excretion compartments. Plasma 
concentrations for CIP achieve their maximum later than TOB and BUD, which is 
explained by its slowest pulmonary absorption (kca) among the three drugs. The 
terminal phase in the plasma concentration-time profile for CIP declines in parallel with 
sputum concentrations and is governed by kcd.  
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Figure 50 Simulations for BUD, TOB, and CIP after INH (500 mg, assuming 
instantaneous deposition into the lung; deposition for 3 devices, respectively) 
 
 
6.3. Comparison of Sensitivity Analysis for Each of the Three Drugs 
6.3.1. Plasma Sensitivity Analysis  
The results for the plasma and sputum sensitivity analyses are shown in Table 
46. 
 
Exposure 
metric 
Plasma AUC Sputum AUC 
Drug BUD TOB CIP TOB CIP 
1st V0 CLtot CLren kca kcm 
2nd k10 kpls1 k12 kcm kca 
3rd Foral kpls2 CLnonren kpm kpd 
 
Table 50 Top three most influential parameters for each of the exposure metrics 
for each of the studied drugs. 
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After INH, the plasma AUC for all three drugs was found to be most sensitive to 
changes in CLtot.  For TOB, this was explicitly seen in the sensitivity analysis, with CLtot 
being the most influential parameter. For CIP, CLren and CLnonren, the sum of which is 
CLtot, were both among the two three most influential parameters on plasma AUC. 
Lastly, for BUD, plasma AUC was most sensitive to V0 and k10, the product of which is 
CLtot.  
Interestingly, for BUD, plasma AUC was also sensitive to Foral. This is likely due 
to the high GI deposition from the Turbuhaler (DtGI = 58%) combined with the low Foral 
of 10%. For TOB, plasma AUC was sensitive to the distribution from the central body 
compartment to the peripheral lung sequestration compartment (kpls1), and the uptake 
from the peripheral lung sequestration compartment into the central body compartment 
(kpls2). This is likely due to the high peripheral lung deposition of drug from the nebulizer 
combined with a low Fpul of 10%. For both BUD and TOB, given that a large fraction of 
their INH dose is deposited in the GI tract and the peripheral lung, a slight increase in 
Foral or Fpul, respectively, is expected to lead to a large increase in plasma AUC. 
6.3.2. Sputum Sensitivity Analysis 
A major underlying assumption of this work was that sputum concentrations 
correlate with pulmonary compartments, specifically, concentration in the central 
(unbound) lung compartment.  
Since the model used for BUD (Model #1) and the final optimized parameter 
space were not validated against sputum data (due to absence of published data), 
sputum AUC sensitivity was not performed for BUD.  
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For TOB and CIP, sputum AUC was consistently sensitive to decreases in kca and 
kcm. The sum of these parameters characterizes the rate of loss from the central lung 
compartment (equivalent of CLtot from a central compartment). It is that rate of loss from 
the central (unbound) lung compartment that is most important for central lung 
(unbound) compartment concentrations, i.e., sputum exposure, for both drugs since 
their pulmonary absorption is slow and low (see Table 45). kpm and kpd appear also to be 
influential parameters with regards to sputum AUC. This is likely due to their influence 
on concentrations in the peripheral (unbound) lung compartment which in turn can 
(indirectly) influence concentrations in the central (unbound) lung compartment/sputum 
as long as some of the inhaled dose is deposited into the peripheral (unbound) lung 
compartment. 
These findings are in line with the hypothesis stated in Chapter 2, specifically that, 
after inhalation, (a) decreasing systemic exposures can be accomplished by increasing 
total systemic clearance (CLtot), but are less sensitive to pulmonary absorption, and (b) 
increasing pulmonary exposures can be accomplished by slowing down uptake from the 
lungs into systemic circulation (kca) and/or slowing down mucociliary clearance from the 
lungs into the GI tract (kcm).  
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Matlab Script to run MCS for BUD 
%Author: Bishoy Erian 
%Start date: May 14th, 2015 
%Purpose: To plot the 95th & 5th percentile after a Monte Carlo Simulation 
%for my inhalation model based on the laplace transformed solution 
 
clear all 
close all 
clc 
clf 
close Figure 1 
Tstart=tic; 
 
digits(10) 
rng('default') 
rng(3) 
%% User input area 
n=20000; %number of simulations to run 
Last_time_point=1440; %I typically think this should be in minutes 
IFS=0.5; %0.5 means every half a minute; Increment for simulation 
 
%Deposition Parameters 
MDem=720; %nmol 
CVDem=0; %60; 
MFex=0.001175; 
CVFex=0;%0.000957; 
MFpd=0.098; 
CVFpd=0;%0.012; 
MFcd=0.117; 
CVFcd=0;%0.00495; 
 
%Lung Parameters 
Mkpm=0.0078; 
CVkpm=0; 
Mkcm=0.01563; 
CVkcm=0; 
Mkpa=0.3333; 
CVkpa=0; 
Mkca=0.166667; 
CVkca=0; 
 
%Oral Absorption Parameters 
Mkga=0.0056; 
CVkga=0.35; 
MForal=0.0995; 
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CVForal=0.3; 
 
%Systemic Disposition Parameters 
MV0=58; 
CVV0=0.15; 
Mk12=0.095; 
CVk12=0.2; 
Mk21=0.0308; 
CVk21=0.2; 
Mk10=0.0273; 
CVk10=0.15; 
 
%Dosing interval 
tau=2000; 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%%%%%%%%%%%%%%%%            End User Input            
%%%%%%%%%%%%%%%%%% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%% Coefficient of Variation to variance conversion 
SDem=(CVDem*MDem)^2; 
SFex=(CVFex*MFex)^2; 
SFpd=(CVFpd*MFpd)^2; 
SFcd=(CVFcd*MFcd)^2; 
Skpm=(CVkpm*Mkpm)^2; 
Skcm=(CVkcm*Mkcm)^2; 
Skpa=(CVkpa*Mkpa)^2; 
Skca=(CVkca*Mkca)^2; 
Skga=(CVkga*Mkga)^2; 
SForal=(CVForal*MForal)^2; 
SV0=(CVV0*MV0)^2; 
Sk12=(CVk12*Mk12)^2; 
Sk21=(CVk21*Mk21)^2; 
Sk10=(CVk10*Mk10)^2; 
 
%% Parameter distribution creation 
 
%Dose parameters 
%Dem1=MDem/5   :  MDem/4166.5 : 5*MDem; 
Dem1=normrnd(MDem,SDem,[1,n]); 
%Fex1=MFex/5   :  MFex/4166.5 : 5*MFex; 
Fex1=normrnd(MFex,SFex,[1,n]); 
%Fpd1=MFpd/5   :  MFpd/4166.5 : 5*MFpd; 
Fpd1=normrnd(MFpd,SFpd,[1,n]); 
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%Fcd1=MFcd/5   :  MFcd/4166.5 : 5*MFcd; 
Fcd1=normrnd(MFcd,SFcd,[1,n]); 
 
 
%Lung parameters 
%kpm1=Mkpm/5   :  Mkpm/4166.5 : 5*Mkpm; 
%kpm1=Mkpm/10   :  Mkpm/2020.2 : 10*Mkpm; 
kpm1=lognrnd(log(Mkpm^2 / sqrt(Skpm+Mkpm^2)),sqrt(log(Skpm/Mkpm^2 + 1)),[1,n]); 
%kcm1=Mkcm/5   :  Mkcm/4166.5 : 5*Mkcm; 
kcm1=lognrnd(log(Mkcm^2 / sqrt(Skcm+Mkcm^2)),sqrt(log(Skcm/Mkcm^2 + 1)),[1,n]); 
%kpa1=Mkpa/5   :  Mkpa/4166.5 : 5*Mkpa; 
kpa1=lognrnd(log(Mkpa^2 / sqrt(Skpa+Mkpa^2)),sqrt(log(Skpa/Mkpa^2 + 1)),[1,n]); 
%kca1=Mkca/5   :  Mkca/4166.5 : 5*Mkca; 
kca1=lognrnd(log(Mkca^2 / sqrt(Skca+Mkca^2)),sqrt(log(Skca/Mkca^2 + 1)),[1,n]); 
 
 
%Oral Deposition Parameters 
%kga1=Mkga/5   :  Mkga/4166.5 : 5*Mkga; 
kga1=lognrnd(log(Mkga^2 / sqrt(Skga+Mkga^2)),sqrt(log(Skga/Mkga^2 + 1)),[1,n]); 
%Foral1=MForal/5   :  MForal/4166.5 : 5*MForal; 
Foral1=lognrnd(log(MForal^2 / sqrt(SForal+MForal^2)),sqrt(log(SForal/MForal^2 + 
1)),[1,n]); 
 
 
%Systemic Disposition Parameters 
%V01=MV0/5  :  MV0/4166.5 : 5*MV0; 
V01=lognrnd(log(MV0^2 / sqrt(SV0+MV0^2)),sqrt(log(SV0/MV0^2 + 1)),[1,n]); 
%k121=Mk12/5   :  Mk12/4166.5 : 5*Mk12; 
k121=lognrnd(log(Mk12^2 / sqrt(Sk12+Mk12^2)),sqrt(log(Sk12/Mk12^2 + 1)),[1,n]); 
%k211=Mk21/5   :  Mk21/4166.5 : 5*Mk21; 
k211=lognrnd(log(Mk21^2 / sqrt(Sk21+Mk21^2)),sqrt(log(Sk21/Mk21^2 + 1)),[1,n]); 
%k101=Mk10/5   :  Mk10/4166.5 : 5*Mk10; 
k101=lognrnd(log(Mk10^2 / sqrt(Sk10+Mk10^2)),sqrt(log(Sk10/Mk10^2 + 1)),[1,n]); 
 
 
%       MU = log(M^2 / sqrt(V+M^2)) 
%       SIGMA = sqrt(log(V/M^2 + 1)) 
%% Matrix setup/allocation 
time=0:IFS:Last_time_point; 
t=0; 
NoP=(Last_time_point/IFS)+1;%plus one accounts for the 
DoseCounter=0; 
 
% the zero time point 
AmtPL=ones(NoP,n); 
AmtCL=ones(NoP,n); 
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AmtGIT=ones(NoP,n); 
AmtPC=ones(NoP,n); 
AmtCC=ones(NoP,n); 
Cp=ones(NoP,n); 
 
ContPL=ones(NoP,n);     ContCL=ones(NoP,n);     ContGIT=ones(NoP,n); 
ContPLCL=ones(NoP,n);   ContCLGIT=ones(NoP,n);  ContPLCLGIT=ones(NoP,n); 
LastCC=ones(NoP,n); 
 
ContPPL=ones(NoP,n);    ContPCL=ones(NoP,n);    ContPGIT=ones(NoP,n); 
ContPPLCL=ones(NoP,n);  ContPCLGIT=ones(NoP,n); ContPPLCLGIT=ones(NoP,n); 
LastPC=ones(NoP,n); 
 
cmax=ones(1,n);     tmax=ones(1,n);     Auc=ones(1,n);      thalfbet=ones(1,n);  
AAUC=ones(1,n);     AUMC=ones(1,n);     MRT=ones(1,n);      CCa=ones(1,n); 
CCb=ones(1,n);      CCc=ones(1,n);      CCp=ones(1,n);      CCg=ones(1,n); 
CC1=ones(1,n);      CC2=ones(1,n);      CC3=ones(1,n);      CC4=ones(1,n); 
CC5=ones(1,n);      CC6=ones(1,n);      CC7=ones(1,n);      CC8=ones(1,n); 
CC9=ones(1,n);      CC10=ones(1,n);     CC11=ones(1,n);     CC12=ones(1,n); 
CC13=ones(1,n);     CC14=ones(1,n);     CC15=ones(1,n);     CC16=ones(1,n); 
CC17=ones(1,n);     CC18=ones(1,n);     CC19=ones(1,n);     CC20=ones(1,n); 
CC21=ones(1,n);     CC22=ones(1,n); 
for  j=1:1:n 
    %Parameter value selection from randomly generated array 
    Dem=Dem1(1,j);          Fex=Fex1(1,j);    Fpd=Fpd1(1,j); 
    Fcd=Fcd1(1,j);          kpm=kpm1(1,j);    kcm=kcm1(1,j); 
    kpa=kpa1(1,j);          kca=kca1(1,j);    kga=kga1(1,j); 
    Foral=Foral1(1,j);      V0=V01(1,j);      k12=k121(1,j); 
    k21=k211(1,j);          k10=k101(1,j); 
     
    %%Calculation secondary Model Parameters 
    kp=kpm+kpa; 
    kc=kcm+kca; 
    alp_p_bet=k12+k21+k10; 
    alp_m_bet=k21*k10; 
    alp=(-alp_p_bet-(   (alp_p_bet^2) - (  4*alp_m_bet)  )^0.5)/-2; 
    bet=(-alp_p_bet+(   (alp_p_bet^2) - (  4*alp_m_bet)  )^0.5)/-2; 
    Fgd=1-Fpd-Fcd-Fex; 
    PL0=Dem*Fpd; 
    CL0=Dem*Fcd; 
    GIT0=Dem*Fgd; 
     
    %% Percentage done 
    if (j*100/n)==0 || (j*100/n)==25 || (j*100/n)==50 || (j*100/n)==75 || (j*100/n)==100 
        clc 
        howmuch=num2str(j*100/n); 
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        disp(strcat('currently',{' '},howmuch, '% done'));    
    end 
for i=1:1:NoP 
    if(rem(time(1,i),tau)==0); 
        if (time(1,i)==0); 
            LastCC(i,j)=0; 
            LastPC(i,j)=0; 
            GIT0=Dem*Fgd; 
            CL0=Dem*Fcd; 
            PL0=Dem*Fpd; 
        else 
            GIT0=(((CL0*kcm*(exp(-kc*(IFS+t))-exp(-kga * (IFS+t)))/(kga-
kc))+(PL0*kcm*kpm*((exp(-kc*(IFS+t))/((kp-kc)*(kga-kc)))+(exp(-kp*(IFS+t))/((kc-
kp)*(kga-kp)))+(exp(-kga*(IFS+t))/((kc-kga)*(kp-kga)))))+ (GIT0*exp(-
kga*(IFS+t))))+(Dem*Fgd)); 
            CL0=(((CL0*exp(-kc*(t+IFS)))+(PL0*kpm*(exp(-kc*(t+IFS))-exp(-kp*(t+IFS)))/(kp-
kc)))+(Dem*Fcd)); 
            PL0=(PL0*exp(-kp*(t+IFS)))  +(Dem*Fpd); 
            LastCC(i,j)=AmtCC(i-1,j); 
            LastPC(i,j)=AmtPC(i-1,j); 
        end 
        t=0; 
        DoseCounter=DoseCounter+1; 
    else 
        LastCC(i,j)=LastCC(i-1,j); 
        LastPC(i,j)=LastPC(i-1,j); 
        GIT0=GIT0; 
        CL0=CL0; 
        PL0=PL0; 
        t=t+IFS; 
    end    
     
    AmtPL(i,j)=PL0*exp(-kp*t); 
     
    AmtCL(i,j)=CL0*exp(-kc*t)+PL0*kpm*(exp(-kc*t)-exp(-kp*t))/(kp-kc); 
     
        GIT1=GIT0*exp(-kga*t); 
        GIT2=CL0*kcm*(exp(-kc*t)-exp(-kga*t))/(kga-kc); 
        GIT3=PL0*kpm*kcm*((exp(-kp*t)/((kc-kp)*(kga-kp)))+(exp(-kc*t)/((kp-kc)*(kga-
kc)))+(exp(-kga*t)/((kp-kga)*(kc-kga)))); 
    AmtGIT(i,j)=GIT1+GIT2+GIT3; 
     
        ContPL(i,j)=PL0*kpa*(  ((k21-kp)*exp(-kp*t)/((alp-kp)*(bet-kp)))  +  ((k21-alp)*exp(-
alp*t)/((kp-alp)*(bet-alp)))   +   ((k21-bet)*exp(-bet*t)/((kp-bet)*(alp-bet)))); 
        ContCL(i,j)=CL0*kca*(  ((k21-kc)*exp(-kc*t)/((alp-kc)*(bet-kc)))  +  ((k21-alp)*exp(-
alp*t)/((kc-alp)*(bet-alp)))   +   ((k21-bet)*exp(-bet*t)/((kc-bet)*(alp-bet)))); 
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        ContGIT(i,j)=GIT0*kga*Foral*(  ((k21-kga)*exp(-kga*t)/((alp-kga)*(bet-kga)))  +  
((k21-alp)*exp(-alp*t)/((kga-alp)*(bet-alp)))   +   ((k21-bet)*exp(-bet*t)/((kga-bet)*(alp-
bet)))); 
        ContPLCL(i,j)=PL0*kpm*kca*(  ((k21-kc)*exp(-kc*t)/((alp-kc)*(bet-kc)*(kp-kc)))  +  
((k21-kp)*exp(-kp*t)/((alp-kp)*(bet-kp)*(kc-kp)))  +  ((k21-alp)*exp(-alp*t)/((kp-alp)*(bet-
alp)*(kc-alp)))  +  ((k21-bet)*exp(-bet*t)/((kp-bet)*(alp-bet)*(kc-bet)))); 
        ContCLGIT(i,j)=CL0*kcm*kga*Foral*(  ((k21-kc)*exp(-kc*t)/((alp-kc)*(bet-kc)*(kga-
kc)))  +  ((k21-kga)*exp(-kga*t)/((alp-kga)*(bet-kga)*(kc-kga)))  +  ((k21-alp)*exp(-
alp*t)/((kga-alp)*(bet-alp)*(kc-alp)))  +  ((k21-bet)*exp(-bet*t)/((kga-bet)*(alp-bet)*(kc-
bet)))); 
        ContPLCLGIT(i,j)=PL0*kpm*kcm*kga*Foral*(  ((k21-kc)*exp(-kc*t)/((alp-kc)*(bet-
kc)*(kga-kc)*(kp-kc)))  +  ((k21-kga)*exp(-kga*t)/((alp-kga)*(bet-kga)*(kc-kga)*(kp-kga)))  
+  ((k21-alp)*exp(-alp*t)/((kga-alp)*(bet-alp)*(kc-alp)*(kp-alp)))  +  ((k21-bet)*exp(-
bet*t)/((kga-bet)*(alp-bet)*(kc-bet)*(kp-bet)))  + ((k21-kp)*exp(-kp*t)/((kga-kp)*(alp-
kp)*(kc-kp)*(bet-kp)))); 
    
AmtCC(i,j)=ContPL(i,j)+ContCL(i,j)+ContGIT(i,j)+ContPLCL(i,j)+ContCLGIT(i,j)+ContPL
CLGIT(i,j)+LastCC(i,j); 
    Cp(i,j)=AmtCC(i,j)/V0; 
     
        ContPPL(i,j)=PL0*kpa*k12*(  (exp(-kp*t)/((alp-kp)*(bet-kp)))  +  (exp(-alp*t)/((kp-
alp)*(bet-alp)))   +   (exp(-bet*t)/((kp-bet)*(alp-bet)))); 
        ContPCL(i,j)=CL0*kca*k12*(  (exp(-kc*t)/((alp-kc)*(bet-kc)))  +  (exp(-alp*t)/((kc-
alp)*(bet-alp)))   +   (exp(-bet*t)/((kc-bet)*(alp-bet)))); 
        ContPGIT(i,j)=GIT0*kga*Foral*k12*(  (exp(-kga*t)/((alp-kga)*(bet-kga)))  +  (exp(-
alp*t)/((kga-alp)*(bet-alp)))   +   (exp(-bet*t)/((kga-bet)*(alp-bet)))); 
        ContPPLCL(i,j)=PL0*kpm*kca*k12*(  (exp(-kc*t)/((alp-kc)*(bet-kc)*(kp-kc)))  +  
(exp(-kp*t)/((alp-kp)*(bet-kp)*(kc-kp)))  +  (exp(-alp*t)/((kp-alp)*(bet-alp)*(kc-alp)))  +  
(exp(-bet*t)/((kp-bet)*(alp-bet)*(kc-bet)))); 
        ContPCLGIT(i,j)=CL0*kcm*kga*Foral*k12*(  (exp(-kc*t)/((alp-kc)*(bet-kc)*(kga-kc)))  
+  (exp(-kga*t)/((alp-kga)*(bet-kga)*(kc-kga)))  +  (exp(-alp*t)/((kga-alp)*(bet-alp)*(kc-
alp)))  +  (exp(-bet*t)/((kga-bet)*(alp-bet)*(kc-bet)))); 
        ContPPLCLGIT(i,j)=PL0*kpm*kcm*kga*Foral*k12*(  (exp(-kc*t)/((alp-kc)*(bet-
kc)*(kga-kc)*(kp-kc)))  +  (exp(-kga*t)/((alp-kga)*(bet-kga)*(kc-kga)*(kp-kga)))  +  (exp(-
alp*t)/((kga-alp)*(bet-alp)*(kc-alp)*(kp-alp)))  +  (exp(-bet*t)/((kga-bet)*(alp-bet)*(kc-
bet)*(kp-bet)))  + (exp(-kp*t)/((kga-kp)*(alp-kp)*(kc-kp)*(bet-kp)))); 
   
AmtPC(i,j)=ContPPL(i,j)+ContPCL(i,j)+ContPGIT(i,j)+ContPPLCL(i,j)+ContPCLGIT(i,j)+
ContPPLCLGIT(i,j)+LastPC(i,j); 
 
    
    
end 
 
%% 
        CC1(1,j)=PL0*kpa*(((k21-kp)/((alp-kp)*(bet-kp)))); 
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        CC2(1,j)=PL0*kpa*(((k21-alp)/((kp-alp)*(bet-alp)))); 
        CC3(1,j)=PL0*kpa*(((k21-bet)/((kp-bet)*(alp-bet)))); 
        CC4(1,j)= CL0*kca*(((k21-kc)/((alp-kc)*(bet-kc)))); 
        CC5(1,j)=CL0*kca*((k21-alp)/((kc-alp)*(bet-alp))); 
        CC6(1,j)=CL0*kca*((k21-bet)/((kc-bet)*(alp-bet))); 
        CC7(1,j)=PL0*kpm*kca*(((k21-kc)/((alp-kc)*(bet-kc)*(kp-kc)))); 
        CC8(1,j)=PL0*kpm*kca*((k21-kp)/((alp-kp)*(bet-kp)*(kc-kp))); 
        CC9(1,j)=PL0*kpm*kca*((k21-alp)/((kp-alp)*(bet-alp)*(kc-alp))); 
        CC10(1,j)=PL0*kpm*kca*((k21-bet)/((kp-bet)*(alp-bet)*(kc-bet))); 
        CC11(1,j)=GIT0*kga*Foral*((k21-kga)/((alp-kga)*(bet-kga))); 
        CC12(1,j)=GIT0*kga*Foral*((k21-alp)/((kga-alp)*(bet-alp))); 
        CC13(1,j)=GIT0*kga*Foral*((k21-bet)/((kga-bet)*(alp-bet))); 
        CC14(1,j)=CL0*kcm*kga*Foral*(((k21-kc)/((alp-kc)*(bet-kc)*(kga-kc)))); 
        CC15(1,j)=CL0*kcm*kga*Foral*((k21-kga)/((alp-kga)*(bet-kga)*(kc-kga))); 
        CC16(1,j)=CL0*kcm*kga*Foral*((k21-alp)/((kga-alp)*(bet-alp)*(kc-alp))); 
        CC17(1,j)=CL0*kcm*kga*Foral*((k21-bet)/((kga-bet)*(alp-bet)*(kc-bet))); 
        CC18(1,j)=PL0*kpm*kcm*kga*Foral*((k21-kc)/((alp-kc)*(bet-kc)*(kga-kc)*(kp-kc))); 
        CC19(1,j)=PL0*kpm*kcm*kga*Foral*((k21-kga)/((alp-kga)*(bet-kga)*(kc-kga)*(kp-
kga))); 
        CC20(1,j)=PL0*kpm*kcm*kga*Foral*((k21-kp)/((kga-kp)*(alp-kp)*(kc-kp)*(bet-kp))); 
        CC21(1,j)=PL0*kpm*kcm*kga*Foral*((k21-alp)/((kga-alp)*(bet-alp)*(kc-alp)*(kp-
alp))); 
        CC22(1,j)=PL0*kpm*kcm*kga*Foral*((k21-bet)/((kga-bet)*(alp-bet)*(kc-bet)*(kp-
bet))); 
         
         
        CCa(1,j)=CC2(1,j)+CC5(1,j)+CC9(1,j)+CC12(1,j)+CC16(1,j)+CC21(1,j); 
        CCb(1,j)=CC3(1,j)+CC6(1,j)+CC10(1,j)+CC13(1,j)+CC17(1,j)+CC22(1,j); 
        CCc(1,j)=CC4(1,j)+CC7(1,j)+CC14(1,j)+CC18(1,j); 
        CCp(1,j)=CC1(1,j)+CC8(1,j)+CC20(1,j); 
        CCg(1,j)=CC11(1,j)+CC15(1,j)+CC19(1,j); 
         
        AAUC(1,j)=CCa(1,j)/alp + CCb(1,j)/bet + CCc(1,j)/kc + CCp(1,j)/kp + CCg(1,j)/kga; 
        Auc(1,j)=AAUC(1,j)/V0; 
        AUMC(1,j)=CCa(1,j)/(alp^2) + CCb(1,j)/(bet^2) + CCc(1,j)/(kc^2) + CCp(1,j)/(kp^2) 
+ CCg(1,j)/(kga^2); 
        Mrt(1,j)=AUMC(1,j)/AAUC(1,j); 
%%  
[cmax(1,j),tmaxloc]=max(Cp(:,j)); 
tmax(1,j)=time(1,tmaxloc); 
thalfbet(1,j)=0.693/bet; 
end 
 
AUC=cell(5,1); 
AUC{1,1}=num2str(mean(Auc),'%.1f'); 
AUC{2,1}=num2str(std(Auc),'%.1f'); 
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AUC{3,1}=num2str(std(Auc)/sqrt(n),'%.1f'); 
AUC{4,1}=num2str(median(Auc),'%.1f'); 
AUC{5,1}=[num2str(prctile(Auc(1,:),5),'%.1f'),' - ',num2str(prctile(Auc(1,:),95),'%.1f')]; 
AUC{6,1}=[num2str(min(Auc),'%.1f'),' - ',num2str(min(Auc)+range(Auc),'%.1f')]; 
 
Cmax=cell(6,1); 
Cmax{1,1}=num2str(mean(cmax),'%.1f'); 
Cmax{2,1}=num2str(std(cmax),'%.1f'); 
Cmax{3,1}=num2str(std(cmax)/sqrt(n),'%.1f'); 
Cmax{4,1}=num2str(median(cmax),'%.1f'); 
Cmax{5,1}=[num2str(prctile(cmax(1,:),5),'%.1f'),' - 
',num2str(prctile(cmax(1,:),95),'%.1f')]; 
Cmax{6,1}=[num2str(min(cmax),'%.1f'),' - ',num2str(min(cmax)+range(cmax),'%.1f')]; 
 
Tmax=cell(6,1); 
Tmax{1,1}=num2str(mean(tmax),'%.1f'); 
Tmax{2,1}=num2str(std(tmax),'%.1f'); 
Tmax{3,1}=num2str(std(tmax)/sqrt(n),'%.1f'); 
Tmax{4,1}=num2str(median(tmax),'%.1f'); 
Tmax{5,1}=[num2str(prctile(tmax(1,:),5),'%.1f'),' - ',num2str(prctile(tmax(1,:),95),'%.1f')]; 
Tmax{6,1}=[num2str(min(tmax),'%.1f'),' - ',num2str(min(tmax)+range(tmax),'%.1f')]; 
 
tbethalf=cell(6,1); 
tbethalf{1,1}=num2str(mean(thalfbet),'%.1f'); 
tbethalf{2,1}=num2str(std(thalfbet),'%.1f'); 
tbethalf{3,1}=num2str(std(thalfbet)/sqrt(n),'%.1f'); 
tbethalf{4,1}=num2str(median(thalfbet),'%.1f'); 
tbethalf{5,1}=[num2str(prctile(thalfbet(1,:),05),'%.1f'),' - 
',num2str(prctile(thalfbet(1,:),95),'%.1f')]; 
tbethalf{6,1}=[num2str(min(thalfbet),'%.1f'),' - 
',num2str(min(thalfbet)+range(thalfbet),'%.1f')]; 
 
MRT=cell(6,1); 
MRT{1,1}=num2str(mean(Mrt),'%.1f'); 
MRT{2,1}=num2str(std(Mrt),'%.1f'); 
MRT{3,1}=num2str(std(Mrt)/sqrt(n),'%.1f'); 
MRT{4,1}=num2str(median(Mrt),'%.1f'); 
MRT{5,1}=[num2str(prctile(Mrt(1,:),5),'%.1f'),' - ',num2str(prctile(Mrt(1,:),95),'%.1f')]; 
MRT{6,1}=[num2str(min(Mrt),'%.1f'),' - ',num2str(min(Mrt)+range(Mrt),'%.1f')]; 
 
Rowname = {'Mean';'SD';'SEM';'Median';'5 - 95 th Percentile';'Range'}; 
Table=table(AUC,Cmax,Tmax,tbethalf,MRT,'RowNames',Rowname) 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
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%%%%%%%%%%%         Finding the Median and Percentiles         
%%%%%%%%%%%% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
mCp=zeros(size(Cp,1),1); 
sdCp=zeros(size(Cp,1),1); 
uci=zeros(size(Cp,1),1); 
lci=zeros(size(Cp,1),1); 
 
for i=1:1:NoP 
    mCp(i,1)=median(Cp(i,:)); 
    sdCp(i,1)=std(Cp(i,:)); 
    uci(i,1)=prctile(Cp(i,:),95); 
    lci(i,1)=prctile(Cp(i,:),05); 
    mecp=mean(Cp(i,:)); 
end 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%%%%%%%%%%%%%%%%%%%%%          Graphing          
%%%%%%%%%%%%%%%%%%%%%%% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
set(0,'DefaultFigureWindowStyle','normal') 
figure ('name','Linear','NumberTitle','off') 
hold on; 
ucig=area(time,uci); 
set(ucig,'FaceColor',[0.8 0.8 0.8]) 
set(ucig,'LineStyle','--') 
plot(time,uci,'--r') 
lcig=area(time,lci); 
set(lcig,'FaceColor',[1 1 1]) 
set(lcig,'LineStyle','--') 
p4=plot(time,lci,'--r'); 
p5=plot(time,mCp,'k'); 
 
TMd90L=[0 15 30 60 120 180 240 360]; 
CMd90L=[0 2.28 2.59 1.53 1.00 0.68 0.46 0.18]; 
p6=plot(TMd90L,CMd90L,'+'); 
TMd45L=[0 15 30 60 120 180 240 360]; 
CMd45L=[0 2.83 2.44 1.94 1.33 0.73 0.45 0.16]; 
p7=plot(TMd45L,CMd45L,'o'); 
TTh60L=[0 15 30 60 120 180 240 360]; 
CTh60L=[0 3.22 2.99 1.91 1.19 0.84 0.61 0.25]; 
p8=plot(TTh60L,CTh60L,'*'); 
TTh30L=[0 15 30 60 120 180 240 360]; 
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CTh30L=[0 1.30 1.46 1.08 0.44 0.24 0.13 0.05]; 
p9=plot(TTh30L,CTh30L,'x'); 
POT201=[0 030 60 90 120 180 240 300 360 480 720 1440]; 
POC201=[0 0.83 2.32 2.60 2.64 2.47 2.09 1.55 1.1 0.73 0.33 0.04]; 
%p10=plot(POT201,POC201,'x'); 
set(gca,'FontSize',14) 
xlabel('Time (min)') 
ylabel('Plasma Conc (nM)') 
legend([p4 p5 p6 p7 p8 p9],{'95% & 5% percentile','Median','Md 90', 'Md 45','Th60', 
'Th30'},'location','east') 
%legend([p4 p5 p10],{'95% & 5% percentile','Median','Ref #201'},'location','northeast') 
title('95 and 5 Percentiles of Plasma Concentration time profile after 20000 MCS ') 
axis([0 Last_time_point 0 max(uci)]) 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%%%%%%%%%%%%%%%%%%%%%      Log-Graphing           
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
figure ('name','Log-Linear','NumberTitle','off') 
hold on; 
sucig=area(time,uci); 
set(sucig,'FaceColor',[0.8 0.8 0.8]) 
set(sucig,'LineStyle','--') 
plot(time,uci,'--r') 
slcig=area(time,lci); 
set(slcig,'FaceColor',[1 1 1]) 
set(slcig,'LineStyle','--') 
s4=plot(time,lci,'--r'); 
s5=plot(time,mCp,'k'); 
 
s6=plot(TMd90L,CMd90L,'+'); 
s7=plot(TMd45L,CMd45L,'o'); 
s8=plot(TTh60L,CTh60L,'*'); 
s9=plot(TTh30L,CTh30L,'x'); 
set(gca,'FontSize',14) 
xlabel('Time (min)') 
ylabel('Plasma Conc (nM)') 
legend([s4 s5 s6 s7 s8 s9],{'95% & 5% percentile','Median','Md 90', 'Md 45','Th60', 
'Th30'},'location','northeast') 
%legend([s4 s5],{'95% & 5% percentile','Median'},'location','east') 
title('95 and 5 Percentiles of Plasma Concentration time profile after 20000 MCS ') 
set(gca,'YScale','log') 
axis([0 500 0.1 10]) 
 
%close Log-Linear 
toc(Tstart) 
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Scientist Fits of IV TOB  
 
 
Figure 1. Simulations results of plasma concentration time profile on a linear-scale for 
TOB 101 based on the parameters estimated from various applied weighting factors.  
 
Figure 2. Simulations results of plasma concentration time profile on a Log-scale for 
TOB 101 based on the parameters estimated from various applied weighting factors.  
 
 
 
0
1
2
3
4
5
6
7
8
9
0 100 200 300 400 500
P
la
sm
a 
C
o
n
ce
n
tr
at
io
n
 (
m
g/
L)
Time (min)
Observed Simulated NF Simulated 1/y Simulated 1/y2
0.10
1.00
10.00
0 100 200 300 400 500
Lo
g-
P
la
sm
a 
co
n
ce
n
tr
at
io
n
 (
m
g/
L)
Time (min) 
Observed Simulated NF Simulated 1/y Simulated 1/y2
 
 
184 
 
 
Figure 3. Simulations results of plasma concentration time profile on a linear-scale for 
TOB 102 based on the parameters estimated from various applied weighting factors.  
 
Figure 4. Simulations results of plasma concentration time profile on a Log-scale for 
TOB 102 based on the parameters estimated from various applied weighting factors.  
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Figure 5. Simulations results of plasma concentration time profile on a linear-scale for 
TOB 103A based on the parameters estimated from various applied weighting factors.  
 
Figure 6. Simulations results of plasma concentration time profile on a Log-scale for 
TOB 103A based on the parameters estimated from various applied weighting factors.  
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Figure 7. Simulations results of plasma concentration time profile on a linear-scale for 
TOB 103B based on the parameters estimated from various applied weighting factors.  
 
Figure 8. Simulations results of plasma concentration time profile on a Log-scale for 
TOB 103B based on the parameters estimated from various applied weighting factors.  
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Table 1. Parameter estimates based on simplex fit with either no weighting factor, a 
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study TOB 101. 
Column highlighted in green represented the weighting factor deemed acceptable for 
this specific data set.  
 
Time 
(min)
Conc. In 
Plasma 
(mg/L)
None 1/y 1/y2
0 0 0 0 0
8 1.69 2.5583 2.3939 2.1752
12 3.81 3.6864 3.4734 3.177
21 6.05 5.9322 5.6645 5.2502
30 8.19 7.8574 7.5825 7.1071
35 7.18 7.1681 7.0156 6.6708
40 6.37 6.5809 6.5170 6.2762
45 6.07 6.0785 6.0772 5.9186
60 4.89 4.9513 5.0360 5.0287
75 4.19 4.2036 4.2940 4.3492
90 3.68 3.6796 3.7469 3.819
105 3.32 3.29 3.3284 3.3958
120 2.95 2.9834 2.9962 3.0503
150 2.58 2.5128 2.4923 2.5169
180 2.15 2.1489 2.1145 2.1177
240 1.63 1.5936 1.5583 1.5432
360 0.83 0.88439 0.8645 0.84911
480 0.47 0.49118 0.4810 0.4709
✓ ✓ ✓
0.99719 0.99369 0.99057
4.1802 3.9724 43644
11.28 12.2530 13.684
0.57 0.7552 0.92067
5.02 6.1634 6.728077
0.013 0.0096 0.006447
0.004 0.0038 0.003371
27.02 39.3457 52.28175
0.020 0.0174 0.015669
0.0065 0.0066 0.0054
32.54 38.2758 34.46295
104.530 105.7800 106.82
8.1734 5.2690 4.783
7.82 4.9811 4.477626
Cltot  (ml*min
-1)
Cltot SD
Cltot CV
k12 SD
k12 CV
k21   (min
-1)
k21 SD
k21 CV
Vo   (Liter)
Vo SD
Vo CV
k12   (min
-1)
Weighting Factor
Visual inspection
R2
MSC
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Table 2. Parameter estimates based on simplex fit with either no weighting factor, a 
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study TOB 102. 
Column highlighted in green represented the weighting factor deemed acceptable for 
this specific data set.  
 
Time 
(min)
Con. In 
Plasma 
(mg/L)
None 1/y 1/y2
0 0 0 0 0
20 8.00 7.8898 7.9262 7.9638
30 10.92 11.034 11.0620 11.09
40 9.43 9.5378 9.5225 9.503
50 8.69 8.3655 8.3371 8.3039
60 7.38 7.4362 7.4108 7.3811
75 6.17 6.3706 6.3617 6.3496
90 5.60 5.5778 5.5874 5.5944
120 4.53 4.4791 4.5118 4.5422
240 2.40 2.3487 2.3508 2.3595
360 1.26 1.3132 1.2849 1.2703
✓ ✓ ✓
0.99961 0.99960 0.99965
5.7219 6.1579 6.9768
11.45 11.3130 11.171
0.03 0.3176 0.033487
0.27 2.8069 0.299767
0.009 0.0100 0.010881
0.002 0.0018 0.001862
18.74 18.0169 17.11148
0.017 0.0193 0.021187
0.0046 0.0037 0.003018
26.30 19.0156 14.24506
95.372 96.2260 96.598
4.3975 1.9270 0.90778
4.61 2.0026 0.93975
Weighting Factor
Cltot CV
Vo   (Liter)
Vo SD
Vo CV
k12   (min
-1)
k12 SD
k12 CV
k21   (min
-1)
k21 SD
k21 CV
Cltot  (ml*min
-1)
Cltot SD
Visual inspection
R2
MSC
 
 
189 
 
 
Table 3. Parameter estimates based on simplex fit with either no weighting factor, a 
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study TOB 
103A. Column highlighted in green represented the weighting factor deemed acceptable 
for this specific data set.  
 
Time 
(min)
Con. In 
Plasma 
(mg/L)
None 1/y 1/y2
0 0 0 0 0
40 15.7 15.6 15.4 14.589
50 11.2 11.5 11.7 11.898
60 9.55 9.35 9.55 9.9445
80 7.78 7.35 7.21 7.4312
90 6.60 6.75 6.54 6.6108
120 5.25 5.43 5.25 5.0427
150 4.16 4.43 4.39 4.128
270 2.09 1.96 2.23 2.2069
480 0.80 0.47 0.68 0.78181
✓ ✓ ✓
0.99913 0.99820 0.99799
5.213 5.1106 5.7534
3.67 5.0473 7.0246
0.73 0.9146 1.0058
19.81 18.12 14.32
0.042 0.0270 0.014505
0.010 0.0073 0.004257
23.37 26.98 29.35
0.024 0.0190 0.014328
0.0026 0.0023 0.002035
10.81 12.12 14.21
87.298 85.9500 88.267
3.6981 3.2398 2.2994
4.24 3.77 2.61
Weighting Factor
Visual inspection
R2
MSC
Vo   (Liter)
Vo SD
Vo CV
k12   (min
-1)
k12 SD
Cltot SD
Cltot CV
k12 CV
k21   (min
-1)
k21 SD
k21 CV
Cltot  (ml*min
-1)
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Table 4. Parameter estimates based on simplex fit with either no weighting factor, a 
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study TOB 
103B. Column highlighted in green represented the weighting factor deemed acceptable 
for this specific data set.  
 
 
MCS Results for IV TOB 
 
Time 
(min)
Con. In 
Plasma 
(mg/L)
None 1/y 1/y2
0 0 0 0 0
60 35.23 36.361 36.5410 36.007
70 34.50 32.864 32.8980 32.619
80 29.40 29.757 29.6940 29.599
90 27.06 26.993 26.8710 26.903
105 23.48 23.405 23.2470 23.39
120 20.44 20.386 20.2320 20.419
150 15.75 15.684 15.6020 15.761
180 11.34 12.303 12.3140 12.381
300 6.43 5.6055 5.7722 5.5746
510 1.98 2.2307 2.1958 2.1108
780 0.79 0.86796 0.7288 0.77255
✓ ✓ ✓
0.99893 0.99849 0.99686
5.1132 6.0122 6.1828
11.27 11.0710 11.459
0.41 0.5230 0.71129
3.68 4.72 6.21
0.003 0.0031 0.002489
0.001 0.0009 0.000687
37.09 30.01 27.62
0.005 0.0071 0.005619
0.0047 0.0023 0.001232
86.74 32.38 21.92
88.812 89.8970 90.337
8.0764 2.2091 1.8016
9.09 2.46 1.99
k21   (min
-1)
Weighting Factor
Visual inspection
R2
MSC
Vo   (Liter)
Vo SD
Vo CV
k12   (min
-1)
k12 SD
k12 CV
k21 SD
k21 CV
Cltot  (ml*min
-1)
Cltot SD
Cltot CV
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Figure 9. TOB 104 VPC predictions using model 2’s inability to capture pre-dose level 
on day 3.  
 
Figure 10. TOB 104 VPC predictions using model 2’s in order to capture pre-dose level, 
the remaining data points would not be captured. 
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Figure 11. TOB 101 VPC and exposure metric variability comparison.  (top left -cp(t) 
profile, top center – cs(t) profile, top right PLU(t) profile, bottom left – cmax box and 
whisker plot (WHP), bottom center- c60 WHP, bottom right – beta WHP) 
Figure 12. TOB 102 VPC and exposure metric variability comparison.  (top left -cp(t) 
profile, top center – cs(t) profile, top right PLU(t) profile, bottom left – cmax box and 
whisker plot (WHP), bottom center- c60 WHP, bottom right – beta WHP) 
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Figure 13. TOB 103A VPC and exposure metric variability comparison.  (top left -cp(t) 
profile, top center – cs(t) profile, top right PLU(t) profile, bottom left – cmax box and 
whisker plot (WHP), bottom center- c60 WHP, bottom right – beta WHP) 
 
 
 
Figure 14. TOB 103B VPC and exposure metric variability comparison.  (top left -cp(t) 
profile, top center – cs(t) profile, top right PLU(t) profile, bottom left – cmax box and 
whisker plot (WHP), bottom center- c60 WHP, bottom right – beta WHP) 
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Table 6. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 102 
 
Table 7. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 103A 
 
Table 8. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 103B 
 
Table 9. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 104 
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SD and RD Sensitivity Analysis Plots for IV TOB 
 
 
Figure 15. Resulting cp(t) and cs(t) from a 25-fold change in CLtot after a SD IV 
administration of 105 mg  
 
Figure 16. Resulting cp(t) and cs(t) from a 25-fold change in k12 after a SD IV 
administration of 105 mg  
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Figure 17. Resulting cp(t) and cs(t) from a 25-fold change in k21 after a SD IV 
administration of 105 mg  
 
Figure 18. Resulting cp(t) and cs(t) from a 25-fold change in kpa after a SD IV 
administration of 105 mg  
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Figure 19. Resulting cp(t) and cs(t) from a 25-fold change in kca after a SD IV 
administration of 105 mg  
 
Figure 20. Resulting cp(t) and cs(t) from a 25-fold change in kpm after a SD IV 
administration of 105 mg  
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Figure 21. Resulting cp(t) and cs(t) from a 25-fold change in kcm after a SD IV 
administration of 105 mg  
 
Figure 22. Resulting cp(t) and cs(t) from a 25-fold change in kpd after a SD IV 
administration of 105 mg  
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Figure 23. Resulting cp(t) and cs (t) from a 25-fold change in kcd after a SD IV 
administration of 105 mg  
 
Figure 24. Resulting cp(t) and cs(t) from a 25-fold change in kpls1 after a SD IV 
administration of 105 mg  
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Figure 25. Resulting cp(t) and cs(t) from a 25-fold change in kpls2 after a SD IV 
administration of 105 mg  
 
Figure 26. Resulting cp(t) and cs(t) from a 25-fold change in kcls1 after a SD IV 
administration of 105 mg  
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Figure 27. Resulting cp(t) and cs(t) from a 25-fold change in kcls2 after a SD IV 
administration of 105 mg  
 
Figure 28. Resulting cp(t) and cs(t) from a 25-fold change in CLtot after a three-day RD 
IV administration of 105 mg  
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Figure 29. Resulting cp(t) and cs(t) from a 25-fold change in k12 after a three-day RD IV 
administration of 105 mg  
 
Figure 30. Resulting cp(t) and cs(t) from a 25-fold change in k21 after a three-day RD IV 
administration of 105 mg  
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Figure 31. Resulting cp(t) and cs(t) from a 25-fold change in kpa after a three-day RD IV 
administration of 105 mg  
 
Figure 32. Resulting cp(t) and cs(t) from a 25-fold change in kca after a three-day RD IV 
administration of 105 mg  
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Figure 33. Resulting cp(t) and cs(t) from a 25-fold change in kpm after a three-day RD IV 
administration of 105 mg  
 
Figure 34. Resulting cp(t) and cs(t) from a 25-fold change in kcm after a three-day RD IV 
administration of 105 mg  
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Figure 35. Resulting cp(t) and cs(t) from a 25-fold change in kpd after a three-day RD IV 
administration of 105 mg  
 
Figure 36. Resulting cp(t) and cs (t) from a 25-fold change in kcd after a three-day RD IV 
administration of 105 mg  
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Figure 37. Resulting cp(t) and cs(t) from a 25-fold change in kpls1 after a three-day RD IV 
administration of 105 mg  
 
Figure 38. Resulting cp(t) and cs(t) from a 25-fold change in kpls2 after a three-day RD IV 
administration of 105 mg  
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Figure 39. Resulting cp(t) and cs(t) from a 25-fold change in kcls1 after a three-day RD IV 
administration of 105 mg  
 
Figure 40. Resulting cp(t) and cs(t) from a 25-fold change in kcls2 after a three-day RD IV 
administration of 105 mg  
 
 
VPC Plots for INH TOB 
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Figure 41. TOB 302A exposure metric variability comparison.  (left -Reported vs 
simulated cp AUC box and whisker plot (WHP), right - Reported vs simulated cp,max 
WHP) 
 
Figure 42. TOB 302B exposure metric variability comparison.  (left -Reported vs 
simulated cp AUC box and whisker plot (WHP), right - Reported vs simulated cp,max 
WHP) 
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Figure 43. TOB 302C exposure metric variability comparison.  (left -Reported vs 
simulated cp AUC box and whisker plot (WHP), right - Reported vs simulated cp, max 
WHP) 
 
Figure 44. TOB 302D exposure metric variability comparison.  (left -Reported vs 
simulated cp AUC box and whisker plot (WHP), right - Reported vs simulated cp, max 
WHP) 
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Figure 45. TOB 303A VPC and exposure metric variability comparison.  (left -cp(t) VPC 
profile, center – Reported vs simulated cp AUC box and whisker plot (WHP), right - 
Reported vs simulated cp, max WHP) 
 
Figure 46. TOB 303B VPC and exposure metric variability comparison.  (left -cp(t) VPC 
profile, center – Reported vs simulated cp AUC box and whisker plot (WHP), right - 
Reported vs simulated cp, max WHP) 
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Figure 47. TOB 307A VPC and exposure metric variability comparison.  (Top left -cp(t) 
VPC profile, top center – cs(t) VPC profile, top right - Reported vs simulated cp AUC box 
and whisker plot (WHP), bottom left - Reported vs simulated cp, max WHP, bottom center 
- Reported vs simulated cs AUC WHP, bottom right - Reported vs simulated cp, max 
WHP) 
 
Figure 48. TOB 307B VPC and exposure metric variability comparison.  (Top left -cp(t) 
VPC profile, top center – cs(t) VPC profile, top right - Reported vs simulated cp AUC box 
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and whisker plot (WHP), bottom left - Reported vs simulated cp,max WHP, bottom center 
- Reported vs simulated cs AUC WHP, bottom right - Reported vs simulated cs,max WHP) 
 
Figure 49. TOB 307C VPC and exposure metric variability comparison.  (Top left -cp(t) 
VPC profile, top center – cs(t) VPC profile, top right - Reported vs simulated cp AUC box 
and whisker plot (WHP), bottom left - Reported vs simulated cp,max WHP, bottom center - 
Reported vs simulated cs AUC WHP, bottom right - Reported vs simulated cs,max WHP) 
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Figure 50. TOB 309A VPC and exposure metric variability comparison.  (Top left - 
Reported vs simulated cp AUC box and whisker plot (WHP), top right - Reported vs 
simulated cp,max WHP bottom left - Reported vs simulated cs AUC WHP, bottom right - 
Reported vs simulated cs,max WHP) 
 
Figure 51. TOB 309b VPC and exposure metric variability comparison.  (Top left - 
Reported vs simulated cp AUC box and whisker plot (WHP), top right - Reported vs 
simulated cp,max WHP bottom left - Reported vs simulated cs AUC WHP, bottom right - 
Reported vs simulated cs,max WHP) 
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Figure 52. TOB 309C VPC and exposure metric variability comparison.  (Top left - 
Reported vs simulated cp AUC box and whisker plot (WHP), top right - Reported vs 
simulated cp,max WHP bottom left - Reported vs simulated cs AUC WHP, bottom right - 
Reported vs simulated cs,max WHP) 
 
Figure 53. TOB 309D VPC and exposure metric variability comparison.  (Top left - 
Reported vs simulated cp AUC box and whisker plot (WHP), top right - Reported vs 
simulated cp,max WHP bottom left - Reported vs simulated cs AUC WHP, bottom right - 
Reported vs simulated cs,max WHP) 
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Figure 54. TOB 309E VPC and exposure metric variability comparison.  (Top left - 
Reported vs simulated cp AUC box and whisker plot (WHP), top right - Reported vs 
simulated cp,max WHP bottom left - Reported vs simulated cs AUC WHP, bottom right - 
Reported vs simulated cs,max WHP) 
 
Figure 55. TOB 309F VPC and exposure metric variability comparison.  (Top left - 
Reported vs simulated cp AUC box and whisker plot (WHP), top right - Reported vs 
simulated cp,max WHP bottom left - Reported vs simulated cs AUC WHP, bottom right - 
Reported vs simulated cs,max WHP) 
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SD and RD Sensitivity Analysis Plots for INH TOB  
 
Figure 60. Resulting cp(t) and cs(t) from a 25-fold change in CLtot after a SD INH 
administration of 300 mg  
 
Figure 61. Resulting cp(t) and cs(t) from a 25-fold change in k12 after a SD INH 
administration of 300 mg  
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Figure 62. Resulting cp(t) and cs(t) from a 25-fold change in k21 after a SD INH 
administration of 300 mg  
 
Figure 63. Resulting cp(t) and cs(t) from a 25-fold change in kpa after a SD INH 
administration of 300 mg  
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Figure 64. Resulting cp(t) and cs(t) from a 25-fold change in kca after a SD INH 
administration of 300 mg  
 
Figure 65. Resulting cp(t) and cs(t) from a 25-fold change in kpm after a SD INH 
administration of 300 mg  
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Figure 66. Resulting cp(t) and cs(t) from a 25-fold change in kcm after a SD INH 
administration of 300 mg  
 
Figure 67. Resulting cp(t) and cs(t) from a 25-fold change in kpd after a SD INH 
administration of 300 mg  
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Figure 68. Resulting cp(t) and cs(t) from a 25-fold change in kcd after a SD INH 
administration of 300 mg  
 
Figure 69. Resulting cp(t) and cs(t) from a 25-fold change in kpls1 after a SD INH 
administration of 300 mg  
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Figure 70. Resulting cp(t) and cs(t) from a 25-fold change in kpls2 after a SD INH 
administration of 300 mg  
 
Figure 71. Resulting cp(t) and cs(t) from a 25-fold change in kcls1 after a SD INH 
administration of 300 mg  
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Figure 72. Resulting cp(t) and cs(t) from a 25-fold change in kcls2 after a SD INH 
administration of 300 mg  
 
 
 
Figure 73. Representative predictions of cp(t) and cs(t) profiles for study 307A after 
attempts to optimize Fpd using Model 3 and IV optimized systemic and pulmonary 
disposition parameters. 
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Figure 74. Predictions of both TOB 104 and 307 aftersimulatenous parameter 
optimization with both data sets. 
 
 
 
Figure 75. Simultaneous predictions of the four cp(t) and cs(t) profiles from TOB 307. 
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Table 10. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 302A 
 
Table 11. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 302B 
 
Table 12. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 302C 
 
Table 13. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 302D 
 
Table 14. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 303A 
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Table 15. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 303B 
 
Table 16. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 307A 
 
Table 17. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 307B 
 
Table 18. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 307C 
 
Table 19. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 307D 
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Table 20. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 309A 
 
Table 21. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 309B 
 
Table 22. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 309C 
 
Table 23. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 309D 
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Table 24. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 309E 
 
Table 25. Reported exposure metric central tendency and dispersion compared to 
simulated values for the same metrics for TOB 309F 
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Table 26. Reported plasma and sputum exposure metrics and relevant study design 
components for the analyzed inhalation studies.  
 
Study ID
307 A
307 B
307C
307D
303A
303B
309A
309B
309C
309D
309E
309F
302A
302B
302C
302D
G
roup
CF
CF
CF
CF
HV
HV
CF
CF
CF
CF
CF
CF
HV
HV
CF
CF
Device
Pari
Pari
Pari
Pari
eFlow
Pari
eFlow
Dose (m
g)
300
30
60
90
300
80
28
56
56
84
112
300
300
300
300
300
DTL (%
)
9.1
35.4
35.4
35.4
5.3
34.3
34.3
34.3
34.3
34.3
34.3
10
14.8
15.1
13.3
8.9
Estim
ated DTL (m
g)
27
11
21
32
16
27
10
19
19
29
38
30
44
45
40
27
Inhalation Tim
e (m
in)
18
2.80
5.40
8.00
15.00
15.00
1.70
4.20
2.50
4.50
4.90
16.00
16.00
8.50
20.00
8.00
Sputum
 Tm
ax (h)
0.26
0.24
0.38
0.33
0.5
0.5
0.5
0.5
0.5
0.5
Sputum
 Cm
ax (ug/g)
986
329
578
958
258
515
574
1092
1048
737
Sputum
 AU
C (ug*h/g)
1471
361
805
1275
2 61
1195
652
1340
1307
974
Sputum
 t1/2 (h)
0.9
1.8
1.3
0.8
2.2
1.7
Serum
 Tm
ax (h)
1.05
1.14
0.98
1.14
2
1.75
1
1
1
1
1
1
1
1
1
1
Serum
 Cm
ax (ug/m
l)
1.12
0.38
0.69
0.96
0.28
0.6
0.33
0.56
0.5
0.7
1.02
1.04
0.6
0.7
1.2
0.5
Serum
 AU
C (ug*h/m
l)
4.96
1.43
2.98
3.94
2.1
4.4
1.3
2.8
2.5
3.5
4.6
4.8
3.3
3.6
5
1.9
Serum
 t1/2 (h)
4.2
3.7
2.8
3.5
3.3
3.4
3.1
3
5.8
4.6
2.7
2.7
Calculated F
inh  %
 
102
76
79
70
74
90
76
82
73
68
67
90
42
45
71
40
Age
BW
Pulm
oSphere
AeroDose
N
A
N
A
57 kg
N
A
24
34
24/22/22/24/21/20
33 /44/22/21
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Mass Balance Total Excretion Plots for TOB 
 
Figure 56. Mass balance drug excretion IV administration simulation results based on the 
final optimized IV parameter space. Left plot represents cumulative drug eliminated from 
the central unbound lung compartment via kcm. Right plot represents cumulative drug 
eliminated from the central compartment via CLtot. 
 
Figure 57. Mass balance drug excretion IV administration simulation results based on the 
final optimized INH parameter space. Left plot represents cumulative drug eliminated from 
 
 
230 
 
the central unbound lung compartment via kcm. Right plot represents cumulative drug 
eliminated from the central compartment via CLtot. 
 
Figure 58. Mass balance drug excretion INH administration simulation results based on 
the final optimized IV parameter space. Left plot represents cumulative drug eliminated 
from the central unbound lung compartment via kcm. Right plot represents cumulative drug 
eliminated from the central compartment via CLtot. 
 
Figure 59. Mass balance drug excretion INH administration simulation results based on 
the final optimized IV parameter space. Left plot represents cumulative drug eliminated 
from the central unbound lung compartment via kcm. Right plot represents cumulative 
drug eliminated from the central compartment via CLtot. 
 
 
231 
 
 
 
  
 
 
232 
 
Various codes utilized for TOB analysis 
IndVars: T 
DepVars: CP1 
Params: D1, Tinf1,V0,  k12, k21, Cltot 
// 
// dose in mg 
// conc in mg/L 
// time in min 
// 
//  Input 
ARATE11=D1/Tinf1 
FLAG1=UNIT(T-Tinf1) 
ARATE=ARATE11*(1-FLAG1) 
// 
//  PK-Model 
AP1'=ARATE+k21*AT1-((Cltot/(V0*1000))+k12)*AP1 
AT1'=k12*AP1-k21*AT1 
CP1=AP1/V0 
// 
//  Initial Conditions 
T=0 
AP1=0 
AT1=0 
*** 
 
Code 1. Two compartment open body model describing TOB disposition after IV 
infusion administration 
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rm(list=ls()); cat("\014");dev.off();set.seed(12301991);Start.time <- proc.time() # start a 
timer 
BW.me <- 57.4 
BW.cv   <- 13*100/BW.me 
n       <- 300 
PerKgDose <- 8 #mg/kg 
tinf <- 10 
t  <- seq(0,3360,10) 
Clpop     <- 70 
Clprop.me  <- 1 
k12.me    <- 0.010 
k21.me    <- 0.015 
V0pop     <- 10 
V0prop.me  <- 1 
Clprop.cv  <- 20 
k12.cv     <- 30 
k21.cv     <- 30 
V0prop.cv  <- 20 
kga.me    <- 1 
Foral.me  <- 0 
kga.cv    <- 0 
Foral.cv  <- 0 
kpa.me    <- 0.006 
kca.me    <- 0.9 
kpm.me    <- 0.16 
kcm.me    <- 0.6 
kpd.me    <- 0.0008 
kcd.me    <- 0.001 
TLV.me    <- 20 #ml 
kpls1.me  <- 0.0005 
kpls2.me  <- 0.0001 
kcls1.me  <- 0.0005 
kcls2.me  <- 0.0002 
kpa.cv    <- 30 
kca.cv    <- 30 
kpm.cv    <- 20 
kcm.cv    <- 20 
kpd.cv    <- 30 
kcd.cv    <- 30 
kpls1.cv  <- 30 
kpls2.cv  <- 30 
kcls1.cv  <- 30 
kcls2.cv  <- 30 
TLVprop.me  <- 1 
TLVprop.cv  <- 20 
kin.me    <- 0 
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Fex.me    <- 0.009 
Fpd.me    <- 0.21 
Fcd.me    <- 0.069 
Din.me    <- 0 
kin.cv    <- 0 
Fex.cv    <- 57 
Fpd.cv    <- 30 
Fcd.cv    <- 30 
Din.cv    <- 9 
######################################################################
######## 
#####################     Normal Distribution Generator     ########### 
######################################################################
######## 
NormGen <- function(simulation.n,samp.m,samp.cv ){ 
  samp.sd <- samp.cv*samp.m/100 
  out <- rnorm(simulation.n,samp.m,samp.sd) 
  return(out) 
} 
LogNormGen <- function(n, Mean, PCV){ 
  CV <- PCV/100 
  SD <- (CV*Mean) 
  Variance <- SD^2 
  mean.in  <- log(Mean^2 / sqrt(Variance+Mean^2)) 
  SD.in    <- sqrt(log(Variance/Mean^2 + 1)) 
  x=rlnorm(n,mean.in,SD.in) 
  return(x) 
} 
######################################################################
######## 
#######################     Generation of numbers       
######################################################################
########BW.n     <- NormGen(n, BW.me,BW.cv) 
Clprop.n <- NormGen(n, Clprop.me,Clprop.cv) 
k12.n    <- LogNormGen(n, k12.me,k12.cv)     
k21.n    <- LogNormGen(n, k21.me,k21.cv) 
V0prop.n <- NormGen(n, V0prop.me,V0prop.cv) 
 
kga.n    <- LogNormGen(n, kga.me,kga.cv) 
if (Foral.me==0){Foral.n<-matrix(0,1,n)} else if (Foral.me>0){Foral.n<-
LogNormGen(n,Foral.me,Foral.cv)} 
 
 
kpa.n    <- LogNormGen(n, kpa.me,kpa.cv) 
kca.n    <- LogNormGen(n, kca.me,kca.cv) 
kpm.n    <- LogNormGen(n, kpm.me,kpm.cv) 
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kcm.n    <- LogNormGen(n, kcm.me,kcm.cv) 
 
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n, 
kpd.me,kpd.cv)} 
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n, 
kcd.me,kcd.cv)} 
 
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n, 
kpls1.me,kpls1.cv)} 
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n, 
kpls2.me,kpls2.cv)} 
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n, 
kcls1.me,kcls1.cv)} 
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n, 
kcls2.me,kcls2.cv)} 
 
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv) 
 
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)} 
  Fex.n    <- NormGen(n, Fex.me,Fex.cv) 
  Fpd.n    <- NormGen(n, Fpd.me,Fpd.cv) 
  Fcd.n    <- NormGen(n, Fcd.me,Fcd.cv) 
if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n, 
Din.me,Din.cv)} 
 
######################################################################
######## 
##############         Set up the ODE Based model function        
####################### 
######################################################################
######## 
TCBM <- function(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, kpls2,  
                 kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, Dose, tinf ){ 
  Dose.Value <- (1-Din)*Dose 
  Fgd        <- 1-Fex-Fpd-Fcd 
  ED <- data.frame(var = c("DOSING"), time = c(t[1],tinf,1440,1450,2880,2890), value = 
c(Dose.Value/tinf,0), method = c("rep")) 
 
  Model.Function <- function(t,IC,Parm) { 
    with(as.list(IC, Parm), { 
       
      dDOSING <- 0 
       
      dIn   <-   -In*kin*(Fex+Fpd+Fcd+Fgd) 
      dPLU  <-   In*kin*Fpd + PLS*kpd - PLU*(kpa + kpm) 
      dCLU  <-   In*kin*Fcd + CLS*kcd - CLU*(kca + kcm) + PLU* kpm 
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      dGI   <-   In*kin*Fgd + CLU* kcm - GI*kga 
      dPLS  <-   PLU*kpa + CC*kpls1 - PLS * (kpd+kpls2) 
      dCLS  <-   CLU*kca + CC*kcls1 - CLS * (kcd+kcls2) 
      dCC   <-   PLS*kpls2 + CLS*kcls2 + GI*kga*Foral + PC*k21 - CC*(kpls1+kcls1 + 
k12 + (Cltot/(V0*1000)))+ DOSING   
      dPC   <-   CC* k12 - PC *k21 
       
      dEx   <-   In*kin*Fex 
      dFe   <-   GI*kga*(1-Foral) 
      dEl   <-   CC*(Cltot/(V0*1000)) 
       
      return(list(c(dIn,dPLU,dCLU,dPLS,dCLS,dGI,dCC,dPC,dEx,dFe,dEl,dDOSING)))   
    }) 
  } 
  IC   <- c(In=0, PLU=0*Fpd, CLU=0*Fcd, PLS=0, CLS=0, GI=0*Fgd, CC=0, PC=0, 
Ex=0*Fex, Fe=0, El=0,DOSING=0) 
  Parm <- c(Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, kpls2, kcls1, 
kcls2, kin, Fex, Fpd, Fcd, Fgd) 
  out  <- ode(IC, t,Model.Function,Parm,events = list(data=ED)) 
  return(out) 
} 
 
######################################################################
######## 
#####################        PBPK Model iterations       #####################         
######################################################################
######## 
Dose.n  <- BW.n*PerKgDose 
Cltot.n <- Clpop*(BW.n/mean(BW.n))^0.75   * Clprop.n  
V0.n    <- V0pop*(BW.n/mean(BW.n))^1      * V0prop.n 
 
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n 
CLV.n <- TLV.n*0.8/1000 
PLV.n <- TLV.n*0.2/1000 
 
In.Data  <- matrix(0,length(t),(n)) 
PLU.Data <- matrix(0,length(t),(n)) 
CLU.Data <- matrix(0,length(t),(n)) 
PLS.Data <- matrix(0,length(t),(n)) 
CLS.Data <- matrix(0,length(t),(n)) 
GI.Data  <- matrix(0,length(t),(n)) 
CC.Data  <- matrix(0,length(t),(n)) 
PC.Data  <- matrix(0,length(t),(n)) 
Ex.Data  <- matrix(0,length(t),(n)) 
Fe.Data  <- matrix(0,length(t),(n)) 
El.Data  <- matrix(0,length(t),(n)) 
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CP.Data  <- matrix(0,length(t),(n)) 
CS.Data  <- matrix(0,length(t),(n)) 
PL.Data  <- matrix(0,length(t),(n)) 
Cmax.n=rep(0,(n)) 
C30.n=rep(0,(n)) 
C60.n=matrix(0,1,n) 
Smax.n=rep(0,n) 
AUC.n=Dose.n*1000/Cltot.n/60 
k10.n   <- Cltot.n/V0.n/1000 
a.p.b.n <- k10.n+k12.n+k21.n    
a.t.b.n <- k10.n*k21.n  
beta.n <- (a.p.b.n -  ( a.p.b.n^2 - 4*a.t.b.n )^0.5   )*0.5 
beta.n <- beta.n*60 
t0.5.n <- 0.693/beta.n 
for (i in 1:n) { 
  Dose   <- Dose.n[i] 
  Cltot  <- Cltot.n[i] 
  k12    <- k12.n[i]      
  k21    <- k21.n[i] 
  V0     <- V0.n[i] 
   kga    <- kga.n[i] 
  Foral  <- Foral.n[i] 
  kpa    <- kpa.n[i] 
  kca    <- kca.n[i] 
  kpm    <- kpm.n[i] 
  kcm    <- kcm.n[i] 
  kpd    <- kpd.n[i] 
  kcd    <- kcd.n[i] 
  kpls1  <- kpls1.n[i] 
  kpls2  <- kpls2.n[i] 
  kcls1  <- kcls1.n[i] 
  kcls2  <- kcls2.n[i] 
  CLV    <- CLV.n[i] 
  PLV    <- PLV.n[i] 
  kin    <- kin.n[i] 
  Fex    <- Fex.n[i] 
  Fpd    <- Fpd.n[i] 
  Fcd    <- Fcd.n[i] 
  Din    <- Din.n[i] 
 Current.Iteration.Data <- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd,  
            kcd, kpls1, kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, Dose, tinf) 
  In.Data[,i]  <- Current.Iteration.Data[,2] 
  PLU.Data[,i] <- Current.Iteration.Data[,3] 
  CLU.Data[,i] <- Current.Iteration.Data[,4] 
  PLS.Data[,i] <- Current.Iteration.Data[,5] 
  CLS.Data[,i] <- Current.Iteration.Data[,6] 
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  GI.Data[,i]  <- Current.Iteration.Data[,7] 
  CC.Data[,i]  <- Current.Iteration.Data[,8] 
  PC.Data[,i]  <- Current.Iteration.Data[,9] 
  Ex.Data[,i]  <- Current.Iteration.Data[,10] 
  Fe.Data[,i]  <- Current.Iteration.Data[,11] 
  El.Data[,i]  <- Current.Iteration.Data[,12] 
   
  CP.Data[,i]  <- Current.Iteration.Data[,8]/V0 
  CS.Data[,i]  <- Current.Iteration.Data[,4]/CLV 
  PL.Data[,i]  <- Current.Iteration.Data[,3]/PLV 
   
  Cmax.n[i]<- max(CP.Data[,i]) 
  C30.n[i] <- CP.Data[292,i] 
  #C60.n[i]=CP.Data[61,i] 
  Smax.n [i] <- max(CS.Data[,i])  
} 
 
######################################################################
######## 
###################   VPC Plotting Function for TS DATA    ################### 
######################################################################
######## 
VPCP <- function(Data,Color,YMin,YMax,XMin,XMax,Title,Ytitle,LogAxis){   
  Size.of.Data<-dim(Data); PlottingData  <- matrix(0,Size.of.Data[1],4) 
  PlottingData[,1] <-Current.Iteration.Data[,1] 
  for(i in 1:length(t)){ 
    PlottingData[i,2] <- quantile(Data[i,],0.05); PlottingData[i,3] <- quantile(Data[i,],0.50) 
    PlottingData[i,4] <- quantile(Data[i,],0.95)  } 
  Time    <- PlottingData[,1];   Bottom  <- PlottingData[,2] 
  Top     <- PlottingData[,4];   Middle  <- PlottingData[,3]   
  ColNumbers <- col2rgb(Color); par(TRUE) 
  mycol4 <- rgb(ColNumbers[1],ColNumbers[2], ColNumbers[3], max = 255, alpha = 90) 
  plot(Time, Bottom, type= "n", col=Color, main=Title, 
       ylim= c(YMin,YMax), log=LogAxis, xlim=c(XMin,XMax), 
       ylab =Ytitle, xlab = 'Time (minutes)', font=2,font.lab =2) 
  polygon(c(Time, rev(Time)), c(Top, rev(Bottom)),col=mycol4,border=NA) 
  lines(Time, Middle, type= "l", col=Color, lwd=2.8) 
  return() 
} 
 
TOB104.Time <- c(0, 30, 60, 240, 360, 480)+2880 
TOB104.Conc <- c(0, 29.5, 20.7, 7.8, 4.4, 3.9) 
TOB104.Conc.upper <- c(0, 33.3, 23.5, 9.5, 5.6, 4.5) 
TOB104.Conc.lower <- c(0, 25.5, 17.9, 5.9, 3.2, 2.8)  
TOB104.STime <- c(2880, 3000, 3120,3300) 
TOB104.SConc <- c(2.2, 3.1, 3.9, 2.5) 
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TOB104.SConc.upper <- c(3.6, 4.3, 5.4, 4.0) 
TOB104.SConc.lower <- c(0.9, 1.7, 2.4, 0.9) 
 
 
#mean(beta.n);max(beta.n);min(beta.n) 
#mean(C30.n);max(C30.n);min(C30.n) 
#mean(AUC.n);max(AUC.n) ;min(AUC.n)  
#mean(Smax.n);max(Smax.n);min(Smax.n); 
 
#dev.off();par(mfrow=c(1,1));hist(TLV.n) 
#mean(TLV.n);quantile(TLV.n,0.5);sd(TLV.n);max(TLV.n);min(TLV.n) 
End.time <- proc.time();Total.time <- End.time-Start.time;Total.time 
 
AUC.BX<-boxplot(AUC.n,AUC.n, names=c("Rep AUC","Sim AUC")) #, ylim=c(20,100) 
AUC.BX$out<-0 
 
AUC.BX$stats[1,1]  <- 60 
AUC.BX$stats[2,1]  <- 82 
AUC.BX$stats[3,1]  <- 82 
AUC.BX$stats[4,1]  <- 82 
AUC.BX$stats[5,1]  <-115 
bxp(AUC.BX,ylim=c(40,120)) 
 
C30.BX<-boxplot(C30.n,C30.n, names=c("Rep C30","Sim C30")) 
C30.BX$out<-0 
 
C30.BX$stats[1,1]  <- 23 
C30.BX$stats[2,1]  <- 29.4 
C30.BX$stats[3,1]  <- 29.4 
C30.BX$stats[4,1]  <- 29.4 
C30.BX$stats[5,1]  <- 36 
 
BET.BX<-boxplot(beta.n,beta.n, names=c("Rep Beta","Sim Beta")) 
BET.BX$out<-0 
 
BET.BX$stats[1,1]  <- 0.22 
BET.BX$stats[2,1]  <- 0.29 
BET.BX$stats[3,1]  <- 0.29 
BET.BX$stats[4,1]  <- 0.29 
BET.BX$stats[5,1]  <- 0.38 
 
dev.off();par(mfrow=c(2,3)); par(TRUE) 
VPCP(CP.Data,'green',1,100,2880,3360,'Cp vs t','Plasma Conc (ug/ml)','y') 
yLine <- seq(0.001,2000,100); xLine1 <- rep(0,length(yLine)) 
xLine2 <- rep(1440,length(yLine)); xLine3 <- rep(2880,length(yLine)) 
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lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty 
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red') 
points(TOB104.Time,TOB104.Conc,col='red',pch=20,cex=2.5) 
points(TOB104.Time,TOB104.Conc.upper,col='red',cex=2.5,pch='-') 
points(TOB104.Time,TOB104.Conc.lower,col='red',cex=2.5,pch='-') 
 
VPCP(CS.Data,'cyan',0.5,10, 2880,3360,'Cs vs t','Sputum Conc (ug/ml)','y') 
points(TOB104.STime,TOB104.SConc,col='black',pch=20,cex=2.5) 
points(TOB104.STime,TOB104.SConc.upper,col='black',cex=2.5,pch='-') 
points(TOB104.STime,TOB104.SConc.lower,col='black',cex=2.5,pch='-') 
lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty 
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red') 
VPCP(PL.Data,'grey',5,90, 2880,3360,'PL Conc vs t','PL Conc (ug/ml)','y') 
lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty 
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red') 
bxp(AUC.BX,ylim=c(60,180), main='AUC',ylab='AUC (mg*hr/l)') 
bxp(C30.BX,ylim=c(22,50),main='C30',ylab='Plasma Conc at t=2910 min (mg/L)') 
bxp(BET.BX,ylim=c(0.1,0.4),main='Beta',ylab='Beta (hr-1)') 
######################################################################
######## 
# ####################    Key under the hood plots    
######################################################################
######## 
dev.off();par(mfrow=c(2,3)); par(TRUE) 
TL <- function(x) {x<-max(x);X<-10^ceiling(log10(x));return(X)} 
LL <- function(x) {x<-max(x);X<-10^ceiling(log10(x));X<-X/100;return(X)} 
yLine <- seq(0.0001,10000.0001,100); xLine1 <- rep(0,length(yLine)) 
xLine2 <- rep(1440,length(yLine)); xLine3 <- rep(2880,length(yLine)) 
lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty 
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red') 
VPCP(PLU.Data,'blue',LL(PLU.Data),TL(PLU.Data), 0,3360,'PLU','PLU (mg)','y') 
lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty 
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red') 
VPCP(CLU.Data,'blue',LL(CLU.Data),TL(CLU.Data), 0,3360,'CLU','CLU (mg)','y') 
lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty 
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red') 
VPCP(PLS.Data,'blue',LL(PLS.Data),TL(PLS.Data), 0,3360,'PLS','PLS (mg)','y') 
lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty 
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red') 
VPCP(CLS.Data,'blue',LL(CLS.Data),TL(CLS.Data), 0,3360,'CLS','CLS (mg)','y') 
lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty 
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red') 
VPCP(CC.Data,'blue',LL(CC.Data),TL(CC.Data), 0,3360,'CC','CC (mg)','y') 
lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty 
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red') 
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VPCP2 <- 
function(Data1,Data2,Color1,Color2,YMin,YMax,XMin,XMax,Title,Ytitle,LogAxis){ 
   Size.of.Data<-dim(Data1); PlottingData  <- matrix(0,Size.of.Data[1],4) 
 PlottingData[,1] <-Current.Iteration.Data[,1] 
 for(i in 1:length(t)){ 
   PlottingData[i,2] <- quantile(Data1[i,],0.05); PlottingData[i,3] <- quantile(Data1[i,],0.50) 
   PlottingData[i,4] <- quantile(Data1[i,],0.95)  } 
 Time    <- PlottingData[,1];   Bottom  <- PlottingData[,2] 
 Top     <- PlottingData[,4];   Middle  <- PlottingData[,3] 
 ColNumbers <- col2rgb(Color1); par(TRUE) 
 mycol4 <- rgb(ColNumbers[1],ColNumbers[2], ColNumbers[3], max = 255, alpha = 90) 
 plot(Time, Bottom, type= "n", col=Color1, main=Title, 
      ylim= c(YMin,YMax), log=LogAxis, xlim=c(XMin,XMax), 
      ylab =Ytitle, xlab = 'Time (minutes)', font=2,font.lab =2) 
 polygon(c(Time, rev(Time)), c(Top, rev(Bottom)),col=mycol4,border=NA) 
 lines(Time, Middle, type= "l", col=Color1, lwd=2.8) 
 Size.of.Data<-dim(Data2); PlottingData  <- matrix(0,Size.of.Data[1],4) 
 PlottingData[,1] <-Current.Iteration.Data[,1] 
 for(i in 1:length(t)){ 
   PlottingData[i,2] <- quantile(Data2[i,],0.05); PlottingData[i,3] <- quantile(Data2[i,],0.50) 
   PlottingData[i,4] <- quantile(Data2[i,],0.95)  } 
 Time<- PlottingData[,1];   Bottom  <- PlottingData[,2] 
 Top <- PlottingData[,4];   Middle  <- PlottingData[,3] 
 ColNumbers <- col2rgb(Color2); par(TRUE) 
 mycol4 <- rgb(ColNumbers[1],ColNumbers[2], ColNumbers[3], max = 255, alpha = 90) 
 polygon(c(Time, rev(Time)), c(Top, rev(Bottom)),col=mycol4,border=NA) 
 lines(Time, Middle, type= "l", col=Color2, lwd=2.8) 
 return() 
} 
 
VPCP2(CP.Data,CS.Data,'green','cyan',0,50, 2880,3360,'Cp(t) & Cs(t)','Concentrations 
(ug/ml)','') 
lines(xLine1,yLine,lty =2, lwd=3,col='red');lines(xLine2,yLine,lty 
=2,lwd=3,col='red');lines(xLine3,yLine,lty =2, lwd=3,col='red') 
points(TOB104.Time,TOB104.Conc,col='red',pch=20) 
points(TOB104.Time,TOB104.Conc.upper,col='red',cex=2,pch='-') 
points(TOB104.Time,TOB104.Conc.lower,col='red',cex=2,pch='-') 
points(TOB104.STime,TOB104.SConc,col='black',pch=20) 
points(TOB104.STime,TOB104.SConc.upper,col='black',cex=2,pch='-') 
points(TOB104.STime,TOB104.SConc.lower,col='black',cex=2,pch='-') 
 
#for(i in 1:length(t)) {print(sum(Current.Iteration.Data[i,seq(2,12)]))} 
 
#Dose.n[n]*3 
 
#Slope <- lm(Current.Iteration.Data[seq(317,337,1),1]~CP.Data[seq(317,337,1),1]) 
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#-0.693/Slope$coefficients[2] 
 
CPRes1 <- abs(TOB104.Conc[2]-mean(CP.Data[292,]))/TOB104.Conc[2] 
CPRes2 <- abs(TOB104.Conc[3]-mean(CS.Data[295,]))/TOB104.Conc[3] 
CPRes3 <- abs(TOB104.Conc[4]-mean(CS.Data[313,]))/TOB104.Conc[4] 
CPRes4 <- abs(TOB104.Conc[5]-mean(CS.Data[325,]))/TOB104.Conc[5] 
CPRes5 <- abs(TOB104.Conc[6]-mean(CS.Data[337,]))/TOB104.Conc[6] 
Res1 <- abs(TOB104.SConc[1]-mean(CS.Data[289,]))/TOB104.SConc[1] 
Res2 <- abs(TOB104.SConc[2]-mean(CS.Data[310,]))/TOB104.SConc[2] 
Res3 <- abs(TOB104.SConc[3]-mean(CS.Data[313,]))/TOB104.SConc[3] 
Res4 <- abs(TOB104.SConc[4]-mean(CS.Data[331,]))/TOB104.SConc[4] 
(CPRes1+CPRes2+CPRes3+CPRes4+CPRes5) 
(Res1+Res2+Res3+Res4)*10 
 
 
Code 2 Rscript utilized for performing optimization and plotting of MCS 
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rm(list=ls()); cat("\014");dev.off();set.seed(12301991);Start.time <- proc.time() # start a 
timer 
BW.me <- 70 
BW.cv   <- 0*100/BW.me 
n       <- 3 
PerKgDose <- 1.5 #mg/kg 
tinf <- 10 
t <- 
c(0,5,10,15,20,30,45,60,90,120,180,240,300,360,420,480,540,600,660,720,780,840,90
0,960,1020,1080,1140,1200,1260,1320,1380,1440,1450,1500,1560,1620,1680,1740,18
00,1860,1920,1980,2040,2100,2160,2220,2280,2340,2400,2460,2520,2580,2640,2700,
2760,2820,2880,2890,seq(49,72)*60) 
Clpop     <- 70 
Clprop.me  <- 1 
k12.me    <- 0.010 
k21.me    <- 0.015 
V0pop     <- 10 
V0prop.me  <- 1 
Clprop.cv  <- 0 
k12.cv     <- 0 
k21.cv     <- 0 
V0prop.cv  <- 0 
kga.me    <- 1 
Foral.me  <- 0 
kga.cv    <- 0 
Foral.cv  <- 0 
kpa.me    <- 0.006 
kca.me    <- 0.9 
kpm.me    <- 0.16 
kcm.me    <- 0.6 
kpd.me    <- 0.0008 
kcd.me    <- 0.001 
TLV.me    <- 20 #ml 
kpls1.me  <- 0.0005 
kpls2.me  <- 0.0001 
kcls1.me  <- 0.0005 
kcls2.me  <- 0.0002 
kpa.cv    <- 0 
kca.cv    <- 0 
kpm.cv    <- 0 
kcm.cv    <- 0 
kpd.cv    <- 0 
kcd.cv    <- 0 
kpls1.cv  <- 0 
kpls2.cv  <- 0 
kcls1.cv  <- 0 
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kcls2.cv  <- 0 
TLVprop.me  <- 1 
TLVprop.cv  <- 0 
kin.me    <- 0 
Fex.me    <- 0.009 
Fpd.me    <- 0.21 
Fcd.me    <- 0.069 
Din.me    <- 0 
kin.cv    <- 0 
Fex.cv    <- 0 
Fpd.cv    <- 0 
Fcd.cv    <- 0 
Din.cv    <- 0 
######################################################################
######## 
#####################     Normal Distribution Generator     
##################### 
######################################################################
######## 
NormGen <- function(simulation.n,samp.m,samp.cv ){ 
  samp.sd <- samp.cv*samp.m/100 
  out <- rnorm(simulation.n,samp.m,samp.sd) 
  return(out) 
} 
 
LogNormGen <- function(n, Mean, PCV){ 
  CV <- PCV/100 
  SD <- (CV*Mean) 
  Variance <- SD^2 
  mean.in  <- log(Mean^2 / sqrt(Variance+Mean^2)) 
  SD.in    <- sqrt(log(Variance/Mean^2 + 1)) 
  x=rlnorm(n,mean.in,SD.in) 
  return(x) 
} 
######################################################################
######## 
#######################     Generation of numbers  
################################ 
######################################################################
######## 
BW.n     <- NormGen(n, BW.me,BW.cv) 
Clprop.n <- NormGen(n, Clprop.me,Clprop.cv) 
Cltot.n  <- Clpop*(BW.n/mean(BW.n))^0.75   * Clprop.n  
#Cltot.n  <- c(Clpop/5,Clpop,5*Clpop) 
 
k12.n    <- LogNormGen(n, k12.me,k12.cv)     
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#k12.n    <- c(k12.me/5,k12.me,5*k12.me) 
 
k21.n    <- LogNormGen(n, k21.me,k21.cv) 
#k21.n    <- c(k21.me/5,k21.me,5*k21.me) 
 
V0prop.n <- NormGen(n, V0prop.me,V0prop.cv) 
V0.n    <- V0pop*(BW.n/mean(BW.n))^1      * V0prop.n 
#V0.n  <- c(V0pop/5,V0pop,5*V0pop) 
 
kga.n    <- LogNormGen(n, kga.me,kga.cv) 
if (Foral.me==0){Foral.n<-matrix(0,1,n)} else if (Foral.me>0){Foral.n<-
LogNormGen(n,Foral.me,Foral.cv)} 
 
 
kpa.n    <- LogNormGen(n, kpa.me,kpa.cv) 
#kpa.n    <- c(kpa.me/5,kpa.me,5*kpa.me) 
 
kca.n    <- LogNormGen(n, kca.me,kca.cv) 
#kca.n    <- c(kca.me/5,kca.me,5*kca.me) 
 
kpm.n    <- LogNormGen(n, kpm.me,kpm.cv) 
#kpm.n    <- c(kpm.me/5,kpm.me,5*kpm.me) 
 
kcm.n    <- LogNormGen(n, kcm.me,kcm.cv) 
#kcm.n    <- c(kcm.me/5,kcm.me,5*kcm.me) 
 
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n, 
kpd.me,kpd.cv)} 
kpd.n    <- c(kpd.me/5,kpd.me,5*kpd.me) 
kpd.n <-c(5*kpd.me,5*kpd.me,5*kpd.me) 
kpd.n <-c(kpd.me,kpd.me,kpd.me) 
#kpd.n <- c(kpd.me/5,kpd.me/5,kpd.me/5) 
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n, 
kcd.me,kcd.cv)} 
#kcd.n    <- c(kcd.me/5,kcd.me,5*kcd.me) 
 
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n, 
kpls1.me,kpls1.cv)} 
#kpls1.n    <- c(kpls1.me/5,kpls1.me,5*kpls1.me) 
 
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n, 
kpls2.me,kpls2.cv)} 
#kpls2.n    <- c(kpls2.me/5,kpls2.me,5*kpls2.me) 
 
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n, 
kcls1.me,kcls1.cv)} 
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#kcls1.n    <- c(kcls1.me/5,kcls1.me,5*kcls1.me) 
 
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n, 
kcls2.me,kcls2.cv)} 
#kcls2.n    <- c(kcls2.me/5,kcls2.me,5*kcls2.me) 
 
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv) 
 
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)} 
  Fex.n    <- NormGen(n, Fex.me,Fex.cv) 
  Fpd.n    <- NormGen(n, Fpd.me,Fpd.cv) 
  Fcd.n    <- NormGen(n, Fcd.me,Fcd.cv) 
if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n, 
Din.me,Din.cv)} 
 
######################################################################
######## 
##############         Set up the ODE Based model function        
####################### 
######################################################################
########TCBM <- function(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, 
kpls2,  
                 kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, Dose, tinf ){ 
  Dose.Value <- (1-Din)*Dose 
  Fgd        <- 1-Fex-Fpd-Fcd 
  ED <- data.frame(var = c("DOSING"), time = c(t[1],tinf,1440,1450,2880,2890), value = 
c(Dose.Value/tinf,0), method = c("rep")) 
    
  Model.Function <- function(t,IC,Parm) { 
    with(as.list(IC, Parm), { 
       
      dDOSING <- 0 
       
      dIn   <-   -In*kin*(Fex+Fpd+Fcd+Fgd) 
      dPLU  <-   In*kin*Fpd + PLS*kpd - PLU*(kpa + kpm) 
      dCLU  <-   In*kin*Fcd + CLS*kcd - CLU*(kca + kcm) + PLU* kpm 
      dGI   <-   In*kin*Fgd + CLU* kcm - GI*kga 
      dPLS  <-   PLU*kpa + CC*kpls1 - PLS * (kpd+kpls2) 
      dCLS  <-   CLU*kca + CC*kcls1 - CLS * (kcd+kcls2) 
      dCC   <-   PLS*kpls2 + CLS*kcls2 + GI*kga*Foral + PC*k21 - CC*(kpls1+kcls1 + 
k12 + (Cltot/(V0*1000)))+ DOSING   
      dPC   <-   CC* k12 - PC *k21 
       
      dEx   <-   In*kin*Fex 
      dFe   <-   GI*kga*(1-Foral) 
      dEl   <-   CC*(Cltot/(V0*1000)) 
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      return(list(c(dIn,dPLU,dCLU,dPLS,dCLS,dGI,dCC,dPC,dEx,dFe,dEl,dDOSING)))   
    }) 
  } 
  IC   <- c(In=0, PLU=0*Fpd, CLU=0*Fcd, PLS=0, CLS=0, GI=0*Fgd, CC=0, PC=0, 
Ex=0*Fex, Fe=0, El=0,DOSING=0) 
  Parm <- c(Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, kpls2, kcls1, 
kcls2, kin, Fex, Fpd, Fcd, Fgd) 
  out  <- ode(IC, t,Model.Function,Parm,events = list(data=ED)) 
  return(out) 
} 
######################################################################
######## 
#####################        PBPK Model iterations       #####################  
######################################################################
######## 
Dose.n  <- BW.n*PerKgDose 
 
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n 
CLV.n <- TLV.n*0.8/1000 
PLV.n <- TLV.n*0.2/1000 
 
In.Data  <- matrix(0,length(t),(n)) 
PLU.Data <- matrix(0,length(t),(n)) 
CLU.Data <- matrix(0,length(t),(n)) 
PLS.Data <- matrix(0,length(t),(n)) 
CLS.Data <- matrix(0,length(t),(n)) 
GI.Data  <- matrix(0,length(t),(n)) 
CC.Data  <- matrix(0,length(t),(n)) 
PC.Data  <- matrix(0,length(t),(n)) 
Ex.Data  <- matrix(0,length(t),(n)) 
Fe.Data  <- matrix(0,length(t),(n)) 
El.Data  <- matrix(0,length(t),(n)) 
CP.Data  <- matrix(0,length(t),(n)) 
CS.Data  <- matrix(0,length(t),(n)) 
PL.Data  <- matrix(0,length(t),(n)) 
 
Cmax.n=rep(0,n) 
tmax.n=rep(0,n) 
Smax.n=rep(0,n) 
tsmax.n=rep(0,n) 
 
AUC.n=Dose.n*1000/Cltot.n/60 
 
for (i in 1:n) { 
  Dose   <- Dose.n[i] 
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  Cltot  <- Cltot.n[i] 
  k12    <- k12.n[i]      
  k21    <- k21.n[i] 
  V0     <- V0.n[i] 
   
  kga    <- kga.n[i] 
  Foral  <- Foral.n[i] 
   
  kpa    <- kpa.n[i] 
  kca    <- kca.n[i] 
  kpm    <- kpm.n[i] 
  kcm    <- kcm.n[i] 
  kpd    <- kpd.n[i] 
  kcd    <- kcd.n[i] 
  kpls1  <- kpls1.n[i] 
  kpls2  <- kpls2.n[i] 
  kcls1  <- kcls1.n[i] 
  kcls2  <- kcls2.n[i] 
  CLV    <- CLV.n[i] 
  PLV    <- PLV.n[i] 
   
  kin    <- kin.n[i] 
  Fex    <- Fex.n[i] 
  Fpd    <- Fpd.n[i] 
  Fcd    <- Fcd.n[i] 
  Din    <- Din.n[i] 
   
  Current.Iteration.Data <- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd,  
            kcd, kpls1, kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, Dose, tinf) 
   
  In.Data[,i]  <- Current.Iteration.Data[,2] 
  PLU.Data[,i] <- Current.Iteration.Data[,3] 
  CLU.Data[,i] <- Current.Iteration.Data[,4] 
  PLS.Data[,i] <- Current.Iteration.Data[,5] 
  CLS.Data[,i] <- Current.Iteration.Data[,6] 
  GI.Data[,i]  <- Current.Iteration.Data[,7] 
  CC.Data[,i]  <- Current.Iteration.Data[,8] 
  PC.Data[,i]  <- Current.Iteration.Data[,9] 
  Ex.Data[,i]  <- Current.Iteration.Data[,10] 
  Fe.Data[,i]  <- Current.Iteration.Data[,11] 
  El.Data[,i]  <- Current.Iteration.Data[,12] 
   
  CP.Data[,i]  <- Current.Iteration.Data[,8]/V0 
  CS.Data[,i]  <- Current.Iteration.Data[,4]/CLV 
  PL.Data[,i]  <- Current.Iteration.Data[,3]/PLV 
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  Cmax.n[i]<- max(CP.Data[57:82,i]) 
  tmax.n[i]<-t[which.max(CP.Data[57:82,i])] 
  Smax.n[i]<- max(CS.Data[57:82,i]) 
  tsmax.n[i]<-t[which.max(CS.Data[57:82,i])] 
} 
 
######################################################################
######## 
###################   VPC Plotting Function for DATA    ################### 
######################################################################
######## 
VPCP <- function(Data,Color,YMin,YMax,XMin,XMax,Title,Ytitle,LogAxis){   
  Size.of.Data<-dim(Data); PlottingData  <- matrix(0,Size.of.Data[1],4) 
  PlottingData[,1] <-Current.Iteration.Data[,1] 
  for(i in 1:length(t)){ 
    PlottingData[i,2] <- quantile(Data[i,],0.05); PlottingData[i,3] <- quantile(Data[i,],0.50) 
    PlottingData[i,4] <- quantile(Data[i,],0.95)  } 
  Time    <- PlottingData[,1];   Bottom  <- PlottingData[,2] 
  Top     <- PlottingData[,4];   Middle  <- PlottingData[,3]   
  ColNumbers <- col2rgb(Color); par(TRUE) 
  mycol4 <- rgb(ColNumbers[1],ColNumbers[2], ColNumbers[3], max = 255, alpha = 90) 
  plot(Time, Bottom, type= "n", col=Color, main=Title, 
       ylim= c(YMin,YMax), log=LogAxis, xlim=c(XMin,XMax), 
       ylab =Ytitle, xlab = 'Time (minutes)', font=2,font.lab =2) 
  polygon(c(Time, rev(Time)), c(Top, rev(Bottom)),col=mycol4,border=NA) 
  lines(Time, Middle, type= "l", col=Color, lwd=2.8) 
  return() 
} 
TL <- function(x) {x<-max(x);X<-10^ceiling(log10(x));return(X)} 
LL <- function(x) {x<-max(x);X<-10^ceiling(log10(x));X<-X/100;return(X)} 
plot(t) 
dev.off();par(mfrow=c(2,3)); par(TRUE) 
dev.off();par(mfrow=c(1,2)); par(TRUE) 
VPCP(CP.Data,'green',LL(CP.Data),TL(CP.Data), 0,max(t),'Cp(t)','Plasma Conc 
(ug/ml)','y') 
VPCP(CS.Data,'blue',LL(CS.Data),TL(CS.Data), 0,max(t),'Cs(t)','Sputum Conc 
(ug/ml)','y') 
dev.off();par(mfrow=c(2,4)); par(TRUE) 
VPCP(PLU.Data,'grey',LL(PLU.Data),TL(PLU.Data), 0,max(t),'PLU(t)','Peripheral Lung 
Unbound (ug)','y') 
VPCP(CLU.Data,'grey',LL(CLU.Data),TL(CLU.Data), 0,max(t),'CLU(t)','Central  Lung 
Unbound (ug)','y') 
VPCP(PLS.Data,'grey',LL(PLS.Data),TL(PLS.Data), 0,max(t),'PLS(t)','Peripheral Lung 
Sequestered (ug)','y') 
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VPCP(CLS.Data,'grey',LL(CLS.Data),TL(CLS.Data), 0,max(t),'CLS(t)','Central  Lung 
Sequestered (ug)','y') 
VPCP(CC.Data,'grey',LL(CC.Data),TL(CC.Data), 0,max(t),'CC(t)','Central Cmpt (ug)','y') 
VPCP(PC.Data,'grey',LL(PC.Data),TL(PC.Data), 0,max(t),'PC(t)','Peripheral Cmpt 
(ug)','y') 
 
VPCP(CP.Data,'green',LL(CP.Data),TL(CP.Data), 0,max(t),'Cp(t)','Plasma Conc 
(ug/ml)','y') 
VPCP(CS.Data,'blue',LL(CS.Data),TL(CS.Data), 0,max(t),'Cs(t)','Sputum Conc 
(ug/ml)','y') 
 
######################################################################
### 
######################################################################
### 
AUC.Trap.Calc <- function(Time, CP){ 
  n <- length(Time);  AUC.Values<-rep(0,n-1) 
  for (i in 1:(n-1)){ 
    if (i==1){      AUC.Values[i]<-(Time[i+1]-Time[i])* (CP[i]+CP[i+1])/2      } 
    if (i>1){      AUC.Values[i]<-(Time[i+1]-Time[i])* (CP[i]+CP[i+1])/2 +AUC.Values[i-1]    } 
  };  return(AUC.Values[i]) 
}  
AUCLowerParmValue <-AUC.Trap.Calc(t[57:82], CP.Data[57:82,1]) 
AUCHigherParmValue <- AUC.Trap.Calc(t[57:82], CP.Data[57:82,3]) 
AUCS <- c(AUCLowerParmValue,AUCHigherParmValue) 
AUCMultiplier=1 
if (AUCHigherParmValue<AUCLowerParmValue){AUCMultiplier=-1} 
AUCMultiplier*max(AUCS)/min(AUCS) 
 
LCP.Data<-log10(CP.Data) 
LowerDataSet<- LCP.Data[70:82,1] 
LowerSlope<-lm(LowerDataSet~t[70:82]) 
thalflower<-log(2)/(LowerSlope$coefficients[2]*-2.303) 
HigherDataSet<- LCP.Data[70:82,3] 
HighSlope<-lm(HigherDataSet~t[70:82]) 
thalfhigher<-log(2)/(HighSlope$coefficients[2]*-2.303) 
thalf<-c(thalfhigher,thalflower) 
thalfmultiplier<-1 
if (thalfhigher<thalflower){thalfmultiplier=-1} 
thalfmultiplier*max(thalf)/min(thalf) 
 
Cmaxlower <- Cmax.n[1] 
Cmaxhigher<- Cmax.n[3] 
Cmaxmultiplier<-1 
if (Cmaxhigher<Cmaxlower){Cmaxmultiplier=-1} 
Cmaxmultiplier*max(Cmax.n)/min(Cmax.n) 
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tmaxlower <- tmax.n[1] 
tmaxhigher <- tmax.n[3] 
tmaxmultiplier<-1 
if (tmaxhigher<tmaxlower){tmaxmultiplier=-1} 
tmaxmultiplier*max(tmax.n)/min(tmax.n) 
############################################## 
############################################## 
SAUCLowerParmValue <-AUC.Trap.Calc(t[57:82], CS.Data[57:82,1]) 
SAUCHigherParmValue <- AUC.Trap.Calc(t[57:82], CS.Data[57:82,3]) 
SAUCS <- c(SAUCLowerParmValue,SAUCHigherParmValue) 
SAUCMultiplier=1 
if (SAUCHigherParmValue<SAUCLowerParmValue){SAUCMultiplier=-1} 
SAUCMultiplier*max(SAUCS)/min(SAUCS) 
SLCP.Data<-log10(CS.Data) 
SLowerDataSet<- SLCP.Data[70:82,1] 
SLowerSlope<-lm(SLowerDataSet~t[70:82]) 
Sthalflower<-log(2)/(SLowerSlope$coefficients[2]*-2.303) 
SHigherDataSet<- SLCP.Data[70:82,3] 
SHighSlope<-lm(SHigherDataSet~t[70:82]) 
Sthalfhigher<-log(2)/(SHighSlope$coefficients[2]*-2.303) 
Sthalf<-c(Sthalfhigher,Sthalflower) 
Sthalfmultiplier<-1 
if (Sthalfhigher<Sthalflower){Sthalfmultiplier=-1} 
Sthalfmultiplier*max(Sthalf)/min(Sthalf) 
 
Smaxlower <- Smax.n[1] 
Smaxhigher<- Smax.n[3] 
Smaxmultiplier<-1 
if (Smaxhigher<Smaxlower){Smaxmultiplier=-1} 
Smaxmultiplier*max(Smax.n)/min(Smax.n) 
tsmaxlower <- tsmax.n[1] 
tsmaxhigher <- tsmax.n[3] 
tsmaxmultiplier<-1 
if (tsmaxhigher<tsmaxlower){tsmaxmultiplier=-1} 
tsmaxmultiplier*max(tsmax.n)/min(tsmax.n) 
AUCMultiplier*max(AUCS)/min(AUCS) 
Cmaxmultiplier*max(Cmax.n)/min(Cmax.n) 
tmaxmultiplier*max(tmax.n)/min(tmax.n) 
thalfmultiplier*max(thalf)/min(thalf) 
SAUCMultiplier*max(SAUCS)/min(SAUCS) 
Smaxmultiplier*max(Smax.n)/min(Smax.n) 
tsmaxmultiplier*max(tsmax.n)/min(tsmax.n) 
Sthalfmultiplier*max(Sthalf)/min(Sthalf) 
 
Code 3. Rscript utilized for performing RD sensitivity analysis simulations. 
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APPENDIX 3 
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Scientist Fits of IV CIP 
 
Figure 1. Simulations results of plasma concentration time profile on a linear-scale for 
CIP 101A based on the parameters estimated from various applied weighting factors.  
 
 
Figure 2. Simulations results of plasma concentration time profile on a linear-scale for 
CIP 102A based on the parameters estimated from various applied weighting factors.  
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Figure 3. Simulations results of plasma concentration time profile on a linear-scale for 
CIP 102B based on the parameters estimated from various applied weighting factors.  
 
 
Figure 4. Simulations results of plasma concentration time profile on a linear-scale for 
CIP 102C based on the parameters estimated from various applied weighting factors.  
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Figure 5. Simulations results of plasma concentration time profile on a linear-scale for 
CIP 104A based on the parameters estimated from various applied weighting factors.  
 
 
Figure 6. Simulations results of plasma concentration time profile on a linear-scale for 
CIP 105A based on the parameters estimated from various applied weighting factors.  
 
 
257 
 
 
Figure 7. Simulations results of plasma concentration time profile on a linear-scale for 
CIP 105B based on the parameters estimated from various applied weighting factors.  
 
 
Figure 8. Simulations results of plasma concentration time profile on a linear-scale for 
CIP 106A based on the parameters estimated from various applied weighting factors.  
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Figure 9. Simulations results of plasma concentration time profile on a linear-scale for 
CIP 107A based on the parameters estimated from various applied weighting factors.  
 
 
Figure 10. Simulations results of plasma concentration time profile on a linear-scale for 
CIP 107C based on the parameters estimated from various applied weighting factors.  
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Figure 11. Simulations results of plasma concentration time profile on a linear-scale for 
CIP 108A based on the parameters estimated from various applied weighting factors.  
 
Figure 12. Simulations results of plasma concentration time profile on a linear-scale for 
CIP 108B based on the parameters estimated from various applied weighting factors.  
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Table 1. Parameter estimates based on simplex fit with either no weighting factor, a 
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 101A. 
Column highlighted in green represented the weighting factor deemed acceptable for 
this specific data set.  
 
Time 
(min)
Conc. In 
Plasma 
(mg/L)
None 1/y 1/y2
15 3.96867 3.9988 4.05 4.165
30 2.26 2.1474 2.0831 2.0137
45 1.27 1.3208 1.2803 1.2297
60 0.81 0.94183 0.9375 0.92404
90 0.70 0.66248 0.6908 0.71046
120 0.58 0.56391 0.5912 0.61289
180 0.50 0.45528 0.4623 0.47336
240 0.46 0.3734 0.3642 0.36674
360 0.22 0.25153 0.2261 0.22016
480 0.14 0.16944 0.1404 0.13217
600 0.07 0.11414 0.0871 0.079345
720 0.05 0.076889 0.0541 0.047633
✓ ✓ ✓
0.9979 0.99425 0.99119
5.01 4.5512 4.5639
36.13 34.6410 32.357
1.20 2.3016 4.9415
3.32 6.6441 15.27181
0.031 0.0342 0.039563
0.003 0.0046 0.00842
9.66 13.5391 21.28251
0.011 0.0132 0.014786
0.0020 0.0017 0.001912
18.10 13.0706 12.9325
607.290 647.2200 654.36
59.1430 27.0520 24.085
9.74 4.1797 3.680696
Weighting Factor
Visual inspection
R2
MSC
Vo   (Liter)
Vo SD
Vo CV
k12   (min
-1)
Cltot  (ml*min
-1)
Cltot SD
Cltot CV
k12 SD
k12 CV
k21   (min
-1)
k21 SD
k21 CV
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Table 2. Parameter estimates based on simplex fit with either no weighting factor, a 
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 102A. 
Column highlighted in green represented the weighting factor deemed acceptable for 
this specific data set.  
 
Time (min)
Conc. In 
Plasma 
(mg/L)
None 1/y 1/y2
16.18060056 0.583895914 0.57537 1 0.47686
19.78731497 0.34 0.37281 0.3973 0.39018
26.20961971 0.27 0.23823 0.2617 0.28764
35 0.21 0.19273 0.1897 0.21155
45 0.18 0.17759 0.1622 0.16996
60 0.16 0.16383 0.1474 0.14346
75 0.14 0.15177 0.1389 0.13157
90 0.13 0.14061 0.1315 0.12395
105 0.12 0.13028 0.1247 0.11772
120 0.11 0.12071 0.1182 0.11207
135 0.10 0.11184 0.1121 0.10677
195 0.08 0.082419 0.0905 0.088042
255 0.07 0.060737 0.0731 0.072609
375 0.05 0.032985 0.0477 0.049385
495 0.03 0.017913 0.0311 0.033589
615 0.02 0.009728 0.0203 0.022846
735 0.02 0.005283 0.0132 0.015539
✓ ✓ ✓
0.99432 0.99171 0.99506
3.8829 3.9461 4.9682
27.73 42.2450 63.364
4.48 6.4174 8.8691
16.16 15.1909 13.99706
0.152 0.0938 0.054836
0.026 0.0171 0.01056
17.10 18.2263 19.25742
0.030 0.0230 0.019937
0.0031 0.0021 0.001667
10.56 9.2410 8.36184
1010.100 876.2200 870.8
87.3000 44.7320 18.908
8.64 5.1051 2.171337Cltot CV
k21   (min
-1)
k21 SD
k21 CV
Cltot  (ml*min
-1)
Cltot SD
Vo SD
Vo CV
k12   (min
-1)
k12 SD
k12 CV
Vo   (Liter)
Weighting Factor
Visual inspection
R2
MSC
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Table 3. Parameter estimates based on simplex fit with either no weighting factor, a 
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 102B. 
Column highlighted in green represented the weighting factor deemed acceptable for 
this specific data set.  
 
Time 
(min)
Conc. In 
Plasma 
(mg/L)
None 1/y 1/y2
16.1806 1.149423 1.1068 1 1.0019
19.78731 0.79 0.87296 0.8307 0.85738
26.20962 0.65 0.62226 0.5970 0.66916
35 0.49 0.4605 0.4496 0.50799
45 0.41 0.38342 0.3810 0.40399
60 0.35 0.33645 0.3395 0.32609
75 0.31 0.3115 0.3170 0.28885
90 0.28 0.2919 0.2988 0.26727
105 0.25 0.27424 0.2822 0.25193
120 0.23 0.25779 0.2667 0.23927
135 0.23 0.24236 0.2520 0.22793
195 0.18 0.18937 0.2010 0.18895
255 0.15 0.14796 0.1603 0.15682
375 0.10 0.090324 0.1020 0.10804
495 0.07 0.055141 0.0649 0.07443
615 0.05 0.033662 0.0413 0.051277
735 0.04 0.02055 0.0263 0.035326
✓ ✓ ✓
0.99581 0.99277 0.99726
4.1288 4.0679 5.5137
49.20 51.4770 67.739
4.26 7.1370 5.56
8.65 13.8644 8.207975
0.069 0.0722 0.039237
0.010 0.0152 0.005372
14.77 20.9979 13.69014
0.025 0.0262 0.017313
0.0032 0.0028 0.001182
12.91 10.7918 6.826084
871.860 819.7400 791.26
77.3670 38.7830 12.449
8.87 4.7311 1.573313
Cltot SD
Cltot CV
k12 CV
k21   (min
-1)
k21 SD
k21 CV
Cltot  (ml*min
-1)
MSC
Weighting Factor
Visual inspection
R2
Vo   (Liter)
Vo SD
Vo CV
k12   (min
-1)
k12 SD
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Table 4. Parameter estimates based on simplex fit with either no weighting factor, a 
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 102C. 
Column highlighted in green represented the weighting factor deemed acceptable for 
this specific data set.  
 
Time 
(min)
Conc. In 
Plasma 
(mg/L)
None 1/y 1/y2
21.84596 1.649272 1.5639 2 1.4246
26.86047 1.20 1.2513 1.2610 1.2371
30.13856 1.04 1.1051 1.1193 1.1354
40 0.86 0.83456 0.8452 0.90491
50 0.77 0.70076 0.7020 0.75247
65 0.64 0.60425 0.5974 0.61391
80 0.56 0.55167 0.5441 0.53425
110 0.47 0.47993 0.4797 0.4492
140 0.42 0.42158 0.4300 0.39944
200 0.31 0.32592 0.3470 0.32752
260 0.26 0.25198 0.2801 0.27043
380 0.17 0.15062 0.1825 0.18457
500 0.13 0.090037 0.1189 0.12597
620 0.09 0.053821 0.0775 0.085981
740 0.06 0.032172 0.0505 0.058684
✓ ✓ ✓
0.99678 0.99589 0.99641
4.219 4.6395 5.52656
70.82 74.8480 98.668
7.42 8.7013 10.239
10.48 11.6253 10.37722
0.049 0.0443 0.024865
0.010 0.0090 0.005299
19.61 20.3875 21.31269
0.025 0.0218 0.016174
0.0037 0.0025 0.001853
14.68 11.2977 11.45913
1018.300 917.0600 915.17
76.4390 33.4900 18.024
7.51 3.6519 1.96947
Cltot SD
Cltot CV
k12 CV
k21   (min
-1)
k21 SD
k21 CV
Cltot  (ml*min
-1)
MSC
Weighting Factor
Visual inspection
R2
Vo   (Liter)
Vo SD
Vo CV
k12   (min
-1)
k12 SD
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Table 5. Parameter estimates based on simplex fit with either no weighting factor, a 
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 104A. 
Column highlighted in green represented the weighting factor deemed acceptable for 
this specific data set.  
Time (min)
Conc. In 
Plasma 
(mg/L)
None 1/y 1/y2
5.906275599 2.888883679 2.876 2.7949 2.3354
14.04837066 1.29 1.3566 1.4375 1.4572
21.87398853 0.88 0.80108 0.84194 0.9568
34.79201215 0.56 0.515 0.48128 0.55153
50.11238537 0.42 0.42163 0.36412 0.36696
65 0.33 0.37583 0.32508 0.29815
95 0.27 0.30673 0.28327 0.24729
125 0.22 0.25105 0.25035 0.22117
185 0.17 0.1682 0.19584 0.18073
245 0.14 0.1127 0.1532 0.14792
365 0.10 0.050588 0.093745 0.099092
485 0.06 0.022709 0.057366 0.066383
605 0.04 0.010194 0.035104 0.044471
725 0.03 0.004576 0.021481 0.029792
✓ ✓ ✓
0.99781 0.99171 0.9914
5.14 4.2042 4.3816
25.31 27.232 35.161
0.73 1.6638 4.2074
2.87 6.1097 11.9661
0.076 0.05479 0.04316
0.006 0.007027 0.006228
8.51 12.8252 14.4291
0.024 0.015382 0.011399
0.0038 0.00186 0.001092
15.83 12.0914 9.58242
900.480 757.91 745.87
84.7920 43.085 22.712
9.42 5.6847 3.045035
k21 SD
k21 CV
Cltot  (ml*min
-1)
Cltot SD
Cltot CV
k21   (min
-1)
Weighting Factor
Visual inspection
R2
MSC
Vo   (Liter)
Vo SD
Vo CV
k12   (min
-1)
k12 SD
k12 CV
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Table 6. Parameter estimates based on simplex fit with either no weighting factor, a 
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 105A. 
Column highlighted in green represented the weighting factor deemed acceptable for 
this specific data set.  
 
Time 
(min)
Conc. In 
Plasma 
(mg/L)
None 1/y 1/y2
30 2.48649 2.4865 2 2.4017
60 3.29 3.2821 3.2768 3.2584
75 1.77 1.8169 1.8819 1.9704
90 1.54 1.4319 1.4011 1.4172
120 1.19 1.1949 1.1094 1.0355
180 0.89 0.92797 0.8847 0.81656
240 0.67 0.72302 0.7172 0.67905
300 0.52 0.56334 0.5816 0.56571
360 0.43 0.43892 0.4716 0.47132
480 0.30 0.26645 0.3101 0.32716
600 0.24 0.16175 0.2039 0.2271
720 0.17 0.098196 0.1341 0.15763
✓ ✓ ✓
0.99876 0.99614 0.99373
5.141 4.4384 4.1086
32.09 37.9460 44.505
3.49 4.6464 7.3965
10.87 12.2448 16.61948
0.064 0.0475 0.035459
0.012 0.0092 0.007943
18.03 19.4007 22.40136
0.018 0.0139 0.011169
0.0019 0.0017 0.001362
10.58 12.0765 12.19357
768.160 735.5200 726.22
28.5890 24.1190 21.659
3.72 3.2792 2.98243
k21 SD
k21 CV
Cltot  (ml*min
-1)
Cltot SD
Cltot CV
k21   (min
-1)
Weighting Factor
Visual inspection
R2
MSC
Vo   (Liter)
Vo SD
Vo CV
k12   (min
-1)
k12 SD
k12 CV
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Table 7. Parameter estimates based on simplex fit with either no weighting factor, a 
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 105B. 
Column highlighted in green represented the weighting factor deemed acceptable for 
this specific data set.  
 
 
Time 
(min)
Conc. In 
Plasma 
(mg/L)
None 1/y 1/y2
30 3.156757 3.035 3 2.9987
60 3.89 4.0115 4.0261 4.0316
75 2.25 2.251 2.3121 2.3896
90 1.84 1.7343 1.7202 1.7354
120 1.47 1.425 1.3615 1.3079
180 1.04 1.121 1.0866 1.0391
240 0.84 0.88758 0.8819 0.85581
300 0.67 0.70277 0.7159 0.70546
360 0.54 0.55644 0.5812 0.58153
480 0.41 0.34884 0.3830 0.39517
600 0.26 0.2187 0.2524 0.26852
720 0.19 0.13711 0.1663 0.18247
✓ ✓ ✓
0.99842 0.99738 0.99728
4.8824 4.8605 4.34
28.07 30.9070 34.037
2.98 3.1193 4.2862
10.61 10.0925 12.59277
0.057 0.0474 0.039398
0.010 0.0075 0.00674
18.05 15.9164 17.1062
0.016 0.0139 0.012159
0.0020 0.0014 0.001072
12.19 9.7405 8.818982
616.120 597.3800 592.58
27.1090 15.9800 12.734
4.40 2.6750 2.148908
k21 SD
k21 CV
Cltot  (ml*min
-1)
Cltot SD
Cltot CV
k21   (min
-1)
Weighting Factor
Visual inspection
R2
MSC
Vo   (Liter)
Vo SD
Vo CV
k12   (min
-1)
k12 SD
k12 CV
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Table 8. Parameter estimates based on simplex fit with either no weighting factor, a 
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 106A. 
Column highlighted in green represented the weighting factor deemed acceptable for 
this specific data set.  
 
 
 
 
 
 
 
Time 
(min)
Conc. In 
Plasma 
(mg/L)
None 1/y 1/y2
120 4.361101381 4.3574 4 4.1982
180 1.94 1.9808 2.0387 2.1136
240 1.43 1.3487 1.3334 1.3602
300 1.14 1.1124 1.0713 1.0562
360 0.91 0.97366 0.9372 0.90659
480 0.72 0.77258 0.7667 0.74016
720 0.50 0.49257 0.5298 0.52757
1440 0.20 0.12781 0.1757 0.19423
✓ ✓ ✓
0.99926 0.99783 0.99709
5.3819 4.6518 4.841
14.92 19.1260 24.875
3.18 4.2319 6.2531
21.30 22.1264 25.13809
0.010 0.0090 0.007868
0.001 0.0011 0.001104
9.43 11.9085 14.03498
0.003 0.0030 0.00283
0.0004 0.0003 0.000237
12.20 10.0579 8.369258
205.150 210.8500 222.83
12.7100 13.7570 16.092
6.20 6.5245 7.221649
k21 SD
k21 CV
Cltot  (ml*min
-1)
Cltot SD
Cltot CV
k21   (min
-1)
Weighting Factor
Visual inspection
R2
MSC
Vo   (Liter)
Vo SD
Vo CV
k12   (min
-1)
k12 SD
k12 CV
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Table 9. Parameter estimates based on simplex fit with either no weighting factor, a 
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 107A. 
Column highlighted in green represented the weighting factor deemed acceptable for 
this specific data set.  
 
Time 
(min)
Conc. In 
Plasma 
(mg/L)
None 1/y 1/y2
15 2.771966 2.6823 3 2.6259
30 3.87 3.8126 3.8409 3.8679
60 4.79 4.9256 4.9776 5.0476
75 2.68 2.651 2.7161 2.8083
90 2.04 1.8937 1.8857 1.9075
120 1.44 1.458 1.3932 1.3392
180 1.06 1.1417 1.1016 1.0482
240 0.87 0.91064 0.9008 0.86772
360 0.57 0.57955 0.6031 0.5965
480 0.38 0.36884 0.4037 0.41008
600 0.29 0.23474 0.2703 0.28191
720 0.19 0.14939 0.1809 0.19381
960 0.10 0.060509 0.0811 0.091596
✓ ✓ ✓
0.99895 0.99829 0.99774
5.4337 5.7345 5.9773
23.53 24.7160 25.896
1.18 1.2223 1.6986
5.02 4.9454 6.559314
0.047 0.0416 0.036588
0.004 0.0036 0.003573
9.56 8.6971 9.765224
0.013 0.0109 0.00967
0.0126 0.0008 0.000546
100.00 6.8805 5.645223
554.250 536.4500 532.77
23.8400 11.2850 8.5459
4.30 2.1036 1.604051
Cltot  (ml*min
-1)
Cltot SD
Cltot CV
k12 SD
k12 CV
k21   (min
-1)
k21 SD
k21 CV
MSC
Vo   (Liter)
Vo SD
Vo CV
k12   (min
-1)
Weighting Factor
Visual inspection
R2
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Table 10. Parameter estimates based on simplex fit with either no weighting factor, a 
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 107C. 
Column highlighted in green represented the weighting factor deemed acceptable for 
this specific data set.  
 
 
Time 
(min)
Conc. In 
Plasma 
(mg/L)
None 1/y 1/y2
30 4.45978 4.3914 4 4.2723
60 5.66 5.7165 5.7211 5.696
75 3.02 3.1039 3.1949 3.3223
90 2.55 2.3277 2.3060 2.3398
120 1.88 1.8846 1.7819 1.6934
180 1.38 1.487 1.4285 1.3394
240 1.11 1.1834 1.1713 1.1158
360 0.71 0.74947 0.7880 0.77683
480 0.52 0.47468 0.5301 0.54085
600 0.37 0.30064 0.3566 0.37656
720 0.26 0.19041 0.2399 0.26217
960 0.14 0.076375 0.1086 0.12708
✓ ✓ ✓
0.99867 0.99715 0.99615
5.1818 5.0873 5.2099
19.32 21.4630 24.212
1.72 0.0039 3.0937
8.91 0.0182 12.77755
0.055 0.0456 0.036815
0.008 0.0065 0.005968
14.89 14.2330 16.21051
0.015 0.0123 0.010531
0.0016 0.0011 0.000872
10.91 9.0675 8.281835
447.910 431.6000 431.03
20.2550 11.9210 10.265
4.52 2.7620 2.381505
Cltot  (ml*min
-1)
Cltot SD
Cltot CV
k12 SD
k12 CV
k21   (min
-1)
k21 SD
k21 CV
MSC
Vo   (Liter)
Vo SD
Vo CV
k12   (min
-1)
Weighting Factor
Visual inspection
R2
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Table 11. Parameter estimates based on simplex fit with either no weighting factor, a 
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 108A. 
Column highlighted in green represented the weighting factor deemed acceptable for 
this specific data set.  
 
Time 
(min)
Conc. In Plasma 
(mg/L)
None 1/y 1/y2
25 4.247037843 4.198 4 3.8746
30 3.19 3.3159 3.3485 3.3304
35.32251 2.77 2.7076 2.7716 2.8728
50 1.96 1.911 1.9268 2.0529
65 1.62 1.6076 1.5718 1.6068
80 1.44 1.4462 1.3931 1.3559
110 1.15 1.2262 1.1848 1.0957
140 1.09 1.0497 1.0313 0.94871
200 0.71 0.77043 0.7862 0.74366
260 0.55 0.56549 0.5996 0.58791
380 0.34 0.30466 0.3488 0.36788
500 0.22 0.16413 0.2029 0.23021
740 0.10 0.047639 0.0687 0.090147
✓ ✓ ✓
0.99913 0.99779 0.99518
5.5089 5.3782 5.3129
35.38 41.1400 54.954
2.98 4.7043 7.9321
8.42 11.4349 14.43407
0.052 0.0416 0.024672
0.006 0.0071 0.006129
11.72 17.0164 24.8403
0.029 0.0197 0.014854
0.0018 0.0017 0.001716
6.13 8.4818 11.55446
718.670 695.7700 698.44
27.4360 19.3410 17.959
3.82 2.7798 2.571302
k21 SD
k21 CV
Cltot  (ml*min
-1)
Cltot SD
Cltot CV
k21   (min
-1)
Weighting Factor
Visual inspection
R2
MSC
Vo   (Liter)
Vo SD
Vo CV
k12   (min
-1)
k12 SD
k12 CV
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Table 12. Parameter estimates based on simplex fit with either no weighting factor, a 
weighting factor of 1/y or a weighting factor of 1/y2 applied to data from study CIP 108B. 
Column highlighted in green represented the weighting factor deemed acceptable for 
this specific data set.  
  
Time 
(min)
Conc. In 
Plasma 
(mg/L)
None 1/y 1/y2
10 10.1236947 10.097 10 9.3897
15 5.72 5.8016 5.8773 5.9486
20.32251 3.73 3.6883 3.7624 3.9884
35 1.99 1.8277 1.7871 1.8435
50 1.51 1.5133 1.4464 1.3922
65 1.34 1.3845 1.3271 1.2516
95 1.07 1.1923 1.1651 1.1036
125 0.97 1.029 1.0265 0.98417
185 0.78 0.7664 0.7970 0.78329
245 0.57 0.57083 0.6188 0.62343
365 0.38 0.31667 0.3731 0.39492
485 0.24 0.17567 0.2249 0.25016
725 0.11 0.054063 0.0817 0.10039
✓ ✓ ✓
0.99959 0.99424 0.99625
6.6979 5.0964 5.5275
10.56 11.7100 13.747
0.32 2.2866 1.8439
2.98 19.5269 13.41311
0.087 0.0868 0.07049
0.003 0.0118 0.007542
3.51 13.5638 10.69953
0.015 0.0131 0.012522
0.0009 0.0010 0.000687
6.19 7.4610 5.487622
496.110 463.6500 475.23
21.4480 16.1260 12.28
4.32 3.4781 2.584012
k21 SD
k21 CV
Cltot  (ml*min
-1)
Cltot SD
Cltot CV
k21   (min
-1)
Weighting Factor
Visual inspection
R2
MSC
Vo   (Liter)
Vo SD
Vo CV
k12   (min
-1)
k12 SD
k12 CV
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MCS Results for IV CIP 
 
Figure 13 MCS results of CIP 101A 
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Figure 14 MCS results of CIP 102A 
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Figure 15 MCS results of CIP 102B 
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Figure 16 MCS results of CIP 102C 
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Figure 17 MCS results of CIP 104A 
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Figure 18 MCS results of CIP 105A 
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Figure 19 MCS results of CIP 105B 
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Figure 20 MCS results of CIP 106A 
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Figure 21 MCS results of CIP 107A 
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Figure 22 MCS results of CIP 108A 
 
 
282 
 
 
Figure 23 MCS results of CIP 108B 
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MCS Results for PO CIP
 
Figure 24 MCS for PO administration in CIP 102A 
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Figure 25 MCS for PO administration in CIP 102B 
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Figure 26 MCS for PO administration in CIP 102C 
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Figure 27 MCS for PO administration in CIP 102D 
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Figure 28 MCS for PO administration in CIP 104A 
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Figure 29 MCS for PO administration in CIP 105A 
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Figure 30 MCS for PO administration in CIP 105B 
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Figure 31 MCS for PO administration in CIP 106A 
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Figure 32 MCS for PO administration in CIP 108A 
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Figure 33 MCS for PO administration in CIP 108B 
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Figure 34 MCS for PO administration in CIP 204A 
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Figure 35 MCS for PO administration in CIP 204B   
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MCS Results for INH CIP 
Figure 36 cp(t) MSC for INH study CIP 301A
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Figure 37 cs(t) MSC for INH study CIP 302A 
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Figure 38 cp(t) MSC for INH study CIP 302A 
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Figure 39 cs(t) MSC for INH study CIP 302B 
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Figure 40 cp(t) MSC for INH study CIP 302B 
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Figure 41 cp(t) MSC for INH study CIP 303A 
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Figure 42 cp(t) MSC for INH study CIP 303B  
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Figure 43 cp(t) MSC for INH study CIP 304A 
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Figure 44 cp(t) MSC for INH study CIP 304B  
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Figure 45 cp(t) MSC for INH study CIP 304C  
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Sensitivity Analysis Plots for INH CIP 
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Code Utilized for CIP MSC After INH 
rm(list=ls()); cat("\014");dev.off();set.seed(123091);Start.time <- proc.time() # start a 
timer 
 
BW.me <- 80.2 
BW.cv   <- 20 
n       <- 300 
Disease <- 1            #  1= Healthy     2= CF 
 
InhalerDose<-32.5#mg 
DtL  <- 0.53 
DtGI <- 0.43 
t<-seq(0,720,5) 
 
Clren.1.me <- 315        #Healthy 
Clren.2.me <- 425        #CF 
Clnonren.1.me <- 315        #Healthy 
Clnonren.2.me <- 225        #CF 
k12.1.me <- 0.025        #Healthy 
k12.2.me <- 0.050        #CF 
k21.1.me <- 0.015       #Healthy 
k21.2.me <- 0.020        #CF 
V0.1.me <- 75        #Healthy 
V0.2.me <- 20        #CF 
 
Clnonren.1.cv <- 20       #Healthy 
Clnonren.2.cv <- 20        #CF 
Clren.1.cv <- 20       #Healthy 
Clren.2.cv <- 20        #CF 
k12.1.cv <- 25       #Healthy 
k12.2.cv <- 20        #CF 
k21.1.cv <- 25       #Healthy 
k21.2.cv <- 20        #CF 
V0.1.cv <- 20       #Healthy 
V0.2.cv <- 20        #CF 
 
 
Foral.1.me  <- 73 
Foral.2.me  <- 85 
kga.1.me    <- 0.020 
kga.2.me    <- 0.011 
Foral.1.cv<-35;    Foral.2.cv<-30;    kga.1.cv<-10;  kga.2.cv<-50 
 
kpa.me    <- 0.010 
kca.me    <- 0.020  
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kpm.me    <- 0.020 
kcm.me    <- 0.02 
kpd.me    <- 0.008 
kcd.me    <- 0.0002 
kpls1.me  <- 10000  
kpls2.me  <- 10000 
kcls1.me  <- 10000 
kcls2.me  <- 10000 
TLV.me    <- 30  
kpa.cv<-75;kca.cv<-75;kpm.cv<-75;kcm.cv<-75;kpd.cv<-75;kcd.cv<-75 
kpls1.cv<-0;kpls2.cv<-0;kcls1.cv<-0;kcls2.cv<-0 
 
TLVprop.me  <- 1 
TLVprop.cv  <- 0 
 
kin.me    <- 0 
Fex.me    <- 0 
Fpd.me    <- 0.25 
Fcd.me    <- 0.75 
Din.me    <- 0 
kin.cv<-0;  Fex.cv<-0; Fpd.cv<-0;  Fcd.cv<-0;  Din.cv<-0 
 
######################################################################
################### 
#####################     Normal Distribution Generator     
############################# 
######################################################################
################### 
NormGen <- function(simulation.n,samp.m,samp.cv ){ 
  samp.sd <- samp.cv*samp.m/100 
  out <- rnorm(simulation.n,samp.m,samp.sd) 
  return(out)} 
LogNormGen <- function(n, Mean, PCV){ 
  CV<-PCV/100;SD<-(CV*Mean);Variance<-SD^2;mean.in<-
log(Mean^2/sqrt(Variance+Mean^2)); 
  SD.in<-sqrt(log(Variance/Mean^2 + 1));x=rlnorm(n,mean.in,SD.in) 
  return(x)} 
AUC.Trap.Calc <- function(Time, CP){ 
  n <- length(Time);  AUC.Values<-rep(0,n-1) 
  for (i in 1:(n-1)){    if (i==1){AUC.Values[i]<-(Time[i+1]-Time[i])* (CP[i]+CP[i+1])/2} 
    if (i>1){AUC.Values[i]<-(Time[i+1]-Time[i])* (CP[i]+CP[i+1])/2 +AUC.Values[i-1]} 
  } ;  return(AUC.Values[i])}  
######################################################################
################### 
#######################     Generation of numbers      
################################## 
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######################################################################
################### 
Cmax.301A.n=rep(0,n);Cmax.302A.n=rep(0,n);Cmax.302B.n=rep(0,n);Cmax.303A.n=re
p(0,n) 
Cmax.303B.n=rep(0,n);Cmax.304A.n=rep(0,n);Cmax.304B.n=rep(0,n);Cmax.304C.n=re
p(0,n) 
CpAUC.301A.n=rep(0,n);CpAUC.302A.n=rep(0,n);CpAUC.302B.n=rep(0,n);CpAUC.303
A.n=rep(0,n) 
CpAUC.303B.n=rep(0,n);CpAUC.304A.n=rep(0,n);CpAUC.304B.n=rep(0,n);CpAUC.304
C.n=rep(0,n) 
 
 
BW.n     <- NormGen(n, BW.me,BW.cv) 
if (Disease==1){Clnonren.n<-NormGen(n, Clnonren.1.me,Clnonren.1.cv)} else if 
(Disease==2) 
{Clnonren.n<-NormGen(n, Clnonren.2.me,Clnonren.2.cv)} 
if (Disease==1){Clren.n<-NormGen(n, Clren.1.me,Clren.1.cv)} else if (Disease==2) 
{Clren.n<-NormGen(n, Clren.2.me,Clren.2.cv)} 
if (Disease==1){k12.n<-NormGen(n, k12.1.me,k12.1.cv)} else if (Disease==2) 
{k12.n<-NormGen(n, k12.2.me,k12.2.cv)} 
if (Disease==1){k21.n<-NormGen(n, k21.1.me,k21.1.cv)} else if (Disease==2) 
{k21.n<-NormGen(n, k21.2.me,k21.2.cv)} 
if (Disease==1){V0.n<-NormGen(n, V0.1.me,V0.1.cv)} else if (Disease==2) 
{V0.n<-NormGen(n, V0.2.me,V0.2.cv)} 
if (Disease==1){kga.n<-LogNormGen(n, kga.1.me,kga.1.cv)} else if (Disease==2) 
{kga.n<-LogNormGen(n, kga.2.me,kga.2.cv)} 
if (Disease==1){Foral.n<-NormGen(n,Foral.1.me,Foral.1.cv)/100} else if (Disease==2) 
{Foral.n<-NormGen(n,Foral.2.me,Foral.2.cv)/100} 
kpa.n<- LogNormGen(n, kpa.me,kpa.cv);kca.n<- LogNormGen(n, kca.me,kca.cv) 
kpm.n<- LogNormGen(n, kpm.me,kpm.cv);kcm.n<- LogNormGen(n, kcm.me,kcm.cv) 
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n, 
kpd.me,kpd.cv)} 
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n, 
kcd.me,kcd.cv)} 
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n, 
kpls1.me,kpls1.cv)} 
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n, 
kpls2.me,kpls2.cv)} 
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n, 
kcls1.me,kcls1.cv)} 
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n, 
kcls2.me,kcls2.cv)} 
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv) 
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)} 
Fex.n<- NormGen(n, Fex.me,Fex.cv);Fpd.n<- NormGen(n, Fpd.me,Fpd.cv);Fcd.n<- 
NormGen(n, Fcd.me,Fcd.cv) 
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if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n, 
Din.me,Din.cv)} 
######################################################################
################### 
##############         Set up the ODE Based model function        
####################### 
######################################################################
################### 
TCBM <- function(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, kpls2,  
                 kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf ){ 
    Fgd        <- 1-Fex-Fpd-Fcd 
  ED <- data.frame(var = c("DOSING"), time = c(0,1), value = c(0,0), method = c("rep")) 
  Model.Function <- function(t,IC,Parm) { 
    with(as.list(IC, Parm), { 
      dDOSING <- 0 
      dIn  <- -In*kin*(Fex+Fpd+Fcd+Fgd);dPLU<-In*kin*Fpd + PLS*kpd - PLU*(kpa + 
kpm) 
      dCLU <-In*kin*Fcd + CLS*kcd - CLU*(kca + kcm) + PLU* kpm 
      dGI  <-In*kin*Fgd + CLU* kcm - GI*kga;dPLS <-PLU*kpa + CC*kpls1 - PLS * 
(kpd+kpls2) 
      dCLS <-CLU*kca + CC*kcls1 - CLS * (kcd+kcls2);dPC  <-CC* k12 - PC *k21 
      dCC  <-PLS*kpls2 + CLS*kcls2 + GI*kga*Foral + PC*k21 - CC*(kpls1+kcls1 + k12 + 
(Cltot/(V0*1000)))+ DOSING   
      dEx  <-In*kin*Fex;      dFe     <-   GI*kga*(1-Foral);      dEl     <-   
CC*(Cltot/(V0*1000)) 
      return(list(c(dIn,dPLU,dCLU,dPLS,dCLS,dGI,dCC,dPC,dEx,dFe,dEl,dDOSING)))   
    })  } 
  IC   <- c(In=0, PLU=LDose*Fpd, CLU=LDose*Fcd, PLS=0, CLS=0, GI=GIDose, 
CC=0, PC=0, Ex=0*Fex, Fe=0, El=0,DOSING=0) 
  Parm <- c(Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, kpls2, kcls1, 
kcls2, kin, Fex, Fpd, Fcd, Fgd) 
  out  <- ode(IC, t,Model.Function,Parm) 
  return(out)} 
######################################################################
################### 
#####################        PBPK Model iterations       
################################ 
######################################################################
################### 
Cltot.n<-Clren.n+Clnonren.n 
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n 
CLV.n <- TLV.n*0.8/1000 
PLV.n <- TLV.n*0.2/1000 
In.Data  <- matrix(0,length(t),(n));PL.Data  <- In.Data 
PLU.Data <- In.Data;CLU.Data <- In.Data;PLS.Data <- In.Data;CLS.Data <- In.Data 
GI.Data  <- In.Data;CC.Data  <- In.Data;PC.Data  <- In.Data;Ex.Data  <- In.Data 
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Fe.Data  <- In.Data;El.Data  <- In.Data;CP.Data  <- In.Data;CS.Data  <- In.Data 
for (i in 1:n) { 
  Cltot<-Cltot.n[i];k12<-k12.n[i];k21<-k21.n[i]; V0<-V0.n[i]; kga<-kga.n[i] 
  Foral<-Foral.n[i];kpa<-kpa.n[i];kca<-kca.n[i];kpm<-kpm.n[i];kcm<-kcm.n[i];kpd<-kpd.n[i] 
  kcd<-kcd.n[i];kpls1<- kpls1.n[i];kpls2<-kpls2.n[i];kcls1<-kcls1.n[i];kcls2<-
kcls2.n[i];CLV<-CLV.n[i] 
  PLV<-PLV.n[i];kin<-kin.n[i];Fex<-Fex.n[i];Fpd<-Fpd.n[i];Fcd<-Fcd.n[i];Din<-Din.n[i] 
  LDose <- InhalerDose*DtL; GIDose <-InhalerDose*DtGI 
  CID<- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, 
             kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf) 
  In.Data[,i]<-CID[,2];PLU.Data[,i]<-CID[,3];CLU.Data[,i]<-CID[,4];PLS.Data[,i]<-CID[,5] 
  CLS.Data[,i]<-CID[,6];GI.Data[,i] <-CID[,7];CC.Data[,i] <-CID[,8];PC.Data[,i] <-CID[,9] 
  Ex.Data[,i]<-CID[,10];Fe.Data[,i]<-CID[,11];El.Data[,i] <-CID[,12];CP.Data[,i]<-
CID[,8]/V0 
  CS.Data[,i]<-CID[,4]/CLV;PL.Data[,i]<-CID[,3]/PLV 
  Cmax.301A.n[i]<-CP.Data[13,i]*1000 
  CpAUC.301A.n[i]<-AUC.Trap.Calc(t, CP.Data[,i])/60*1000 
} 
######################################################################
################### 
###################   VPC Plotting Function for TS DATA    
############################## 
######################################################################
################### 
VPCP <- function(Data,Color,YMin,YMax,XMin,XMax,Title,Ytitle,LogAxis){   
  Size.of.Data<-dim(Data); PlottingData  <- matrix(0,Size.of.Data[1],4) 
  PlottingData[,1] <-CID[,1] 
  for(i in 1:length(t)){PlottingData[i,2] <- quantile(Data[i,],0.05); PlottingData[i,3] <- 
quantile(Data[i,],0.50) 
    PlottingData[i,4] <- quantile(Data[i,],0.95)  } 
  Time<-PlottingData[,1];Bottom<-PlottingData[,2];Top <-PlottingData[,4];Middle<-
PlottingData[,3]   
  ColNumbers <- col2rgb(Color); par(TRUE) 
  mycol4 <- rgb(ColNumbers[1],ColNumbers[2], ColNumbers[3], max = 255, alpha = 90) 
  plot(Time, Bottom, type= "n", col=Color, main=Title,ylim= 
c(YMin,YMax),log=LogAxis,xlim=c(XMin,XMax), 
       ylab =Ytitle,xlab ='Time (minutes)',font=2,font.lab =2) 
  polygon(c(Time, rev(Time)), c(Top, rev(Bottom)),col=mycol4,border=NA) 
  lines(Time, Middle, type= "l", col=Color, lwd=2.8);  return()} 
 
png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip301
A.png") 
T301A <- c(15,30,45,60,90,120,150,180,240,360,480,720,960,1440) 
C301A <- 
c(0.0498,0.0448,0.0444,0.0430,0.0398,0.0320,0.0294,0.0256,0.0212,0.0172,0.0132,0.0
076,0.0052,0.0030) 
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VPCP(CP.Data,'green',0.005,0.5,0,720,'CIP 301A Cp(t)   -- HV, Inhaler Dose = 
32.5mg','Plasma Conc (mg/l)','y') 
points(T301A,C301A,col='red',pch=20,cex=2.5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
dev.off();set.seed(123091) 
BW.me <- 59 
Disease <- 2 
InhalerDose<-32.5#mg 
t<-seq(0,720,5) 
######################################################################
################### 
#######################     Generation of numbers      
################################## 
######################################################################
################### 
BW.n     <- NormGen(n, BW.me,BW.cv) 
if (Disease==1){Clnonren.n<-NormGen(n, Clnonren.1.me,Clnonren.1.cv)} else if 
(Disease==2) 
{Clnonren.n<-NormGen(n, Clnonren.2.me,Clnonren.2.cv)} 
if (Disease==1){Clren.n<-NormGen(n, Clren.1.me,Clren.1.cv)} else if (Disease==2) 
{Clren.n<-NormGen(n, Clren.2.me,Clren.2.cv)} 
if (Disease==1){k12.n<-NormGen(n, k12.1.me,k12.1.cv)} else if (Disease==2) 
{k12.n<-NormGen(n, k12.2.me,k12.2.cv)} 
if (Disease==1){k21.n<-NormGen(n, k21.1.me,k21.1.cv)} else if (Disease==2) 
{k21.n<-NormGen(n, k21.2.me,k21.2.cv)} 
if (Disease==1){V0.n<-NormGen(n, V0.1.me,V0.1.cv)} else if (Disease==2) 
{V0.n<-NormGen(n, V0.2.me,V0.2.cv)} 
if (Disease==1){kga.n<-LogNormGen(n, kga.1.me,kga.1.cv)} else if (Disease==2) 
{kga.n<-LogNormGen(n, kga.2.me,kga.2.cv)} 
if (Disease==1){Foral.n<-NormGen(n,Foral.1.me,Foral.1.cv)/100} else if (Disease==2) 
{Foral.n<-NormGen(n,Foral.2.me,Foral.2.cv)/100} 
kpa.n<- LogNormGen(n, kpa.me,kpa.cv);kca.n<- LogNormGen(n, kca.me,kca.cv) 
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kpm.n<- LogNormGen(n, kpm.me,kpm.cv);kcm.n<- LogNormGen(n, kcm.me,kcm.cv) 
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n, 
kpd.me,kpd.cv)} 
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n, 
kcd.me,kcd.cv)} 
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n, 
kpls1.me,kpls1.cv)} 
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n, 
kpls2.me,kpls2.cv)} 
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n, 
kcls1.me,kcls1.cv)} 
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n, 
kcls2.me,kcls2.cv)} 
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv) 
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)} 
Fex.n<- NormGen(n, Fex.me,Fex.cv);Fpd.n<- NormGen(n, Fpd.me,Fpd.cv);Fcd.n<- 
NormGen(n, Fcd.me,Fcd.cv) 
if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n, 
Din.me,Din.cv)} 
######################################################################
################### 
#####################        PBPK Model iterations       
################################ 
######################################################################
################### 
Cltot.n<-Clren.n+Clnonren.n 
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n 
CLV.n <- TLV.n*0.8/1000 
PLV.n <- TLV.n*0.2/1000 
for (i in 1:n) { 
  Cltot<-Cltot.n[i];k12<-k12.n[i];k21<-k21.n[i]; V0<-V0.n[i]; kga<-kga.n[i] 
  Foral<-Foral.n[i];kpa<-kpa.n[i];kca<-kca.n[i];kpm<-kpm.n[i];kcm<-kcm.n[i];kpd<-kpd.n[i] 
  kcd<-kcd.n[i];kpls1<- kpls1.n[i];kpls2<-kpls2.n[i];kcls1<-kcls1.n[i];kcls2<-
kcls2.n[i];CLV<-CLV.n[i] 
  PLV<-PLV.n[i];kin<-kin.n[i];Fex<-Fex.n[i];Fpd<-Fpd.n[i];Fcd<-Fcd.n[i];Din<-Din.n[i] 
  LDose <- InhalerDose*DtL; GIDose <-InhalerDose*DtGI 
  CID<- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, 
             kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf) 
  In.Data[,i]<-CID[,2];PLU.Data[,i]<-CID[,3];CLU.Data[,i]<-CID[,4];PLS.Data[,i]<-CID[,5] 
  CLS.Data[,i]<-CID[,6];GI.Data[,i] <-CID[,7];CC.Data[,i] <-CID[,8];PC.Data[,i] <-CID[,9] 
  Ex.Data[,i]<-CID[,10];Fe.Data[,i]<-CID[,11];El.Data[,i] <-CID[,12];CP.Data[,i]<-
CID[,8]/V0 
  CS.Data[,i]<-CID[,4]/CLV;PL.Data[,i]<-CID[,3]/PLV 
  Cmax.302A.n[i]<-CP.Data[13,i]*1000 
  CpAUC.302A.n[i]<-AUC.Trap.Calc(t, CP.Data[,i])/60*1000 
} 
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png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip302
A.png") 
T302A <- c(5,15,30,45,60,90,120,150,180,240,360,480,720,960,1440) 
C302A <- 
c(0.008,0.020,0.051,0.060,0.065,0.071,0.065,0.055,0.051,0.043,0.021,0.014,0.006,0.00
4,0.001) 
VPCP(CP.Data,'green',0.005,0.5,0,720,'CIP 302A Cp(t)   -- CF, Inhaler Dose = 
32.5mg','Plasma Conc (mg/l)','y') 
points(T302A,C302A,col='red',pch=20,cex=2.5) 
dev.off() 
png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip302
A Sputum.png") 
ST302A <- c(0.75,2.00,4.00,8.00,24.00)*60 
SC302A <- c(67.58,15.54,1.48,0.39,0.03) 
VPCP(CS.Data,'cyan',0.001,100,0,720,'CIP 302A Cs(t)   -- CF, Inhaler Dose = 
32.5mg','Sputum Conc (mg/l)','y') 
points(ST302A,SC302A,col='red',pch=20,cex=2.5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
dev.off();set.seed(123091) 
BW.me <- 65 
Disease <- 2 
InhalerDose<-65#mg 
t<-seq(0,720,5) 
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######################################################################
################### 
#######################     Generation of numbers      
################################## 
######################################################################
################### 
BW.n     <- NormGen(n, BW.me,BW.cv) 
if (Disease==1){Clnonren.n<-NormGen(n, Clnonren.1.me,Clnonren.1.cv)} else if 
(Disease==2) 
{Clnonren.n<-NormGen(n, Clnonren.2.me,Clnonren.2.cv)} 
if (Disease==1){Clren.n<-NormGen(n, Clren.1.me,Clren.1.cv)} else if (Disease==2) 
{Clren.n<-NormGen(n, Clren.2.me,Clren.2.cv)} 
if (Disease==1){k12.n<-NormGen(n, k12.1.me,k12.1.cv)} else if (Disease==2) 
{k12.n<-NormGen(n, k12.2.me,k12.2.cv)} 
if (Disease==1){k21.n<-NormGen(n, k21.1.me,k21.1.cv)} else if (Disease==2) 
{k21.n<-NormGen(n, k21.2.me,k21.2.cv)} 
if (Disease==1){V0.n<-NormGen(n, V0.1.me,V0.1.cv)} else if (Disease==2) 
{V0.n<-NormGen(n, V0.2.me,V0.2.cv)} 
if (Disease==1){kga.n<-LogNormGen(n, kga.1.me,kga.1.cv)} else if (Disease==2) 
{kga.n<-LogNormGen(n, kga.2.me,kga.2.cv)} 
if (Disease==1){Foral.n<-NormGen(n,Foral.1.me,Foral.1.cv)/100} else if (Disease==2) 
{Foral.n<-NormGen(n,Foral.2.me,Foral.2.cv)/100} 
kpa.n<- LogNormGen(n, kpa.me,kpa.cv);kca.n<- LogNormGen(n, kca.me,kca.cv) 
kpm.n<- LogNormGen(n, kpm.me,kpm.cv);kcm.n<- LogNormGen(n, kcm.me,kcm.cv) 
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n, 
kpd.me,kpd.cv)} 
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n, 
kcd.me,kcd.cv)} 
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n, 
kpls1.me,kpls1.cv)} 
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n, 
kpls2.me,kpls2.cv)} 
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n, 
kcls1.me,kcls1.cv)} 
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n, 
kcls2.me,kcls2.cv)} 
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv) 
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)} 
Fex.n<- NormGen(n, Fex.me,Fex.cv);Fpd.n<- NormGen(n, Fpd.me,Fpd.cv);Fcd.n<- 
NormGen(n, Fcd.me,Fcd.cv) 
if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n, 
Din.me,Din.cv)} 
######################################################################
################### 
#####################        PBPK Model iterations       
################################ 
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######################################################################
################### 
Cltot.n<-Clren.n+Clnonren.n 
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n 
CLV.n <- TLV.n*0.8/1000 
PLV.n <- TLV.n*0.2/1000 
for (i in 1:n) { 
  Cltot<-Cltot.n[i];k12<-k12.n[i];k21<-k21.n[i]; V0<-V0.n[i]; kga<-kga.n[i] 
  Foral<-Foral.n[i];kpa<-kpa.n[i];kca<-kca.n[i];kpm<-kpm.n[i];kcm<-kcm.n[i];kpd<-kpd.n[i] 
  kcd<-kcd.n[i];kpls1<- kpls1.n[i];kpls2<-kpls2.n[i];kcls1<-kcls1.n[i];kcls2<-
kcls2.n[i];CLV<-CLV.n[i] 
  PLV<-PLV.n[i];kin<-kin.n[i];Fex<-Fex.n[i];Fpd<-Fpd.n[i];Fcd<-Fcd.n[i];Din<-Din.n[i] 
  LDose <- InhalerDose*DtL; GIDose <-InhalerDose*DtGI 
  CID<- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, 
             kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf) 
  In.Data[,i]<-CID[,2];PLU.Data[,i]<-CID[,3];CLU.Data[,i]<-CID[,4];PLS.Data[,i]<-CID[,5] 
  CLS.Data[,i]<-CID[,6];GI.Data[,i] <-CID[,7];CC.Data[,i] <-CID[,8];PC.Data[,i] <-CID[,9] 
  Ex.Data[,i]<-CID[,10];Fe.Data[,i]<-CID[,11];El.Data[,i] <-CID[,12];CP.Data[,i]<-
CID[,8]/V0 
  CS.Data[,i]<-CID[,4]/CLV;PL.Data[,i]<-CID[,3]/PLV 
  Cmax.302B.n[i]<-CP.Data[10,i]*1000 
  CpAUC.302B.n[i]<-AUC.Trap.Calc(t, CP.Data[,i])/60*1000 
} 
png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip302
B.png") 
T302B <- c(5,15,30,45,60,90,120,150,180,240,360,480,720,960,1440) 
C302B <- 
c(0.020,0.050,0.111,0.155,0.137,0.152,0.119,0.104,0.115,0.089,0.053,0.036,0.018,0.01
0,0.004) 
VPCP(CP.Data,'green',0.005,0.5,0,720,'CIP 302B Cp(t)   -- CF, Inhaler Dose = 
65mg','Plasma Conc (mg/l)','y') 
points(T302B,C302B,col='red',pch=20,cex=2.5) 
dev.off() 
 
png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip302
B Sputum.png") 
ST302B <- c(0.75,2.00,4.00,8.00,24.00)*60 
SC302B <- c(138.95,208.30,55.88,5.73,0.59) 
VPCP(CS.Data,'cyan',0.5,500,0,720,'CIP 302B Cs(t)   -- CF, Inhaler Dose = 
65mg','Sputum Conc (mg/l)','y') 
points(ST302B,SC302B,col='red',pch=20,cex=2.5) 
dev.off() 
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dev.off();set.seed(123091) 
BW.me <- 75 
Disease <- 1 
InhalerDose<-32.5#mg 
t<-seq(0,720,5) 
######################################################################
################### 
#######################     Generation of numbers      
################################## 
######################################################################
################### 
BW.n     <- NormGen(n, BW.me,BW.cv) 
if (Disease==1){Clnonren.n<-NormGen(n, Clnonren.1.me,Clnonren.1.cv)} else if 
(Disease==2) 
{Clnonren.n<-NormGen(n, Clnonren.2.me,Clnonren.2.cv)} 
if (Disease==1){Clren.n<-NormGen(n, Clren.1.me,Clren.1.cv)} else if (Disease==2) 
{Clren.n<-NormGen(n, Clren.2.me,Clren.2.cv)} 
if (Disease==1){k12.n<-NormGen(n, k12.1.me,k12.1.cv)} else if (Disease==2) 
{k12.n<-NormGen(n, k12.2.me,k12.2.cv)} 
if (Disease==1){k21.n<-NormGen(n, k21.1.me,k21.1.cv)} else if (Disease==2) 
{k21.n<-NormGen(n, k21.2.me,k21.2.cv)} 
if (Disease==1){V0.n<-NormGen(n, V0.1.me,V0.1.cv)} else if (Disease==2) 
{V0.n<-NormGen(n, V0.2.me,V0.2.cv)} 
if (Disease==1){kga.n<-LogNormGen(n, kga.1.me,kga.1.cv)} else if (Disease==2) 
{kga.n<-LogNormGen(n, kga.2.me,kga.2.cv)} 
if (Disease==1){Foral.n<-NormGen(n,Foral.1.me,Foral.1.cv)/100} else if (Disease==2) 
{Foral.n<-NormGen(n,Foral.2.me,Foral.2.cv)/100} 
kpa.n<- LogNormGen(n, kpa.me,kpa.cv);kca.n<- LogNormGen(n, kca.me,kca.cv) 
kpm.n<- LogNormGen(n, kpm.me,kpm.cv);kcm.n<- LogNormGen(n, kcm.me,kcm.cv) 
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n, 
kpd.me,kpd.cv)} 
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if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n, 
kcd.me,kcd.cv)} 
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n, 
kpls1.me,kpls1.cv)} 
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n, 
kpls2.me,kpls2.cv)} 
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n, 
kcls1.me,kcls1.cv)} 
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n, 
kcls2.me,kcls2.cv)} 
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv) 
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)} 
Fex.n<- NormGen(n, Fex.me,Fex.cv);Fpd.n<- NormGen(n, Fpd.me,Fpd.cv);Fcd.n<- 
NormGen(n, Fcd.me,Fcd.cv) 
if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n, 
Din.me,Din.cv)} 
######################################################################
################### 
#####################        PBPK Model iterations       
################################ 
######################################################################
################### 
Cltot.n<-Clren.n+Clnonren.n 
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n 
CLV.n <- TLV.n*0.8/1000 
PLV.n <- TLV.n*0.2/1000 
for (i in 1:n) { 
  Cltot<-Cltot.n[i];k12<-k12.n[i];k21<-k21.n[i]; V0<-V0.n[i]; kga<-kga.n[i] 
  Foral<-Foral.n[i];kpa<-kpa.n[i];kca<-kca.n[i];kpm<-kpm.n[i];kcm<-kcm.n[i];kpd<-kpd.n[i] 
  kcd<-kcd.n[i];kpls1<- kpls1.n[i];kpls2<-kpls2.n[i];kcls1<-kcls1.n[i];kcls2<-
kcls2.n[i];CLV<-CLV.n[i] 
  PLV<-PLV.n[i];kin<-kin.n[i];Fex<-Fex.n[i];Fpd<-Fpd.n[i];Fcd<-Fcd.n[i];Din<-Din.n[i] 
  LDose <- InhalerDose*DtL; GIDose <-InhalerDose*DtGI 
  CID<- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, 
             kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf) 
  In.Data[,i]<-CID[,2];PLU.Data[,i]<-CID[,3];CLU.Data[,i]<-CID[,4];PLS.Data[,i]<-CID[,5] 
  CLS.Data[,i]<-CID[,6];GI.Data[,i] <-CID[,7];CC.Data[,i] <-CID[,8];PC.Data[,i] <-CID[,9] 
  Ex.Data[,i]<-CID[,10];Fe.Data[,i]<-CID[,11];El.Data[,i] <-CID[,12];CP.Data[,i]<-
CID[,8]/V0 
  CS.Data[,i]<-CID[,4]/CLV;PL.Data[,i]<-CID[,3]/PLV 
  Cmax.302A.n[i]<-CP.Data[13,i]*1000 
  CpAUC.302A.n[i]<-AUC.Trap.Calc(t, CP.Data[,i])/60*1000 
} 
png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip303
A.png") 
T303A <- c(30,60,90,120,150,180,240,360,480,720,1440) 
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C303A <- c(0.077,0.095,0.083,0.073,0.065,0.059,0.049,0.034,0.027,0.014,0.004) 
VPCP(CP.Data,'green',0.005,0.5,0,720,'CIP 303A Cp(t)   -- HV, Inhaler Dose = 
32.5mg','Plasma Conc (mg/l)','y') 
points(T303A,C303A,col='red',pch=20,cex=2.5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
dev.off();set.seed(123091) 
BW.me <- 75 
Disease <- 1 
InhalerDose<-32.5#mg 
t<-seq(0,720,5) 
######################################################################
################### 
#######################     Generation of numbers      
################################## 
######################################################################
################### 
BW.n     <- NormGen(n, BW.me,BW.cv) 
if (Disease==1){Clnonren.n<-NormGen(n, Clnonren.1.me,Clnonren.1.cv)} else if 
(Disease==2) 
{Clnonren.n<-NormGen(n, Clnonren.2.me,Clnonren.2.cv)} 
if (Disease==1){Clren.n<-NormGen(n, Clren.1.me,Clren.1.cv)} else if (Disease==2) 
{Clren.n<-NormGen(n, Clren.2.me,Clren.2.cv)} 
if (Disease==1){k12.n<-NormGen(n, k12.1.me,k12.1.cv)} else if (Disease==2) 
{k12.n<-NormGen(n, k12.2.me,k12.2.cv)} 
if (Disease==1){k21.n<-NormGen(n, k21.1.me,k21.1.cv)} else if (Disease==2) 
{k21.n<-NormGen(n, k21.2.me,k21.2.cv)} 
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if (Disease==1){V0.n<-NormGen(n, V0.1.me,V0.1.cv)} else if (Disease==2) 
{V0.n<-NormGen(n, V0.2.me,V0.2.cv)} 
if (Disease==1){kga.n<-LogNormGen(n, kga.1.me,kga.1.cv)} else if (Disease==2) 
{kga.n<-LogNormGen(n, kga.2.me,kga.2.cv)} 
if (Disease==1){Foral.n<-NormGen(n,Foral.1.me,Foral.1.cv)/100} else if (Disease==2) 
{Foral.n<-NormGen(n,Foral.2.me,Foral.2.cv)/100} 
kpa.n<- LogNormGen(n, kpa.me,kpa.cv);kca.n<- LogNormGen(n, kca.me,kca.cv) 
kpm.n<- LogNormGen(n, kpm.me,kpm.cv);kcm.n<- LogNormGen(n, kcm.me,kcm.cv) 
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n, 
kpd.me,kpd.cv)} 
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n, 
kcd.me,kcd.cv)} 
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n, 
kpls1.me,kpls1.cv)} 
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n, 
kpls2.me,kpls2.cv)} 
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n, 
kcls1.me,kcls1.cv)} 
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n, 
kcls2.me,kcls2.cv)} 
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv) 
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)} 
Fex.n<- NormGen(n, Fex.me,Fex.cv);Fpd.n<- NormGen(n, Fpd.me,Fpd.cv);Fcd.n<- 
NormGen(n, Fcd.me,Fcd.cv) 
if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n, 
Din.me,Din.cv)} 
######################################################################
################### 
#####################        PBPK Model iterations       
################################ 
######################################################################
################### 
Cltot.n<-Clren.n+Clnonren.n 
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n 
CLV.n <- TLV.n*0.8/1000 
PLV.n <- TLV.n*0.2/1000 
for (i in 1:n) { 
  Cltot<-Cltot.n[i];k12<-k12.n[i];k21<-k21.n[i]; V0<-V0.n[i]; kga<-kga.n[i] 
  Foral<-Foral.n[i];kpa<-kpa.n[i];kca<-kca.n[i];kpm<-kpm.n[i];kcm<-kcm.n[i];kpd<-kpd.n[i] 
  kcd<-kcd.n[i];kpls1<- kpls1.n[i];kpls2<-kpls2.n[i];kcls1<-kcls1.n[i];kcls2<-
kcls2.n[i];CLV<-CLV.n[i] 
  PLV<-PLV.n[i];kin<-kin.n[i];Fex<-Fex.n[i];Fpd<-Fpd.n[i];Fcd<-Fcd.n[i];Din<-Din.n[i] 
  LDose <- InhalerDose*DtL; GIDose <-InhalerDose*DtGI 
  CID<- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, 
             kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,0, tinf) 
  In.Data[,i]<-CID[,2];PLU.Data[,i]<-CID[,3];CLU.Data[,i]<-CID[,4];PLS.Data[,i]<-CID[,5] 
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  CLS.Data[,i]<-CID[,6];GI.Data[,i] <-CID[,7];CC.Data[,i] <-CID[,8];PC.Data[,i] <-CID[,9] 
  Ex.Data[,i]<-CID[,10];Fe.Data[,i]<-CID[,11];El.Data[,i] <-CID[,12];CP.Data[,i]<-
CID[,8]/V0 
  CS.Data[,i]<-CID[,4]/CLV;PL.Data[,i]<-CID[,3]/PLV 
  Cmax.302A.n[i]<-CP.Data[13,i]*1000 
  CpAUC.302A.n[i]<-AUC.Trap.Calc(t, CP.Data[,i])/60*1000 
} 
png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip303
B.png") 
T303B <- c(30,60,90,120,150,180,240,360,480,720,1440) 
C303B <- c(0.040,0.032,0.027,0.024,0.022,0.021,0.018,0.013,0.010,0.006,0.001) 
VPCP(CP.Data,'green',0.001,0.1,0,720,'CIP 303B Cp(t)   -- HV, Inhaler Dose = 
32.5mg','Plasma Conc (mg/l)','y') 
points(T303B,C303B,col='red',pch=20,cex=2.5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
dev.off();set.seed(123091) 
BW.me <- 58 
Disease <- 2 
InhalerDose<-32.5#mg 
t<-seq(0,720,5) 
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######################################################################
################### 
#######################     Generation of numbers      
################################## 
######################################################################
################### 
BW.n     <- NormGen(n, BW.me,BW.cv) 
if (Disease==1){Clnonren.n<-NormGen(n, Clnonren.1.me,Clnonren.1.cv)} else if 
(Disease==2) 
{Clnonren.n<-NormGen(n, Clnonren.2.me,Clnonren.2.cv)} 
if (Disease==1){Clren.n<-NormGen(n, Clren.1.me,Clren.1.cv)} else if (Disease==2) 
{Clren.n<-NormGen(n, Clren.2.me,Clren.2.cv)} 
if (Disease==1){k12.n<-NormGen(n, k12.1.me,k12.1.cv)} else if (Disease==2) 
{k12.n<-NormGen(n, k12.2.me,k12.2.cv)} 
if (Disease==1){k21.n<-NormGen(n, k21.1.me,k21.1.cv)} else if (Disease==2) 
{k21.n<-NormGen(n, k21.2.me,k21.2.cv)} 
if (Disease==1){V0.n<-NormGen(n, V0.1.me,V0.1.cv)} else if (Disease==2) 
{V0.n<-NormGen(n, V0.2.me,V0.2.cv)} 
if (Disease==1){kga.n<-LogNormGen(n, kga.1.me,kga.1.cv)} else if (Disease==2) 
{kga.n<-LogNormGen(n, kga.2.me,kga.2.cv)} 
if (Disease==1){Foral.n<-NormGen(n,Foral.1.me,Foral.1.cv)/100} else if (Disease==2) 
{Foral.n<-NormGen(n,Foral.2.me,Foral.2.cv)/100} 
kpa.n<- LogNormGen(n, kpa.me,kpa.cv);kca.n<- LogNormGen(n, kca.me,kca.cv) 
kpm.n<- LogNormGen(n, kpm.me,kpm.cv);kcm.n<- LogNormGen(n, kcm.me,kcm.cv) 
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n, 
kpd.me,kpd.cv)} 
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n, 
kcd.me,kcd.cv)} 
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n, 
kpls1.me,kpls1.cv)} 
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n, 
kpls2.me,kpls2.cv)} 
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n, 
kcls1.me,kcls1.cv)} 
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n, 
kcls2.me,kcls2.cv)} 
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv) 
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)} 
Fex.n<- NormGen(n, Fex.me,Fex.cv);Fpd.n<- NormGen(n, Fpd.me,Fpd.cv);Fcd.n<- 
NormGen(n, Fcd.me,Fcd.cv) 
if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n, 
Din.me,Din.cv)} 
######################################################################
################### 
#####################        PBPK Model iterations       
################################ 
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######################################################################
################### 
Cltot.n<-Clren.n+Clnonren.n 
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n 
CLV.n <- TLV.n*0.8/1000 
PLV.n <- TLV.n*0.2/1000 
for (i in 1:n) { 
  Cltot<-Cltot.n[i];k12<-k12.n[i];k21<-k21.n[i]; V0<-V0.n[i]; kga<-kga.n[i] 
  Foral<-Foral.n[i];kpa<-kpa.n[i];kca<-kca.n[i];kpm<-kpm.n[i];kcm<-kcm.n[i];kpd<-kpd.n[i] 
  kcd<-kcd.n[i];kpls1<- kpls1.n[i];kpls2<-kpls2.n[i];kcls1<-kcls1.n[i];kcls2<-
kcls2.n[i];CLV<-CLV.n[i] 
  PLV<-PLV.n[i];kin<-kin.n[i];Fex<-Fex.n[i];Fpd<-Fpd.n[i];Fcd<-Fcd.n[i];Din<-Din.n[i] 
  LDose <- InhalerDose*DtL; GIDose <-InhalerDose*DtGI 
  CID<- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, 
             kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf) 
  In.Data[,i]<-CID[,2];PLU.Data[,i]<-CID[,3];CLU.Data[,i]<-CID[,4];PLS.Data[,i]<-CID[,5] 
  CLS.Data[,i]<-CID[,6];GI.Data[,i] <-CID[,7];CC.Data[,i] <-CID[,8];PC.Data[,i] <-CID[,9] 
  Ex.Data[,i]<-CID[,10];Fe.Data[,i]<-CID[,11];El.Data[,i] <-CID[,12];CP.Data[,i]<-
CID[,8]/V0 
  CS.Data[,i]<-CID[,4]/CLV;PL.Data[,i]<-CID[,3]/PLV 
  Cmax.302A.n[i]<-CP.Data[13,i]*1000 
  CpAUC.302A.n[i]<-AUC.Trap.Calc(t, CP.Data[,i])/60*1000 
} 
png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip304
A.png") 
T304A <- c(5,15,60,90,120,150,180,240,360,480,720,960,1440) 
C304A <- 
c(0.017,0.024,0.085,0.072,0.062,0.060,0.046,0.036,0.021,0.013,0.006,0.003,0.002) 
VPCP(CP.Data,'green',0.005,0.5,0,720,'CIP 304A Cp(t)   -- CF, Inhaler Dose = 
32.5mg','Plasma Conc (mg/l)','y') 
points(T304A,C304A,col='red',pch=20,cex=2.5) 
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dev.off();set.seed(123091) 
BW.me <- 60 
Disease <- 2 
InhalerDose<-65#mg 
t<-seq(0,720,5) 
######################################################################
################### 
#######################     Generation of numbers      
################################## 
######################################################################
################### 
BW.n     <- NormGen(n, BW.me,BW.cv) 
if (Disease==1){Clnonren.n<-NormGen(n, Clnonren.1.me,Clnonren.1.cv)} else if 
(Disease==2) 
{Clnonren.n<-NormGen(n, Clnonren.2.me,Clnonren.2.cv)} 
if (Disease==1){Clren.n<-NormGen(n, Clren.1.me,Clren.1.cv)} else if (Disease==2) 
{Clren.n<-NormGen(n, Clren.2.me,Clren.2.cv)} 
if (Disease==1){k12.n<-NormGen(n, k12.1.me,k12.1.cv)} else if (Disease==2) 
{k12.n<-NormGen(n, k12.2.me,k12.2.cv)} 
if (Disease==1){k21.n<-NormGen(n, k21.1.me,k21.1.cv)} else if (Disease==2) 
{k21.n<-NormGen(n, k21.2.me,k21.2.cv)} 
if (Disease==1){V0.n<-NormGen(n, V0.1.me,V0.1.cv)} else if (Disease==2) 
{V0.n<-NormGen(n, V0.2.me,V0.2.cv)} 
if (Disease==1){kga.n<-LogNormGen(n, kga.1.me,kga.1.cv)} else if (Disease==2) 
{kga.n<-LogNormGen(n, kga.2.me,kga.2.cv)} 
if (Disease==1){Foral.n<-NormGen(n,Foral.1.me,Foral.1.cv)/100} else if (Disease==2) 
{Foral.n<-NormGen(n,Foral.2.me,Foral.2.cv)/100} 
kpa.n<- LogNormGen(n, kpa.me,kpa.cv);kca.n<- LogNormGen(n, kca.me,kca.cv) 
kpm.n<- LogNormGen(n, kpm.me,kpm.cv);kcm.n<- LogNormGen(n, kcm.me,kcm.cv) 
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n, 
kpd.me,kpd.cv)} 
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n, 
kcd.me,kcd.cv)} 
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n, 
kpls1.me,kpls1.cv)} 
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n, 
kpls2.me,kpls2.cv)} 
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n, 
kcls1.me,kcls1.cv)} 
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n, 
kcls2.me,kcls2.cv)} 
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv) 
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)} 
Fex.n<- NormGen(n, Fex.me,Fex.cv);Fpd.n<- NormGen(n, Fpd.me,Fpd.cv);Fcd.n<- 
NormGen(n, Fcd.me,Fcd.cv) 
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if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n, 
Din.me,Din.cv)} 
######################################################################
################### 
#####################        PBPK Model iterations       
################################ 
######################################################################
################### 
Cltot.n<-Clren.n+Clnonren.n 
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n 
CLV.n <- TLV.n*0.8/1000 
PLV.n <- TLV.n*0.2/1000 
for (i in 1:n) { 
  Cltot<-Cltot.n[i];k12<-k12.n[i];k21<-k21.n[i]; V0<-V0.n[i]; kga<-kga.n[i] 
  Foral<-Foral.n[i];kpa<-kpa.n[i];kca<-kca.n[i];kpm<-kpm.n[i];kcm<-kcm.n[i];kpd<-kpd.n[i] 
  kcd<-kcd.n[i];kpls1<- kpls1.n[i];kpls2<-kpls2.n[i];kcls1<-kcls1.n[i];kcls2<-
kcls2.n[i];CLV<-CLV.n[i] 
  PLV<-PLV.n[i];kin<-kin.n[i];Fex<-Fex.n[i];Fpd<-Fpd.n[i];Fcd<-Fcd.n[i];Din<-Din.n[i] 
  LDose <- InhalerDose*DtL; GIDose <-InhalerDose*DtGI 
  CID<- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, 
             kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf) 
  In.Data[,i]<-CID[,2];PLU.Data[,i]<-CID[,3];CLU.Data[,i]<-CID[,4];PLS.Data[,i]<-CID[,5] 
  CLS.Data[,i]<-CID[,6];GI.Data[,i] <-CID[,7];CC.Data[,i] <-CID[,8];PC.Data[,i] <-CID[,9] 
  Ex.Data[,i]<-CID[,10];Fe.Data[,i]<-CID[,11];El.Data[,i] <-CID[,12];CP.Data[,i]<-
CID[,8]/V0 
  CS.Data[,i]<-CID[,4]/CLV;PL.Data[,i]<-CID[,3]/PLV 
  Cmax.302B.n[i]<-CP.Data[10,i]*1000 
  CpAUC.302B.n[i]<-AUC.Trap.Calc(t, CP.Data[,i])/60*1000 
} 
png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip304
B.png") 
T304B <- c(5,15,45,60,90,120,150,180,240,360,480,720,960,1440) 
C304B <- 
c(0.055,0.115,0.249,0.259,0.249,0.190,0.190,0.151,0.107,0.070,0.044,0.022,0.011,0.00
7) 
VPCP(CP.Data,'green',0.005,0.5,0,720,'CIP 304B Cp(t)   -- Inhaler CF, Dose = 
65mg','Plasma Conc (mg/l)','y') 
points(T304B,C304B,col='red',pch=20,cex=2.5) 
dev.off() 
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dev.off();set.seed(123091) 
BW.me <- 64 
Disease <- 2 
InhalerDose<-32.5#mg 
t<-seq(0,720,5) 
######################################################################
################### 
#######################     Generation of numbers      
################################## 
######################################################################
################### 
BW.n     <- NormGen(n, BW.me,BW.cv) 
if (Disease==1){Clnonren.n<-NormGen(n, Clnonren.1.me,Clnonren.1.cv)} else if 
(Disease==2) 
{Clnonren.n<-NormGen(n, Clnonren.2.me,Clnonren.2.cv)} 
if (Disease==1){Clren.n<-NormGen(n, Clren.1.me,Clren.1.cv)} else if (Disease==2) 
{Clren.n<-NormGen(n, Clren.2.me,Clren.2.cv)} 
if (Disease==1){k12.n<-NormGen(n, k12.1.me,k12.1.cv)} else if (Disease==2) 
{k12.n<-NormGen(n, k12.2.me,k12.2.cv)} 
if (Disease==1){k21.n<-NormGen(n, k21.1.me,k21.1.cv)} else if (Disease==2) 
{k21.n<-NormGen(n, k21.2.me,k21.2.cv)} 
if (Disease==1){V0.n<-NormGen(n, V0.1.me,V0.1.cv)} else if (Disease==2) 
{V0.n<-NormGen(n, V0.2.me,V0.2.cv)} 
if (Disease==1){kga.n<-LogNormGen(n, kga.1.me,kga.1.cv)} else if (Disease==2) 
{kga.n<-LogNormGen(n, kga.2.me,kga.2.cv)} 
if (Disease==1){Foral.n<-NormGen(n,Foral.1.me,Foral.1.cv)/100} else if (Disease==2) 
{Foral.n<-NormGen(n,Foral.2.me,Foral.2.cv)/100} 
kpa.n<- LogNormGen(n, kpa.me,kpa.cv);kca.n<- LogNormGen(n, kca.me,kca.cv) 
kpm.n<- LogNormGen(n, kpm.me,kpm.cv);kcm.n<- LogNormGen(n, kcm.me,kcm.cv) 
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n, 
kpd.me,kpd.cv)} 
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n, 
kcd.me,kcd.cv)} 
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n, 
kpls1.me,kpls1.cv)} 
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n, 
kpls2.me,kpls2.cv)} 
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if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n, 
kcls1.me,kcls1.cv)} 
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n, 
kcls2.me,kcls2.cv)} 
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv) 
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)} 
Fex.n<- NormGen(n, Fex.me,Fex.cv);Fpd.n<- NormGen(n, Fpd.me,Fpd.cv);Fcd.n<- 
NormGen(n, Fcd.me,Fcd.cv) 
if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n, 
Din.me,Din.cv)} 
######################################################################
################### 
#####################        PBPK Model iterations       
################################ 
######################################################################
################### 
Cltot.n<-Clren.n+Clnonren.n 
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n 
CLV.n <- TLV.n*0.8/1000 
PLV.n <- TLV.n*0.2/1000 
for (i in 1:n) { 
  Cltot<-Cltot.n[i];k12<-k12.n[i];k21<-k21.n[i]; V0<-V0.n[i]; kga<-kga.n[i] 
  Foral<-Foral.n[i];kpa<-kpa.n[i];kca<-kca.n[i];kpm<-kpm.n[i];kcm<-kcm.n[i];kpd<-kpd.n[i] 
  kcd<-kcd.n[i];kpls1<- kpls1.n[i];kpls2<-kpls2.n[i];kcls1<-kcls1.n[i];kcls2<-
kcls2.n[i];CLV<-CLV.n[i] 
  PLV<-PLV.n[i];kin<-kin.n[i];Fex<-Fex.n[i];Fpd<-Fpd.n[i];Fcd<-Fcd.n[i];Din<-Din.n[i] 
  LDose <- InhalerDose*DtL; GIDose <-InhalerDose*DtGI 
  CID<- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, 
             kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf) 
  In.Data[,i]<-CID[,2];PLU.Data[,i]<-CID[,3];CLU.Data[,i]<-CID[,4];PLS.Data[,i]<-CID[,5] 
  CLS.Data[,i]<-CID[,6];GI.Data[,i] <-CID[,7];CC.Data[,i] <-CID[,8];PC.Data[,i] <-CID[,9] 
  Ex.Data[,i]<-CID[,10];Fe.Data[,i]<-CID[,11];El.Data[,i] <-CID[,12];CP.Data[,i]<-
CID[,8]/V0 
  CS.Data[,i]<-CID[,4]/CLV;PL.Data[,i]<-CID[,3]/PLV 
  Cmax.302A.n[i]<-CP.Data[13,i]*1000 
  CpAUC.302A.n[i]<-AUC.Trap.Calc(t, CP.Data[,i])/60*1000 
} 
png(width=10,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/Cip304
C.png") 
T304C <- c(5,15,45,60,90,120,180,240,360,480,720) 
C304C <- c(0.029,0.032,0.107,0.124,0.120,0.115,0.099,0.070,0.042,0.028,0.012) 
VPCP(CP.Data,'green',0.005,0.5,0,720,'CIP 304C Cp(t)   -- CF, Inhaler Dose = 
32.5mg','Plasma Conc (mg/l)','y') 
points(T304C,C304C,col='red',pch=20,cex=2.5) 
dev.off() 
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mean(CpAUC.301A.n) 
mean(CpAUC.302A.n) 
mean(CpAUC.302B.n) 
 
 
sd(CpAUC.301A.n) 
sd(CpAUC.302A.n) 
sd(CpAUC.302B.n) 
 
 
mean(Cmax.301A.n) 
mean(Cmax.302A.n) 
mean(Cmax.302B.n) 
 
sd(Cmax.301A.n) 
sd(Cmax.302A.n) 
sd(Cmax.302B.n) 
 
 
 
(mean(CpAUC.301A.n)-482)*100/482 
(mean(CpAUC.302A.n)-520)*100/520 
(mean(CpAUC.302B.n)-1237)*100/1237 
 
 
(mean(Cmax.301A.n)-79)*100/79 
(mean(Cmax.302A.n)-128)*100/128 
(mean(Cmax.302B.n)-289)*100/289 
 
 
 
(((mean(CpAUC.301A.n)-482)*100/482)+ 
    ((mean(CpAUC.302A.n)-520)*100/520)+ 
    ((mean(CpAUC.302B.n)-1237)*100/1237))/4 
 
sd(c(((mean(CpAUC.301A.n)-482)*100/482), 
     ((mean(CpAUC.302A.n)-520)*100/406), 
     ((mean(CpAUC.302B.n)-1237)*100/1237))) 
 
 
 
(((mean(Cmax.301A.n)-79)*100/79)+ 
  ((mean(Cmax.302A.n)-128)*100/128)+ 
  ((mean(Cmax.302B.n)-289)*100/289))/4 
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sd(c(((mean(Cmax.301A.n)-79)*100/79), 
     ((mean(Cmax.302A.n)-127)*100/127), 
     ((mean(Cmax.302B.n)-289)*100/289))) 
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Code Utilized for Sensitivity Analysis After INH 
rm(list=ls()); cat("\014");dev.off();set.seed(123091) 
 
BW.me <- 70 
BW.cv   <- 0 
n       <- 3 
Disease <- 1            #  1= Healthy     2= CF 
 
InhalerDose<-32.5#mg 
DtL  <- 0.53 
DtGI <- 0.43 
t<-seq(0,720,5) 
 
Clren.1.me <- 315        #Healthy 
Clren.2.me <- 425        #CF 
Clnonren.1.me <- 315        #Healthy 
Clnonren.2.me <- 225        #CF 
k12.1.me <- 0.025        #Healthy 
k12.2.me <- 0.050        #CF 
k21.1.me <- 0.015       #Healthy 
k21.2.me <- 0.020        #CF 
V0.1.me <- 75        #Healthy 
V0.2.me <- 20        #CF 
 
Clnonren.1.cv <- 0       #Healthy 
Clnonren.2.cv <- 0        #CF 
Clren.1.cv <- 0       #Healthy 
Clren.2.cv <- 0        #CF 
k12.1.cv <- 0       #Healthy 
k12.2.cv <- 0        #CF 
k21.1.cv <- 0       #Healthy 
k21.2.cv <- 0        #CF 
V0.1.cv <- 0       #Healthy 
V0.2.cv <- 0        #CF 
 
 
Foral.1.me  <- 73 
Foral.2.me  <- 85 
kga.1.me    <- 0.020 
kga.2.me    <- 0.011 
Foral.1.cv<-0;    Foral.2.cv<-0;    kga.1.cv<-0;  kga.2.cv<-0 
 
kpa.me    <- 0.010 
kca.me    <- 0.020  
kpm.me    <- 0.020 
 
 
342 
 
kcm.me    <- 0.02 
kpd.me    <- 0.008 
kcd.me    <- 0.0002 
kpls1.me  <- 10000  
kpls2.me  <- 10000 
kcls1.me  <- 10000 
kcls2.me  <- 10000 
TLV.me    <- 30  
kpa.cv<-0;kca.cv<-0;kpm.cv<-0;kcm.cv<-0;kpd.cv<-0;kcd.cv<-0 
kpls1.cv<-0;kpls2.cv<-0;kcls1.cv<-0;kcls2.cv<-0 
 
TLVprop.me  <- 1 
TLVprop.cv  <- 0 
 
kin.me    <- 0 
Fex.me    <- 0 
Fpd.me    <- 0.25 
Fcd.me    <- 0.75 
Din.me    <- 0 
kin.cv<-0;  Fex.cv<-0; Fpd.cv<-0;  Fcd.cv<-0;  Din.cv<-0 
######################################################################
################### 
#####################     Normal Distribution Generator     
############################# 
######################################################################
################### 
NormGen <- function(simulation.n,samp.m,samp.cv ){ 
  samp.sd <- samp.cv*samp.m/100;  out <- rnorm(simulation.n,samp.m,samp.sd);  
return(out)} 
LogNormGen <- function(n, Mean, PCV){ 
  CV<-PCV/100;SD<-(CV*Mean);Variance<-SD^2;mean.in<-
log(Mean^2/sqrt(Variance+Mean^2)); 
  SD.in<-sqrt(log(Variance/Mean^2 + 1));x=rlnorm(n,mean.in,SD.in);  return(x)} 
AUC.Trap.Calc <- function(Time, CP){ 
  n <- length(Time);  AUC.Values<-rep(0,n-1) 
  for (i in 1:(n-1)){    if (i==1){AUC.Values[i]<-(Time[i+1]-Time[i])* (CP[i]+CP[i+1])/2} 
    if (i>1){AUC.Values[i]<-(Time[i+1]-Time[i])* (CP[i]+CP[i+1])/2 +AUC.Values[i-1]} 
  } ;  return(AUC.Values[i])}  
######################################################################
################### 
#######################     Generation of numbers      
################################## 
######################################################################
################### 
BW.n     <- NormGen(n, BW.me,BW.cv) 
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if (Disease==1){Clnonren.n<-NormGen(n, Clnonren.1.me,Clnonren.1.cv)} else if 
(Disease==2) 
{Clnonren.n<-NormGen(n, Clnonren.2.me,Clnonren.2.cv)} 
if (Disease==1){Clren.n<-NormGen(n, Clren.1.me,Clren.1.cv)} else if (Disease==2) 
{Clren.n<-NormGen(n, Clren.2.me,Clren.2.cv)} 
if (Disease==1){k12.n<-NormGen(n, k12.1.me,k12.1.cv)} else if (Disease==2) 
{k12.n<-NormGen(n, k12.2.me,k12.2.cv)} 
if (Disease==1){k21.n<-NormGen(n, k21.1.me,k21.1.cv)} else if (Disease==2) 
{k21.n<-NormGen(n, k21.2.me,k21.2.cv)} 
if (Disease==1){V0.n<-NormGen(n, V0.1.me,V0.1.cv)} else if (Disease==2) 
{V0.n<-NormGen(n, V0.2.me,V0.2.cv)} 
if (Disease==1){kga.n<-LogNormGen(n, kga.1.me,kga.1.cv)} else if (Disease==2) 
{kga.n<-LogNormGen(n, kga.2.me,kga.2.cv)} 
if (Disease==1){Foral.n<-NormGen(n,Foral.1.me,Foral.1.cv)/100} else if (Disease==2) 
{Foral.n<-NormGen(n,Foral.2.me,Foral.2.cv)/100} 
kpa.n<- LogNormGen(n, kpa.me,kpa.cv);kca.n<- LogNormGen(n, kca.me,kca.cv) 
kpm.n<- LogNormGen(n, kpm.me,kpm.cv);kcm.n<- LogNormGen(n, kcm.me,kcm.cv) 
if (kpd.me==0){kpd.n<-rep(0,n)} else if (kpd.me>0){kpd.n<-LogNormGen(n, 
kpd.me,kpd.cv)} 
if (kcd.me==0){kcd.n<-rep(0,n)} else if (kcd.me>0){kcd.n<-LogNormGen(n, 
kcd.me,kcd.cv)} 
if (kpls1.me==0){kpls1.n<-rep(0,n)} else if (kpls1.me>0){kpls1.n<-LogNormGen(n, 
kpls1.me,kpls1.cv)} 
if (kpls2.me==0){kpls2.n<-rep(0,n)} else if (kpls2.me>0){kpls2.n<-LogNormGen(n, 
kpls2.me,kpls2.cv)} 
if (kcls1.me==0){kcls1.n<-rep(0,n)} else if (kcls1.me>0){kcls1.n<-LogNormGen(n, 
kcls1.me,kcls1.cv)} 
if (kcls2.me==0){kcls2.n<-rep(0,n)} else if (kcls2.me>0){kcls2.n<-LogNormGen(n, 
kcls2.me,kcls2.cv)} 
TLVprop.n <- NormGen(n, TLVprop.me,TLVprop.cv) 
if (kin.me==0){kin.n<-rep(0,n)} else if (kin.me>0){kin.n<-NormGen(n, kin.me,kin.cv)} 
Fex.n<- NormGen(n, Fex.me,Fex.cv);Fpd.n<- NormGen(n, Fpd.me,Fpd.cv);Fcd.n<- 
NormGen(n, Fcd.me,Fcd.cv) 
if (Din.me==0){Din.n<-rep(0,n)} else if (Din.me>0){Din.n<-LogNormGen(n, 
Din.me,Din.cv)} 
 
Clren.n    <- c(Clren.1.me/5,Clren.1.me,5*Clren.1.me) 
#Clnonren.n    <- c(Clnonren.1.me/5,Clnonren.1.me,5*Clnonren.1.me) 
#k12.n    <- c(k12.1.me/5,k12.1.me,5*k12.1.me) 
#k21.n    <- c(k21.1.me/5,k21.1.me,5*k21.1.me) 
#V0.n    <- c(V0.1.me/5,V0.1.me,5*V0.1.me) 
#kga.n <- c(kga.1.me/5,kga.1.me,5*kga.1.me) 
#Foral.n <- c(Foral.1.me/5,Foral.1.me,5*Foral.1.me) 
#kpa.n    <- c(kpa.me/10,kpa.me,10*kpa.me) 
#kca.n    <- c(kca.me/10,kca.me,10*kca.me) 
#kpm.n    <- c(kpm.me/10,kpm.me,10*kpm.me) 
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#kcm.n    <- c(kpm.me/10,kpm.me,10*kpm.me) 
#kpd.n    <- c(kpd.me/10,kpd.me,10*kpd.me) 
#kcd.n    <- c(kcd.me/10,kcd.me,10*kcd.me) 
 
 
#Clren.n    <- c(Clren.2.me/5,Clren.2.me,5*Clren.2.me) 
#Clnonren.n    <- c(Clnonren.2.me/5,Clnonren.2.me,5*Clnonren.2.me) 
#k12.n    <- c(k12.2.me/5,k12.2.me,5*k12.2.me) 
#k21.n    <- c(k21.2.me/5,k21.2.me,5*k21.2.me) 
#V0.n    <- c(V0.2.me/5,V0.2.me,5*V0.2.me) 
#kga.n <- c(kga.2.me/5,kga.2.me,5*kga.2.me) 
#Foral.n <- c(Foral.2.me/5,Foral.2.me,5*Foral.2.me) 
#kpa.n    <- c(kpa.me/10,kpa.me,10*kpa.me) 
#kca.n    <- c(kca.me/10,kca.me,10*kca.me) 
#kpm.n    <- c(kpm.me/10,kpm.me,10*kpm.me) 
#kcm.n    <- c(kpm.me/10,kpm.me,10*kpm.me) 
#kpd.n    <- c(kpd.me/10,kpd.me,10*kpd.me) 
#kcd.n    <- c(kcd.me/10,kcd.me,10*kcd.me) 
######################################################################
################### 
##############         Set up the ODE Based model function        
####################### 
######################################################################
################### 
TCBM <- function(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, kpls2,  
                 kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf ){ 
    Fgd        <- 1-Fex-Fpd-Fcd;ED <- data.frame(var = c("DOSING"), time = c(0,1), value 
= c(0,0), method = c("rep")) 
  Model.Function <- function(t,IC,Parm) { 
    with(as.list(IC, Parm), { 
      dDOSING <- 0 
      dIn  <- -In*kin*(Fex+Fpd+Fcd+Fgd);dPLU<-In*kin*Fpd + PLS*kpd - PLU*(kpa + 
kpm) 
      dCLU <-In*kin*Fcd + CLS*kcd - CLU*(kca + kcm) + PLU* kpm 
      dGI  <-In*kin*Fgd + CLU* kcm - GI*kga;dPLS <-PLU*kpa + CC*kpls1 - PLS * 
(kpd+kpls2) 
      dCLS <-CLU*kca + CC*kcls1 - CLS * (kcd+kcls2);dPC  <-CC* k12 - PC *k21 
      dCC  <-PLS*kpls2 + CLS*kcls2 + GI*kga*Foral + PC*k21 - CC*(kpls1+kcls1 + k12 + 
(Cltot/(V0*1000)))+ DOSING   
      dEx  <-In*kin*Fex;      dFe     <-   GI*kga*(1-Foral);      dEl     <-   
CC*(Cltot/(V0*1000)) 
      return(list(c(dIn,dPLU,dCLU,dPLS,dCLS,dGI,dCC,dPC,dEx,dFe,dEl,dDOSING)))   
    })  } 
  IC   <- c(In=0, PLU=LDose*Fpd, CLU=LDose*Fcd, PLS=0, CLS=0, GI=GIDose, 
CC=0, PC=0, Ex=0*Fex, Fe=0, El=0,DOSING=0) 
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  Parm <- c(Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, kpls2, kcls1, 
kcls2, kin, Fex, Fpd, Fcd, Fgd) 
  out  <- ode(IC, t,Model.Function,Parm) 
  return(out)} 
######################################################################
################### 
#####################        PBPK Model iterations       
################################ 
######################################################################
################### 
Cltot.n<-Clren.n+Clnonren.n 
TLV.n <- TLV.me*(BW.n/mean(BW.n))^0.8*TLVprop.n 
CLV.n <- TLV.n*0.8/1000 
PLV.n <- TLV.n*0.2/1000 
In.Data  <- matrix(0,length(t),(n));PL.Data<-In.Data;Cmax.n=rep(0,n);Smax.n<-Cmax.n 
PLU.Data <- In.Data;CLU.Data <- In.Data;PLS.Data <- In.Data;CLS.Data <- In.Data 
GI.Data  <- In.Data;CC.Data  <- In.Data;PC.Data  <- In.Data;Ex.Data  <- In.Data 
Fe.Data  <- In.Data;El.Data  <- In.Data;CP.Data  <- In.Data;CS.Data  <- In.Data 
for (i in 1:n) { 
  Cltot<-Cltot.n[i];k12<-k12.n[i];k21<-k21.n[i]; V0<-V0.n[i]; kga<-kga.n[i] 
  Foral<-Foral.n[i];kpa<-kpa.n[i];kca<-kca.n[i];kpm<-kpm.n[i];kcm<-kcm.n[i];kpd<-kpd.n[i] 
  kcd<-kcd.n[i];kpls1<- kpls1.n[i];kpls2<-kpls2.n[i];kcls1<-kcls1.n[i];kcls2<-
kcls2.n[i];CLV<-CLV.n[i] 
  PLV<-PLV.n[i];kin<-kin.n[i];Fex<-Fex.n[i];Fpd<-Fpd.n[i];Fcd<-Fcd.n[i];Din<-Din.n[i] 
  LDose <- InhalerDose*DtL; GIDose <-InhalerDose*DtGI 
  CID<- TCBM(t,Cltot, k12, k21, V0, kpa, kca, kpm, kcm, kpd, kcd, kpls1, 
             kpls2, kcls1, kcls2, kin, Fex, Fpd, Fcd, Din, LDose,GIDose, tinf) 
  In.Data[,i]<-CID[,2];PLU.Data[,i]<-CID[,3];CLU.Data[,i]<-CID[,4];PLS.Data[,i]<-CID[,5] 
  CLS.Data[,i]<-CID[,6];GI.Data[,i] <-CID[,7];CC.Data[,i] <-CID[,8];PC.Data[,i] <-CID[,9] 
  Ex.Data[,i]<-CID[,10];Fe.Data[,i]<-CID[,11];El.Data[,i] <-CID[,12];CP.Data[,i]<-
CID[,8]/V0 
  CS.Data[,i]<-CID[,4]/CLV;PL.Data[,i]<-CID[,3]/PLV;Cmax.n[i]<- 
max(CP.Data[,i]);Smax.n[i]<- max(CS.Data[,i])} 
######################################################################
################### 
###################   VPC Plotting Function for TS DATA    
############################## 
######################################################################
################### 
VPCP <- function(Data,Color,YMin,YMax,XMin,XMax,Title,Ytitle,LogAxis){   
  Size.of.Data<-dim(Data); PlottingData<-matrix(0,Size.of.Data[1],4);PlottingData[,1] <-
CID[,1] 
  for(i in 1:length(t)){ 
    PlottingData[i,2] <-min(Data[i,]);PlottingData[i,3] <- mean(Data[i,]);PlottingData[i,4] <- 
max(Data[i,])} 
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  Time<-PlottingData[,1];Bottom<-PlottingData[,2];Top<-PlottingData[,4];Middle<-
PlottingData[,3]   
  ColNumbers<-col2rgb(Color);par(TRUE);mycol4<-
rgb(ColNumbers[1],ColNumbers[2],ColNumbers[3],max=255,alpha=90) 
  
plot(Time,Bottom,type="n",col=Color,main=Title,ylim=c(YMin,YMax),log=LogAxis,xlim=c
(XMin,XMax), 
       ylab =Ytitle, xlab = 'Time (minutes)', font=2,font.lab =2) 
  polygon(c(Time, rev(Time)), c(Top, rev(Bottom)),col=mycol4,border=NA) 
  lines(Time, Middle, type= "l", col=Color, lwd=2.8);  return()} 
png(width=12,height=7,units='in',res=1200,filename="C:/Users/Laptop/Desktop/ HV 
Clrenal.png");par(mfrow=c(1,2)) 
VPCP(CP.Data,'green',0.001,10,0,720,'','Plasma Conc (mg/l)','y') 
VPCP(CS.Data,'cyan',0.1,1000,0,720,'','Sputum Conc (mg/l)','y') 
mtext("Sensitivity of cp(t) (left plot) and cs(t) (right plot) to Clrenal after INH Dosing in 
HV", cex=1.2,side = 3,line =-2,outer=T,font=2);dev.off() 
AUCLowerParmValue<-AUC.Trap.Calc(t,CP.Data[,1]);AUCHigherParmValue<-
AUC.Trap.Calc(t,CP.Data[,3]) 
AUCS <- c(AUCLowerParmValue,AUCHigherParmValue);AUCMultiplier=1 
if (AUCHigherParmValue<AUCLowerParmValue){AUCMultiplier=-1} 
Cmaxlower <- Cmax.n[1];Cmaxhigher<- Cmax.n[3];Cmaxmultiplier<-1 
if (Cmaxhigher<Cmaxlower){Cmaxmultiplier=-1} 
SAUCLowerParmValue<-AUC.Trap.Calc(t,CS.Data[,1]);SAUCHigherParmValue<-
AUC.Trap.Calc(t,CS.Data[,3]) 
SAUCS <- c(SAUCLowerParmValue,SAUCHigherParmValue);SAUCMultiplier=1 
if (SAUCHigherParmValue<SAUCLowerParmValue){SAUCMultiplier=-1} 
Smaxlower <- Smax.n[1];Smaxhigher<- Smax.n[3];Smaxmultiplier<-1 
if (Smaxhigher<Smaxlower){Smaxmultiplier=-1} 
Clrenal.1.AUC<-AUCMultiplier*max(AUCS)/min(AUCS) 
Clrenal.1.cmax<- Cmaxmultiplier*max(Cmax.n)/min(Cmax.n) 
Clrenal.1.SAUC<-SAUCMultiplier*max(SAUCS)/min(SAUCS) 
Clrenal.1.smax <- Smaxmultiplier*max(Smax.n)/min(Smax.n) 
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